ivabradine profile

Ivabradine: A benzazepine derivative and selective HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNELS inhibitor that lowers the heart rate. It is used in the treatment of CHRONIC STABLE ANGINA in patients unable to take BETA-ADRENERGIC BLOCKERS, and in the treatment of HEART FAILURE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ivabradine : A member of the class of benzazepines that is 7,8-dimethoxy-1,3,4,5-tetrahydro-3-benzazepin-2-one in which the amide hydrogen is replaced by a [{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino]propyl} group. Used (as its hydrochloride salt) to treat patients with angina who have intolerance to beta blockers and/or heart failure. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	132999
CHEMBL ID	471737
CHEBI ID	85966
SCHEMBL ID	23472
MeSH ID	M0234009

Synonym
3-[3-[[(8s)-3,4-dimethoxy-8-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1h-3-benzazepin-4-one
gtpl2357
s-16257
(s)-3-(3-(((3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-2h-3-benzazepin-2-one
s 16257-2
7,8-dimethoxy-3-(3-(((4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2h-benzazepin-2-one
2h-3-benzazepin-2-one, 3-(3-(((3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-, (s)-
ivabradine [inn]
ivabradine
s 16257
3-(3-((((7s)-3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-2h-3-benzazepin-2-one
155974-00-8
ivabradine (usan/inn)
D07165
chebi:85966 ,
CHEMBL471737 ,
3-[3-[[(7s)-3,4-dimethoxy-7-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1h-3-benzazepin-4-one
bdbm50326992
3-{3-[{[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)-amino]propyl}-7,8-dimethoxy-1,3,4,5-tetrahydro-2h-3-benzazepin-2-one
3-{3-[{[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino]-propyl}-7.8-dimethoxy-1,3,4,5-tetrahydro-2h-3-benzazepin-2-one
3-{3-[{[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino]propyl}-7,8-dimethoxy-1,3,4,5-tetrahydro-2h-3-benzazepin-2-one
ACRHBAYQBXXRTO-OAQYLSRUSA-N
3h48l0lpzq ,
unii-3h48l0lpzq
ivabradine [usan:inn:ban]
ivabradine [usan]
ivabradine [who-dd]
ivabradine [mart.]
ivabradine [mi]
ivabradine [ema epar]
ivabradine [orange book]
S16257 ,
AKOS015896494
SCHEMBL23472
DTXSID2048240 ,
AB01566878_01
3-[3-({[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino)propyl]-7,8-dimethoxy-2,3,4,5-tetrahydro-1h-3-benzazepin-2-one
DB09083
AC-8848
BCP21052
Q425729
AR-270/43507923
NCGC00181343-03
AT22349
2h-3-benzazepin-2-one, 3-(3-((((7s)-3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-
2h-3-benzazepin-2-one, 3-[3-[[[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl]methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-
CS-0012360
HY-B0162
EN300-20600170
c01eb17
3-(3-((((7s)-3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)(methyl)amino)propyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-2h-3-benzazepin-2-one
ivabradina
3-(3-((((7s)-3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)(methyl)amino)propyl)-7,8-dimethoxy-2,3,4,5-tetrahydro-1h-3-benzazepin-2-one
dtxcid3028215
ivabradin
ivabradine (mart.)
ivabradinum

Research Excerpts

Overview

Excerpt	Reference
"Ivabradine is a 'heart rate-reducing' agent able to slow heart rate, without complicating side-effects. "	( Baruscotti, M; Bucchi, A; DiFrancesco, D; Milanesi, R; Tognati, A, 2006)
"Ivabradine is an effective treatment for focal atrial tachycardia. "	( He, R; Liu, Y; She, F; Xie, Y; Zhang, P; Zhao, L, 2022)
"Ivabradine is a drug that selectively reduces HR via If current inhibition in the sinoatrial node without a negative effect on inotropy."	( Baka, T; Luptak, I; Repova, K; Simko, F, 2022)
"Ivabradine is an inhibitor of the If channel, the main determinant of the pacemaker function of the sinus node. "	( Arias, MÁ; Arribas, F; Fontenla, A; Gómez de la Cámara, A; López-Gil, M; Matía-Francés, R; Mejía-Martínez, E; Miracle-Blanco, Á; Montilla, I; Pastor-Fuentes, A; Rey-Blas, JR; Salgado-Aranda, R; Tamargo-Menéndez, J; Toquero-Ramos, J, 2020)
"Ivabradine (IVA) is a pure heart rate-lowering agent with well-documented anti-anginal and anti-ischemic properties comparable to well-established anti-anginal agents, such as beta-blockers and calcium channel blockers."	( D'Orazio, N; Gammone, MA; Massari, F; Riccioni, G, 2020)
"Ivabradine is a selective inhibitor of hyperpolarization-activated cyclic nucleotide-gated potassium channel 4 generated funny current (I"	( Aziz, Z; Beaser, AD; Kohli, U; Nayak, HM, 2020)
"Ivabradine is a bradycardic drug used worldwide in the treatment of chronic stable angina and chronic heart failure. "	( Alvarez, JC; de la Grandamison, GL; Knapp-Gisclon, A; Mayer-Duverneuil, C; Rambaud, C; Zerah, M, 2020)
"Ivabradine is a unique medication that reduces the intrinsic heart rate by specifically blocking the inward funny current that controls the pacemaker activity of the sinus node. "	( Grubb, BP; Karabin, B; Mangi, MA; Nesheiwat, Z; Towheed, A, 2020)
"Ivabradine is a heart rate lowering drug with protective effects on heart failure despite increasing the risk of atrial fibrillation."	( Barhdadi, A; de Denus, S; Dubé, MP; Legault, MA; Lemieux Perreault, LP; Lumbers, RT; Provost, S; Sandoval, J; Shah, S; Tardif, JC; Tyl, B, 2020)
"Ivabradine is a selective inhibitor of the sinoatrial node "funny" current, prolonging the slow diastolic depolarization. "	( Beak, YS; Choi, SH; Jang, JH; Kim, DH; Ko, KY; Kwan, J; Kwon, SW; Lee, MJ; Park, JH; Park, SD; Shin, SH; Woo, SI; Yoon, GS, 2020)
"Ivabradine is a recently introduced selective I"	( Hori, M; Imamura, T; Kinugawa, K; Nakamura, M, 2021)
"Ivabradine is a new class of HR lowering drug and a specific inhibitor of the I"	( Hatani, Y; Hayashi, T; Hirata, KI; Imanishi, J; Tanaka, H; Yamauchi, Y, 2021)
"Ivabradine is a unique agent that is distinct from beta-blockers and calcium channel blockers as it reduces heart rate without affecting myocardial contractility or vascular tone. "	( Bangalore, S; Chen, C; Godoy, LC; Kaur, G; Mehta, PK; Morrone, D; Sidhu, MS, 2021)
"Ivabradine is a new pure bradycardic agent that has been used to treat angina or heart failure reduced ejection fraction (HFrEF) with sinus heart rate above 70 beats per minute."	( Bryan Richard, S; Huang, B; Liu, G; Luo, S; Yang, Y, 2021)
"Ivabradine is a selective heart rate-reducing agent, an inhibitor of hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels, currently approved for treatment of coronary artery disease and chronic heart failure."	( Mackiewicz, U; Mączewski, M; Marciszek, M; Oknińska, M; Paterek, A; Zambrowska, Z, 2021)
"Ivabradine is a pure heart rate-lowering drug that acts directly on the sinus node and does not affect atrioventricular or intraventricular conduction times, myocardial contractility or ventricular repolarization. "	( Greco, S; Guadagnino, G; Mastroianni, A; Urso, F; Vangeli, V, 2021)
"Ivabradine is an original drug that has been approved in two indications (systolic heart failure and angina). "	( Bouvaist, H; Cosgrove, S; Ennezat, PV; Le Jemtel, TH; Marechaux, S; Vital Durand, D, 2017)
"Ivabradine is a selective I"	( Alhazmi, L; Ammari, Z; Dasa, O; Grubb, B; Karabin, B; Ruzieh, M; Sirianni, N, 2017)
"Ivabradine is a selective and specific inhibitor of the I(f) current in the sinoatrial and atrioventricular nodes. "	( Daubeney, PEF; Delle Donne, G; Prasad, SK; Rosés Noguer, F; Salukhe, T; Till, J, 2018)
"Ivabradine is a novel heart rate (HR) lowering agent that acts on the sinoatrial node cells by selectively inhibiting the If-current."	( Brown, JN; Gee, ME; Watkins, AK; Young, EJA, 2018)
"Ivabradine is a pure HR-lowering agent, and it does not affect myocardial contractility, blood pressure, intracardiac conduction, or ventricular repolarization."	( Banach, M; Bielecka-Dabrowa, A; Rysz, J; von Haehling, S, 2018)
": Ivabradine is a selective and specific inhibitor of If current. "	( Fragasso, G; Gemma, M; Godino, C; Margonato, A; Montanaro, C; Pinto, G; Salerno, A; Slavich, M; Spoladore, R; Tondi, L, 2018)
"Ivabradine is a heart rate lowering agent that acts on the funny current (I"	( Chow, SL; Depre, C; Page, RL, 2018)
"Ivabradine is a selective bradycardic agent that inhibits hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. "	( Hayama, Y; Kawada, T; Nishikawa, T; Shimizu, S; Shishido, T; Sugimachi, M; Uemura, K; Yamamoto, H, 2019)
"Ivabradine is a selective inhibitor of the sinoatrial pacemaker modulating "f-current" (I"	( Dodd, K; Lampert, BC, 2018)
"Ivabradine is a funny current inhibitor which is administered to patients with congestive heart failure to reduce their heart rate (HR) and attenuate oxidative stress. "	( Chang, CC; Chuang, CL; Hsin, IF; Hsu, SJ; Huang, HC; Lee, FY; Lee, SD; Lee, WS, 2019)
"Ivabradine is a heart rate-lowering drug that does not cause hypotension and may be used in heart failure with reduced left ventricular ejection fraction (LVEF)."	( Arboscello, E; Balbi, M; Bighin, C; Brunelli, C; Ghigliotti, G; Gualandi, F; Murialdo, R; Sarocchi, M; Sicbaldi, V; Spallarossa, P, 2018)
"Ivabradine appears to be an effective alternative to Amiodarone in children with post-operative JET based on our initial clinical experience."	( Balaji, S; Krishna, MR; Kumar, RK; Kunde, MF, 2019)
"Ivabradine is an interesting substance since it is known to produce migraine-like phosphenes frequently and the patient we report developed de novo migraine with aura. "	( Goadsby, PJ; Sprenger, T; Supronsinchai, W, 2013)
"Ivabradine is an anti-anginal and anti-ischaemic agent, which selectively and specifically inhibits the I f current in the sino-atrial node and provides pure heart rate reduction without altering other cardiac parameters, including conduction, and without directly affecting other haemodynamic parameters."	( Deedwania, P, 2013)
"Ivabradine is a pure heart rate-lowering agent that acts by inhibiting I(f), an important ionic current involved in pacemaker activity in the cells of the sinoatrial node. "	( Huang, Y; Jiang, J; Li, Y; Tian, L; Xu, L, 2013)
"Ivabradine is a new heart-rate-lowering drug; the aim of this review was to analyze its role in heart failure (HF)."	( Brunelli, C; Ferrero, S; Ghione, P; Rosa, GM; Valbusa, A, 2014)
"Ivabradine is a pure heart rate-reducing agent that has no effect on blood pressure and contractility, and can reverse left ventricular (LV) remodelling in patients with heart failure."	( Bonnet, J; Chasseriaud, W; Cochet, H; Coste, P; Douard, H; Gerbaud, E; Gilbert, S; Horovitz, A; Montaudon, M; Pucheu, Y, 2014)
"Ivabradine is a selective inhibitor of the pacemaker current If and since If is impaired by lipopolysaccharide (LPS, endotoxin), a trigger of sepsis, we aimed to explore If blocking potency of ivabradine under elevated endotoxin levels in human atrial cardiomyocytes."	( Hallström, S; Koyani, CN; Lang, P; Lohner, K; Mächler, H; Malle, E; Pelzmann, B; Platzer, D; Scheruebel, S; Zorn-Pauly, K, 2014)
"Ivabradine is a drug used for the treatment of angina and chronic heart failure in cases of intolerance or insufficiency of response to beta-blocker treatment. "	( Dulaurent, S; Gaulier, JM; Julia, F; Mathiaux, F, 2014)
"Ivabradine is a heart rate (HR)-lowering agent acting by inhibiting the If-channel. "	( Cavusoglu, Y; Mert, U; Morrad, B; Mutlu, F; Nadir, A; Ulus, T, 2015)
"Ivabradine is a novel specific heart rate (HR)-lowering agent that improves event-free survival in patients with heart failure (HF)."	( Balta, S; Cuglan, B; Gozubuyuk, G; Kaplan, O; Karakus, Y; Kurtoglu, E; Yasar, E, 2014)
"Ivabradine is a useful, effective and safe drug for therapy in NM patients with HF and should be considered when resting HR remains high despite beta-blockers' full titration or beta-blockers' underdosing due to intolerance or side effects."	( Baviera, EP; Di Franco, A; Lanza, GA; Mandalà, G; Marazia, S; Salerno, Y; Sarullo, FM; Sarullo, S; Vassallo, L; Vitale, G, 2015)
"Ivabradine is an effective and well-tolerated anti-anginal treatment in patients with stable angina after PCI. "	( Ebelt, H; Höpfner, F; Müller-Werdan, U; Nuding, S; Stöckl, G; Werdan, K, 2015)
"Ivabradine is a specific bradycardic agent used in coronary artery disease and heart failure, lowering heart rate through inhibition of sinoatrial nodal HCN-channels. "	( Brack, KE; Dempsey, CE; El Harchi, A; Hancox, JC; Melgari, D; Mitcheson, JS; Ng, GA; Zhang, C; Zhang, Y, 2015)
"Ivabradine is an inhibitor of mixed Na+-K+ current that could combine with HCN channels to reduce the transmembrane velocity of funny current (If), heart rate, and cardiac efficiency, and thus be used for the treatment of cardiovascular diseases such as chronic heart failure. "	( Hong, YF; Ji, YT; Jiang, T; Li, JX; Li, YD; Tang, BP; Xing, Q; Xiong, J; Yusufuaji, Y; Zhou, XH, 2015)
"Ivabradine is an effective treatment for angina in patients with stable coronary artery disease (CAD) and for heart failure. "	( Agricola, E; Camici, PG; Maranta, F; Margonato, A; Rimoldi, O; Tondi, L, 2015)
"Ivabradine is a recent treatment option for heart failure."	( Pereira-Barretto, AC, 2015)
"Ivabradine is a novel If-channel antagonist that controls heart rate and may be helpful in treating patients with left ventricular dysfunction (LVD) who are unable to tolerate β-blockers or achieve a heart rate of 70 beats/min with standard therapy. "	( Cammarano, C; Comee, M; Donovan, JL; Malloy, MJ; Silva, M, 2016)
"Ivabradine is a newly approved medication which reduces the heart rate by antagonizing the If channel. "	( Maskell, K; Troendle, M; Tse, A; Wolf, CE, 2016)
"Ivabradine is a promising therapy in HFrEF based on the results of the SHIFT, but it is an adjunctive therapy, not a substitute for drugs with proven mortality benefits."	( Nguyen, E; Weeda, ER; White, CM, 2016)
"Ivabradine is a selective If channel blocker and acts by reducing firing rate of pacemaker cells in the sinoatrial node, without affecting the duration of action potential."	( Cacciapuoti, F, 2016)
"Ivabradine is a well-tolerated, safe and effective treatment option with the objective to improve prognosis, left ventricular structure and function, exercise tolerance and quality of life."	( De Denus, S; Elzir, L; Henri, C; O'Meara, E; Tardif, JC, 2016)
"Ivabradine is a novel sinus node If 'funny current' inhibitor, which reduces the HR."	( Abed, HS; Fulcher, JR; Keech, AC; Kilborn, MJ, 2016)
"Ivabradine is a heart rate-lowering agent approved to reduce the risk of hospitalization for worsening heart failure. "	( Cowie, MR; Kansal, AR; Kielhorn, A; Krotneva, S; Tafazzoli, A; Yurgin, N; Zheng, Y, 2016)
"Ivabradine is a safe and effective medication for HR reduction to reduce hospitalizations in patients with stable, symptomatic HF (ejection fraction < 35%), in sinus rhythm, and HR > 70 bpm."	( Bobadilla, RV; Foster, JL, 2016)
"Ivabradine is a unique medication recently approved in the USA for the treatment of select heart failure patients. "	( Bolorunduro, OB; Jha, SK; Oliphant, CS; Owens, RE, 2016)
"Ivabradine is a blocker of the funny current channels in the sinoatrial node cells. "	( Komajda, M, 2017)
"Ivabradine is a heart rate reducing agent that exhibits anti-ischemic effects through the inhibition of funny electrical current in the sinus node resulting in heart rate reduction, thus enabling longer diastolic perfusion time, and reduced myocardial oxygen consumption without detrimental changes in arterial blood pressure, coronary vasomotion, and ventricular contractility. "	( Borovac, JA; Camici, PG; Crea, F; Niccoli, G; Vetrugno, V, 2017)
"Ivabradine is an inhibitor of mixed Na"	( Bögeholz, N; Dechering, DG; Eckardt, L; Ellermann, C; Fehr, M; Frommeyer, G; Kochhäuser, S; Pott, C; Sterneberg, M, 2017)
"Ivabradine is a selective heart rate-lowering agent that acts by inhibiting the pacemaker current If in sinoatrial node cells. "	( Ferrari, R; Ford, I; Fox, K; Steg, PG; Tendera, M, 2008)
"Ivabradine is a new selective HR-lowering agent that selectively inhibits the pacemaker current I (f) in the sinus atrial node."	( D'Orazio, N; Riccioni, G; Vitulano, N, 2009)
"Ivabradine is a novel pure heart rate-lowering agent that selectively and specifically inhibits pacemaker I(f) current. "	( Lévy, S; Macher, JP, 2009)
"Ivabradine is a new efficient and safe therapeutic option in the treatment of coronary artery disease."	( Mach, F, 2009)
"Ivabradine is a specific heart rate-lowering antianginal agent that was evaluated in a clinical development program involving approximately 3,000 patients with stable coronary artery disease, most with angina pectoris. "	( Borer, JS; Tardif, JC, 2010)
"Ivabradine (IVA) is a novel, specific, heart rate (HR)-lowering agent that acts in sinoatrial node (SAN) cells by selectively inhibiting the pacemaker If current in a dose-dependent manner by slowing the diastolic depolarization slope of SAN cells, and reducing HR at rest and during exercise with minimal effect on myocardial contractility, blood pressure, and intracardiac conduction. "	( Riccioni, G, 2010)
"Ivabradine is a pure heart-rate-lowering agent with well-documented antianginal and anti-ischemic properties comparable to well-established anti-anginal agents."	( Riccioni, G, 2011)
"Ivabradine is a selective I(f) current inhibitor in the sinus node that decreases heart rate without negative inotropic effects. "	( Feola, M; Lombardo, E; Menditto, E; Nervo, E; Piccolo, S; Taglieri, C, 2010)
"Ivabradine is a novel heart rate-lowering agent that selectively and specifically inhibits the depolarizing cardiac pacemaker If current in the sinus node. "	( Bâldea, I; Leucuta, SE; Muntean, D; Neag, M; Popa, A; Vlase, L, 2011)
"Ivabradine is a safe and effective drug in reducing resting heart rate, improving NYHA functional class without undesirable effects on conduction parameters or ectopic activity."	( Alabd, A; Gamal, A; Rayan, M; Tawfik, M, 2011)
"Ivabradine is a novel, heart rate-lowering drug which inhibits the pacemaker (I(f)) current in the heart with high selectivity and with minimal effect on haemodynamic parameters."	( Baczkó, I; Cerbai, E; Gy Papp, J; Jaeger, K; Koncz, I; Romanelli, MN; Szél, T; Varró, A, 2011)
"Ivabradine is a novel antianginal agent which inhibits the pacemaker current. "	( Baczkó, I; Bitay, M; Cerbai, E; Fülöp, F; Jaeger, K; Jost, N; Koncz, I; Kristóf, A; Orvos, P; Papp, JG; Szél, T; Tálosi, L; Varró, A; Virág, L, 2011)
"Ivabradine is a novel heart rate decreasing agent with selective and specific antagonist effects on the pacemaker current (I(f)). "	( Chen, SA; Chen, YC; Chen, YJ; Cheng, CC; Kihara, Y; Lin, YK; Nakano, Y; Suenari, K, 2012)
"Ivabradine is a selective HR-lowering agent that exclusively inhibits the I(f) current in sinoatrial node cells without having any effect on cardiac contractility or atrioventricular conduction."	( Dock, W; Mendel, H; Pichler, P; Pichler-Cetin, E; Sochor, H; Syeda, B; Vertesich, M, 2012)
"Ivabradine is a new drug that reduces the firing rate of pacemaker cells in the sinoatrial node through a different mechanism with respect to betablockers."	( Bonadei, I; Bontempi, L; Curnis, A; D'Aloia, A; Dei Cas, L; Del Magro, F; Piovanelli, B; Vizzardi, E, 2011)
"Ivabradine is a selective inhibitor of the hyperpolarisation activated cyclic-nucleotide-gated funny current (If) involved in pacemaker generation and responsiveness of the sino-atrial node (SAN), which result in HR reduction with no other apparent direct cardiovascular effects."	( Franceschelli, S; Riccioni, G; Speranza, L, 2012)
"Ivabradine is a novel heart rate lowering agent that inhibits I(f) ionic current in the sinus node and demonstrates antiischaemic and antianginal activity. "	( Jasińska-Stroschein, M; Orszulak-Michalak, D; Owczarek, J, 2012)
"Ivabradine is a new agent inhibiting sinus node I(f) current, resulting in a decrease of HR without haemodynamic compromise."	( Kaczmarek, K; Klingenheben, T; Ptaszynski, P; Ruta, J; Wranicz, JK, 2013)
"Ivabradine is a selective inhibitor of the I(f) current, which primarily contributes to sinus node pacemaker activity, and has no significant direct cardiovascular effects such as reduction of blood pressure, cardiac contractility or impairment of cardiac conduction."	( Adile, KK; Garg, N; Goel, PK; Gupta, A; Jain, SK; Kapoor, A; Kumar, S; Tewari, S, 2012)
"Ivabradine is a potentially attractive alternative to currently used drugs for reduction of heart rate in patients undergoing CTCA."	( Adile, KK; Garg, N; Goel, PK; Gupta, A; Jain, SK; Kapoor, A; Kumar, S; Tewari, S, 2012)
"Ivabradine is a new selective antagonist of funny channels."	( De Santis, V; Magliocca, A; Nencini, C; Porto, AG; Santoro, A; Tritapepe, L; Vitale, D, 2013)
"Ivabradine is a new heart rate (HR)-decreasing agent inhibiting sinus node If current."	( Kaczmarek, K; Klingenheben, T; Ptaszynski, P; Ruta, J; Wranicz, JK, 2013)
"Ivabradine is an effective treatment option to reduce HR and symptoms in patients with IST after RF ablation of atrioventricular node slow pathway. "	( Kaczmarek, K; Klingenheben, T; Ptaszynski, P; Ruta, J; Wranicz, JK, 2013)
"Ivabradine is a specific blocker of the pacemaker current (I(f)) used to decrease the sinus rate. "	( Adler, A; Meir, I; Rosso, R; Viskin, S, 2013)
"Ivabradine (IVA) is a novel specific HR-lowering agent that acts in sinus atrial node (SAN) cells by selectively inhibiting the pacemaker I(f) current in a dose-dependent manner by slowing the diastolic depolarization slope of SAN cells, and by reducing HR at rest during exercise in humans."	( Riccioni, G, 2012)
"Ivabradine (Procoralan®) is a pure heart rate-lowering drug that produces selective and specific inhibition of the cardiac pacemaker funny current (I(f)) in the sinus node that regulates heart rate. "	( Perry, CM, 2012)
"Ivabradine is a specific heart rate-reducing agent approved as a treatment of chronic stable angina. "	( Barbuti, A; Baruscotti, M; Bolognesi, M; Bucchi, A; DiFrancesco, D; Micheloni, S; Nardini, M, 2013)
"Ivabradine is a new antiarrhythmic agent with direct inhibition of the pacemaker (If) current. "	( Al-Fayyadh, MI; Al-Ghamdi, S; Hamilton, RM, 2013)
"Ivabradine is a new bradycardic agent with a potential indication for stable angina pectoris. "	( Boissel, JP; Chabaud, S; Girard, P; Nony, P, 2002)
"Ivabradine is a heart rate-lowering agent that selectively inhibits the pacemaker current, I(f), in the sinoatrial node. "	( Camm, AJ; Lau, CP, 2003)
"Ivabradine (Procoralan) is a selective and specific I(f) inhibitor that acts on one of the most important ionic currents for the regulation of the pacemaker activity of sinoatrial node cells."	( Diaz, A; Tardif, JC, 2006)
"Ivabradine is a novel heart-rate-lowering agent that acts specifically on the sinoatrial node by selectively inhibiting the I(f) current, which is the current predominantly responsible for the slow diastolic depolarization of pacemaker cells. "	( Camm, AJ; Savelieva, I, 2006)
"Ivabradine is a new specific HR-reducing agent, which has been shown to have antianginal and anti-ischemic properties in patients with stable angina."	( Ferrari, R; Ford, I; Fox, K; Steg, PG; Tendera, M, 2006)
"Ivabradine is a novel selective and specific I(f) inhibitor in the sinus node that reduces heart rate without any negative inotropic effect."	( Bois, P; El Chemaly, A; Guinamard, R; Jayle, C; Magaud, C; Patri, S, 2007)
"Ivabradine is a selective inhibitor of the If currents of the sinoatrial node cells."	( Andrikopoulos, G; Dasopoulou, C; Kappos, K; Koulouris, S; Kranidis, A; Manolis, AS; Sakellariou, D; Tzeis, S, 2006)
"Ivabradine is a specific heart rate-lowering agent that acts via I(f) pacemaker channels in the sinoatrial node with no beta-adrenoreceptor activity."	( Babu, KS; Gadzik, F; Holgate, ST, 2008)
"Ivabradine (S-16257) is a new bradycardic agent with a direct effect on the sinus node. "	( Funck-Brentano, C; Jaillon, P; Jochemsen, R; Laveille, C; Ragueneau, I; Resplandy, G, 1998)
"Ivabradine is a novel bradycardic agent that has been developed for the prevention of angina. "	( Aarons, L; Duffull, SB, 2000)
"Ivabradine is a novel bradycardic agent that has been developed for the prevention of angina. "	( Aarons, L; Chabaud, S; Duffull, SB; Girard, P; Laveille, C; Nony, P, 2000)
"Ivabradine is an open-channel blocker; however, block is exerted preferentially when channels deactivate on depolarization, and is relieved by long hyperpolarizing steps."	( Baruscotti, M; Bucchi, A; DiFrancesco, D, 2002)

Effects

Excerpt	Reference
"Ivabradine also has a beneficial effect on hospital admissions (-26 %, p < 0.0001), which is clinically relevant since a quarter of HF patients can expect to be readmitted to hospital for HF within 1 month of discharge."	( Pereira-Barretto, AC, 2016)
"Ivabradine has an active metabolite S-18982."	( Aarons, L; Duffull, SB, 2000)
"Ivabradine has an active metabolite S-18982."	( Aarons, L; Chabaud, S; Duffull, SB; Girard, P; Laveille, C; Nony, P, 2000)
"Ivabradine has potent actions in reducing heart rate and improving clinical outcomes of chronic heart failure with reduced ejection fraction (HFrEF). "	( Cui, D; Li, J; Liu, G; Liu, K; Lou, D; Lu, S; Ma, S; Pang, X; Wang, J; Wang, X; Wu, S; Xie, X; Xue, L; Yang, Z; Ye, F; Yu, H; Zhang, Y; Zhong, M, 2022)
"Ivabradine has been shown to improve heart failure with sinus tachycardia by reducing the heart rate without affecting left ventricular systolic function or blood pressure. "	( Bekki, M; Chibana, H; Fukumoto, Y; Honda, A; Itaya, N; Nohara, S; Sato, H; Shibao, K; Shibata, R; Takahashi, J, 2023)
"Ivabradine has potential in the treatment of ventricular arrhythmias in heart failure patients with reduced ejection fraction patients."	( Çetin, T; Çınar, T; Çinier, G; Eren, S; Hayıroğlu, Mİ; Keskin, K; Pay, L; Tekkeşin, Aİ; Tezen, O; Yumurtaş, AÇ, 2023)
"Ivabradine has been approved in heart failure with reduced ejection fraction (HFrEF) and elevated heart rate despite guideline-directed medical therapy (GDMT) to reduce cardiovascular (CV) death and hospitalization for worsening HF. "	( Bernier, V; Bohm, M; Borer, JS; Bouabdallaoui, N; Ford, I; Komajda, M; O'Meara, E; Swedberg, K; Tardif, JC; Tavazzi, L, 2019)
"Oral ivabradine has the potential to be used as an adjunct to amiodarone in the treatment of JET in infants after surgery for congenital heart disease."	( Joshi, S; Kumar, G; Kumar, V; Ramamurthy, R; Sharma, V; Tiwari, N, 2019)
"Ivabradine has been reported to be efficacious in an adult with paroxysmal atrial fibrillation as well as in children with junctional or ectopic atrial tachycardias."	( Cohen, JA; Cohen, MI; Collazo, L; Shope, C; Stollar, L, 2020)
"Ivabradine has no negative effect on inotropic contractility, conductivity, and systemic vascular resistance."	( Fang, H; Shen, Z; Wang, L; Zhang, Y; Zhou, Z, 2020)
"Ivabradine has been approved for the treatment of chronic heart failure and chronic stable angina pectoris in Europe. "	( Beck, E; Dathe, K; Hoeltzenbein, M; Lehmann, ML; Schaefer, C, 2021)
"Ivabradine has been used in patients who have chronic heart failure (HF) with reduced ejection fraction (HFrEF) and concomitant sinus heart rate ≥70 bpm. "	( Chang, HY; Chiou, WR; Chung, FP; Hsu, CY; Huang, JL; Lee, YH; Liang, HW; Liao, CT; Lin, PL; Lin, WY, 2021)
"Ivabradine has shown promising efficacy, but has not been evaluated in children."	( Berger, F; Bonnet, D; Daubeney, PEF; Jokinen, E; Kantor, PF, 2017)
"Ivabradine has recently been demonstrated to have antiarrhythmic properties in atrial fibrillation. "	( Dechering, DG; Eckardt, L; Ellermann, C; Frommeyer, G; Kochhäuser, S; Lange, PS; Leitz, P; Weller, J, 2019)
"Ivabradine has been successfully used in some patients."	( Benezet-Mazuecos, J; Farré, J; Macía, E; Quiñones, MÁ; Rubio, JM; Sanchez-Borque, P, 2013)
"Ivabradine has demonstrated efficacy in reducing rehospitalizations and mortality in heart failure and in improving exercise tolerance and reducing angina attacks in patients with coronary artery disease, whereas selective heart rate reduction may also prove to be beneficial in therapeutic areas outside those in which ivabradine has already demonstrated clinical efficacy."	( Böhm, M; Borer, JS; Deedwania, P; Kim, JB; Reil, JC, 2015)
"Ivabradine that has been introduced in medical practice in last decade is a pure heart rate-slowing agent."	( Gvishiani, M; Isakadze, A; Makharadze, T, 2015)
"Ivabradine has opened up new possibilities for treating stable angina and chronic heart failure by lowering heart rate. "	( Chmelarova, A; Fedacko, J; Jackova, L; Janicko, M; Jedlickova, L; Majernik, J; Merkovska, L; Novakova, B; Pella, D, 2015)
"Ivabradine, a new agent has been added to the current medical options for managing heart failure."	( Chaudhary, R; Freudenberger, R; Garg, J; Krishnamoorthy, P; Lanier, G; Martinez, MW; Shah, N, 2016)
"Ivabradine also has a beneficial effect on hospital admissions (-26 %, p < 0.0001), which is clinically relevant since a quarter of HF patients can expect to be readmitted to hospital for HF within 1 month of discharge."	( Pereira-Barretto, AC, 2016)
"Ivabradine has been approved as a heart rate-lowering agent for use in the treatment of chronic stable angina pectoris in case of contraindication or intolerance to beta-blockers. "	( Stieber, J, 2008)
"Ivabradine has been shown to have antianginal and anti-ischaemic properties in patients with stable angina pectoris."	( Lévy, S; Macher, JP, 2009)
"Ivabradine has been shown to be effective in reducing sinus rate. "	( Bohora, S; Lokhandwala, Y; Parekh, P; Vasavda, A, 2011)
"Ivabradine has recently been recognized as a pure heart-rate-reducing agent and is being extensively studied."	( Bhargava, B; Parakh, N, 2011)
"Ivabradine has anti-ischemic and antianginal efficacy equivalent to that of β-blockers and calcium channel antagonists in the treatment of chronic stable angina pectoris."	( Riccioni, G, 2011)
"Ivabradine has anti-ischemic and antianginal efficacy in monotherapy, as well as in combination with other antianginals, such as beta-blockers, and is safe and well tolerated."	( Canet, E; Lerebours, G; Vilaine, JP, 2011)
"Ivabradine has not been reported to improve cardiac involvement in Becker muscular dystrophy (BMD)."	( Berger, E; Finsterer, J; Stöllberger, C, 2012)
"Ivabradine (Iva) has shown beneficial structural and functional effects in clinical and experimental heart failure (HF), but its action in combination with mechanical unloading (MU), such as during treatment with left ventricular assist devices (LVAD), is unknown. "	( Dias, P; Gandhi, A; Ibrahim, M; Navaratnarajah, M; Sarathchandra, P; Shah, A; Siedlecka, U; Terracciano, CM; van Doorn, C; Yacoub, MH, 2013)
"Ivabradine has shown anti-ischaemic and anti-anginal activity in a placebo-controlled trial."	( Bourassa, MG; Ford, I; Fox, K; Tardif, JC; Tendera, M, 2005)
"Ivabradine has no negative inotropic or lusitropic effects, preserving ventricular contractility, and does not change any major electrophysiological parameters unrelated to heart rate."	( Sulfi, S; Timmis, AD, 2006)
"Ivabradine has been shown to reduce heart rate, preserve myocardial contractility, increase diastolic filling and maintain both small and large coronary artery vasodilation, whatever the level of exercise, thus ensuring adequate endocardial blood perfusion during exercise."	( Cargnoni, A; Ceconi, C; Ferrari, R; Stavroula, G, 2006)
"Ivabradine has demonstrated dosedependent anti-ischemic and antianginal effects in a placebo-controlled study."	( Diaz, A; Tardif, JC, 2006)
"Ivabradine has little effect on the atrioventricular node and ventricular refractoriness, but because of its effect on the sinus node, it should be avoided in patients with sick sinus syndrome."	( Camm, AJ; Savelieva, I, 2006)
"Ivabradine has been recently approved for the treatment of stable angina."	( Babu, KS; Gadzik, F; Holgate, ST, 2008)
"Ivabradine has proven therapeutic efficacy for cardiac ischaemia and, until proved otherwise, is a very specific inhibitor of the cardiac sinoatrial node I(f) current. "	( Triggle, CR, 2008)
"Ivabradine has an active metabolite S-18982."	( Aarons, L; Duffull, SB, 2000)
"Ivabradine has an active metabolite S-18982."	( Aarons, L; Chabaud, S; Duffull, SB; Girard, P; Laveille, C; Nony, P, 2000)

Actions

Excerpt	Reference
"Ivabradine seemed to increase quality of life on the Kansas City Cardiomyopathy Questionnaire (KCCQ) (mean difference (MD)=2.92; 95% CI 1.34 to 4.50; p=0.0003; low certainty of evidence), but the effect size was small and possibly without relevance to patients, and on the Minnesota Living With Heart Failure Questionnaire (MLWHFQ) (MD=-5.28; 95% CI -6.60 to -3.96; p<0.00001; very low certainty of evidence), but the effects were uncertain."	( Gluud, C; Jakobsen, JC; Liang, N; Maagaard, M; Nielsen, EE; Sethi, NJ; Yang, SH, 2022)
"Ivabradine seems to increase the risk of atrial fibrillation, bradycardia and non-serious adverse events.PROSPERO registration number: CRD42018112082."	( Gluud, C; Jakobsen, JC; Liang, N; Maagaard, M; Nielsen, EE; Sethi, NJ; Yang, SH, 2022)
"Ivabradine seemed to increase the risk of serious adverse events after removal of outliers (RR 1.07; 95% CI 1.03 to 1.11) as well as the following adverse events classified as serious: bradycardia, prolonged QT interval, photopsia, atrial fibrillation and hypertension."	( Gluud, C; Jakobsen, JC; Maagaard, M; Nielsen, EE; Ning, L; Sethi, NJ; Yang, SH, 2020)
"Ivabradine did not increase the prevalence of bradycardia in patients with LBBB."	( Böhm, M; Borer, J; Ford, I; Komajda, M; Reil, JC; Robertson, M; Swedberg, K; Tavazzi, L, 2013)
"The ivabradine-induced increase in A-H interval was inversely correlated with VR (r = -0.85, P = .03, at 130 bpm; r = -0.95, P = .003, at 180 bpm)."	( Batatinha, JA; Belardinelli, L; Bonatti, R; Liu, G; Nearing, BD; Rajamani, S; Silva, AF; Verrier, RL; Zeng, D, 2014)
"Ivabradine did not increase serious adverse drug reactions (OR, 0.99 [95% CI, 0.88-1.13]; P = 0.93) or cardiac disorders (OR, 1.03 [95% CI, 0.87-1.22]; P = 0.74)."	( Cammarano, C; Comee, M; Donovan, JL; Malloy, MJ; Silva, M, 2016)
"Ivabradine induced an increase of aAPD (+9ms) and aERP (+30ms, p<0.05) leading to a marked increase of atrial post-repolarization refractoriness (aPRR), defined as the difference of aERP and aAPD (+21ms, p<0.05)."	( Bögeholz, N; Dechering, DG; Eckardt, L; Ellermann, C; Fehr, M; Frommeyer, G; Kochhäuser, S; Pott, C; Sterneberg, M, 2017)

Treatment

Excerpt	Reference
"Ivabradine treatment was associated with an increased risk of HF hospitalization in symptomatic HFrEF patients with a history of paroxysmal AF. "	( Chang, JJ; Chen, MC; Jan, JY; Lin, MS; Lin, YS; Wang, PC; Yang, TY, 2022)
"Ivabradine treatment resulted in significant reduction in resting heart rate, average 24hECG heart rate, improvement in exercise capacity and reduction of symptoms in both subgroups."	( Cygankiewicz, I; Kaczmarek, K; Klingenheben, T; Poddebska, I; Ptaszyński, P; Urbanek, I; Wranicz, JK, 2020)
"Ivabradine treatment had a more significant benefit on improving haemodynamic stability, whereas sacubitril/valsartan treatment showed a more significant effect on improving LVEF."	( Chang, HY; Chiou, WR; Chung, FP; Hsu, CY; Huang, JL; Lee, YH; Liang, HW; Liao, CT; Lin, PL; Lin, WY, 2021)
"Ivabradine treatment improved left ventricular ejection fraction, and clinical status and QOL showed favorable trends."	( Berger, F; Bonnet, D; Daubeney, PEF; Jokinen, E; Kantor, PF, 2017)
"Ivabradine treatment resulted in occurrence of EAD and polymorphic VT in 9 of 12 sotalol-treated hearts (212 episodes), and 8 of 12 veratridine-treated hearts (155 episodes)."	( Dechering, DG; Eckardt, L; Ellermann, C; Frommeyer, G; Kochhäuser, S; Lange, PS; Leitz, P; Weller, J, 2019)
"Ivabradine treatment produced dose-dependent reductions in heart rate at rest and at peak exercise (91.9 ± 6.3 to 71.7 ± 4.8 and 114.4 ± 7.6 to 96.8 ± 4.8; P = 0.001 and P = 0.001, respectively). "	( Akpek, M; Ates, I; Cetinkaya, R; Doğru, M; Genç, A; Kaya, MG; Keser, A; Sarıkaya, M; Ulucan, Ş; Yavuz, AH, 2013)
"Ivabradine treatment prevents dobutamine-induced increase in HR and may be useful in reducing HR-related adverse effects of dobutamine."	( Cavusoglu, Y; Mert, U; Morrad, B; Mutlu, F; Nadir, A; Ulus, T, 2015)
"Ivabradine treatment was associated with a relative risk of AF of 1.15 (95% CI 1.07 to 1.24, p=0.0027) among 21 571 patients in the meta-analysis."	( Bourke, JP; Keavney, BD; Koref, MS; Martin, RI; Pogoryelova, O; Teare, MD, 2014)
"Ivabradine treatment was initiated according to the latest HF guidelines."	( Balta, S; Cuglan, B; Gozubuyuk, G; Kaplan, O; Karakus, Y; Kurtoglu, E; Yasar, E, 2014)
"Ivabradine-treated patients had a lower HR, and improved left ventricular dimensions and systolic function, versus placebo-treated ones (p < 0.05 for all)."	( Abdel-Barr, MG; Abdel-Salam, Z; Hussain, M; Nammas, W; Rayan, M; Saleh, A, 2015)
"Ivabradine treatment led to a significant improvement in cardiac function."	( Chen, SL; Hu, ZY; Li, B; Li, MH; Zuo, GF, 2014)
"Ivabradine is a recent treatment option for heart failure."	( Pereira-Barretto, AC, 2015)
"Ivabradine-treated patients are also at significantly lower risk of experiencing a second or third hospitalization for worsening HF."	( Pereira-Barretto, AC, 2016)
"Ivabradine treatment on top of metoprolol decreases angina symptoms and improves QoL in patients with stable angina and coronary artery disease (CAD)."	( Kallistratos, M; Katsivas, A; Zarifis, J, 2016)
"Ivabradine treatment was not associated with adverse effects on glucose metabolism."	( Borer, JS; Tardif, JC, 2010)
"Ivabradine treatment significantly improves hyperaemic coronary flow velocity and CFR in patients with stable CAD. "	( Chlouverakis, G; Hamilos, MI; Skalidis, EI; Vardas, PE; Zacharis, EA, 2011)
"Ivabradine (0.6 mg/kg) treatment reduced the MDA levels and elevated the SOD and CAT enzyme activity."	( Acet, A; Beytur, A; Binbay, M; Gunaydin, MO; Parlakpinar, H; Polat, A; Sarihan, ME, 2012)
"Ivabradine treatment was discontinued in three patients due to adverse events within the first week."	( Bara, C; Bobylev, D; Haverich, A; Stiefel, P; Zhang, R, 2012)
"Ivabradine-treated patients evidenced lower risk for a second or third additional HF hospitalization [hazard ratio (HR): 0.66, 95% CI, 0.55-0.79, P < 0.001 and HR: 0.71, 95% CI, 0.54-0.93, P = 0.012, respectively]."	( Alings, M; Böhm, M; Borer, JS; Ford, I; Komajda, M; Lopez-de-Sa, E; Sendon, JL; Swedberg, K; Tavazzi, L, 2012)
"Treatment with ivabradine for 6 months effectively reduced HR and improved functional class and QoL in Chinese patients with chronic HF. "	( Baopeng, T; Caizhen, Q; Huiyuan, H; Jingmin, Z; Junbo, G; Wenhui, D; Yamei, X; Yuhui, Z, 2022)
"Treatment with ivabradine should not be deferred in patients in sinus rhythm with a HR of ≥70 bpm to reduce the primary outcome and HF hospitalizations, in particular in patients with HR ≥75 bpm. "	( Abdin, A; Batailler, C; Böhm, M; Borer, J; Ford, I; Komajda, M; Mahfoud, F; Slawik, J; Swedberg, K; Tavazzi, L, 2023)
"Treatment with ivabradine became a new therapeutic alternative for patients with inappropriate sinus tachycardia (IST). "	( Cygankiewicz, I; Kaczmarek, K; Klingenheben, T; Poddebska, I; Ptaszyński, P; Urbanek, I; Wranicz, JK, 2020)
"Treatment with ivabradine in patients within 2 years after HTX significantly reduced post-transplant heart rate and LV mass and was associated with a superior survival in comparison with patients receiving metoprolol succinate."	( Bruckner, T; Darche, FF; Doesch, AO; Ehlermann, P; Helmschrott, M; Katus, HA; Rahm, AK; Rivinius, R; Ruhparwar, A; Thomas, D, 2018)
"Pre-treatment with ivabradine (10 μM) significantly attenuated the contractile response to CCh (1 μM; mean peak amplitude from 1493 ±216 mg to 680 ±95 mg; p < 0.003; n = 7)."	( Ayar, A; Aydin, HR; Eren, H; Kalkan, ÖF; Kurt, A; Sahan, R; Turgut, H, 2018)
"Treatment with ivabradine in experimental models of LQT2 and LQT3 increases proarrhythmia."	( Dechering, DG; Eckardt, L; Ellermann, C; Frommeyer, G; Kochhäuser, S; Lange, PS; Leitz, P; Weller, J, 2019)
"Treatment with ivabradine significantly lowered the HR (174 ± 20 vs. "	( Chang, CC; Chuang, CL; Hsin, IF; Hsu, SJ; Huang, HC; Lee, FY; Lee, SD; Lee, WS, 2019)
"Treatment with ivabradine was associated with a 13% relative risk reduction for the composite of cardiovascular mortality or HF hospitalization (P < 0.001 vs."	( Böhm, M; Borer, JS; Ferrari, R; Ford, I; Fox, K; Komajda, M; Robertson, M; Steg, PG; Swedberg, K; Tavazzi, L; Tendera, M, 2013)
"Treatment with ivabradine in severe HF was associated with relative risk reductions indistinguishable from those of less severe disease for the primary end point (16% reduction), all-cause death (22%), cardiovascular death (22%), HF death (37%), and HF hospitalization (17%; all p values for interaction: NS)."	( Böhm, M; Borer, JS; Ford, I; Komajda, M; Robertson, M; Swedberg, K; Tavazzi, L, 2014)
"Treatment with ivabradine was associated with a significant reduction in resting heart rate after 3 weeks versus no change with placebo (-15.8±7.7 versus +0.3±5.8 bpm; P=0.0010)."	( Allée, G; Dillinger, JG; Henry, P; Levy, BI; Logeart, D; Maher, V; Manzo Silberman, S; Vitale, C, 2015)
"Treatment with ivabradine did not affect the primary outcome of change in physical limitation score at 12 months. "	( Chassany, O; Ferrari, R; Ford, I; Fox, K; Steg, PG; Tardif, JC; Tendera, M, 2016)
"Pre-treatment with ivabradine reduced infarct size from 35 +/- 4 (SEM) to 19 +/- 4% of area at risk (AAR)."	( Gres, P; Heusch, G; Schilawa, D; Schulz, R; Skyschally, A; van Caster, P, 2008)
"Treatment with ivabradine, a pure HR-reducing agent, provides an opportunity to assess the effects of selectively lowering HR without altering other aspects of cardiac function."	( Tardif, JC, 2009)
"Treatment with ivabradine significantly reduced heart rate (p<0.01), with no effect on blood pressure. "	( Baumhäkel, M; Böhm, M; Custodis, F; Laufs, U; Schlimmer, N, 2010)
"Treatment with ivabradine (5 mg twice a day) resulted in disappearance of syncopal episodes both during upright position and CSM."	( Aliyev, F; Celiker, C; Türkoğlu, C; Uzunhasan, I, 2010)
"Treatment with ivabradine was associated with a decrease in the primary end-point LVESVI (change from baseline to last value, -1.48 ± 13.00 mL/m(2)) versus an increase with placebo (1.85 ± 10.54 mL/m(2)) (P=0.018)."	( Ceconi, C; Ferrari, R; Ford, I; Fox, K; Freedman, SB; Gueret, P; Hildebrandt, P; McDonagh, T; Parrinello, G; Robertson, M; Steg, PG; Tardif, JC; Tendera, M, 2011)
"Treatment with ivabradine was associated with a decrease in 24-hour heart rate of 6.3 ± 9.5 beats/min at last assessment versus no change with placebo (0.4 ± 7.2 beats/min, p <0.001, between-group difference), with a greater decrease in waking heart rate with ivabradine than during sleep (6.8 ± 10.4 vs 5.2 ± 8.9 beats/min, respectively, at last visit)."	( Ferrari, R; Ford, I; Fox, K; Robertson, M; Steg, PG; Talajic, M; Tardif, JC; Tendera, M, 2011)
"Treatment with ivabradine reduced LVESVI (primary substudy endpoint) vs."	( Böhm, M; Borer, JS; Ford, I; Komajda, M; O'Meara, E; Swedberg, K; Tardif, JC; Tavazzi, L, 2011)
"Treatment with ivabradine resulted in a significant reduction of HR, rate-pressure product, and LV contractile function and a significant increase in LV end-diastolic pressure, LV end-diastolic wall stress, and LV relaxation time constant (tau) in cats with HCM. "	( Bonagura, JD; Li, X; Otoni, CC; Riesen, SC; Schober, KE; Smith, DN, 2012)
"Treatment with ivabradine irreversibly depressed basal firing frequency and markedly attenuated the enhancement effect of EtOH on firing."	( Chen, H; Chen, Y; Fan, X; Huang, C; Song, T; Wu, P; Yang, J, 2012)
"Treatment with ivabradine, on a background of guidelines-based HF therapy, is associated with a substantial reduction in the likelihood of recurrent hospitalizations for worsening HF. "	( Alings, M; Böhm, M; Borer, JS; Ford, I; Komajda, M; Lopez-de-Sa, E; Sendon, JL; Swedberg, K; Tavazzi, L, 2012)
"Treatment with ivabradine significantly reduced HR and LVESD, improved SRcirc, S long and SRlong in the T4 group, and the average I Ca,L density at 0 mV in T4-Iva groups (9.9 ± 1.6 pA/pF) was restored to the control level."	( Cho, KI; Han, J; Kim, BH; Kim, IJ; Kim, JY; Kim, N; Kim, SM, 2013)
"When treated with ivabradine, these parameters of HRV such as square root of the mean of the squared differences between adjacent NN intervals (RMSSD) and HFnu were in the upward tendency, but low frequency normalized unit and low frequency/high frequency were in the opposite tendency."	( Deng, X; Guan, C; Hao, L; Li, G; Li, S; Sun, G; Wang, Y; Zhang, B, 2013)

Role	Description
cardiotonic drug	A drug that has a strengthening effect on the heart or that can increase cardiac output.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
benzazepine	A group of two-ring heterocyclic compounds consisting of a benzene ring fused to an azepine ring.
tertiary amino compound	A compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
carbobicyclic compound	A bicyclic compound in which all the ring atoms are carbon.
aromatic ether	Any ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	39.8107	0.0096	10.5250	35.4813	AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2	Mus musculus (house mouse)	EC50 (µMol)	4.5200	4.5200	4.9850	5.4500	AID515584
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1	Mus musculus (house mouse)	EC50 (µMol)	4.5000	4.5000	4.5000	4.5000	AID515582
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)	EC50 (µMol)	4.2800	4.2800	6.4250	8.5700	AID515585
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
regulation of heart rate	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
sinoatrial node development	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
regulation of membrane depolarization	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
monoatomic cation transport	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
muscle contraction	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
blood circulation	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
sodium ion transmembrane transport	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
regulation of membrane potential	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
regulation of cardiac muscle contraction	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
cellular response to cAMP	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
cellular response to cGMP	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
potassium ion transmembrane transport	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potential	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
SA node cell action potential	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
membrane depolarization during SA node cell action potential	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
sodium ion import across plasma membrane	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
regulation of cardiac muscle cell action potential involved in regulation of contraction	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
potassium ion import across plasma membrane	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
intracellularly cAMP-activated cation channel activity	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
voltage-gated sodium channel activity	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
protein binding	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
cAMP binding	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
identical protein binding	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
voltage-gated potassium channel activity involved in SA node cell action potential depolarization	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
plasma membrane	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
perinuclear region of cytoplasm	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
HCN channel complex	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
axon	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
dendrite	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1346502	Mouse HCN1 (Cyclic nucleotide-regulated channels)	2006	The Journal of physiology, Apr-15, Volume: 572, Issue:Pt 2	Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels.
AID1346533	Mouse HCN2 (Cyclic nucleotide-regulated channels)	2006	Molecular pharmacology, Apr, Volume: 69, Issue:4	Bradycardic and proarrhythmic properties of sinus node inhibitors.
AID1346525	Human HCN1 (Cyclic nucleotide-regulated channels)	2006	Molecular pharmacology, Apr, Volume: 69, Issue:4	Bradycardic and proarrhythmic properties of sinus node inhibitors.
AID1346522	Human HCN3 (Cyclic nucleotide-regulated channels)	2006	Molecular pharmacology, Apr, Volume: 69, Issue:4	Bradycardic and proarrhythmic properties of sinus node inhibitors.
AID1346517	Human HCN4 (Cyclic nucleotide-regulated channels)	2006	Molecular pharmacology, Apr, Volume: 69, Issue:4	Bradycardic and proarrhythmic properties of sinus node inhibitors.
AID515581	Blockade of mouse HCN1 expressed in HEK293 cells at 5 uM at -120 f-current amplitude by patch-clamp electrophysiological assay relative to control	2010	Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18	Design, synthesis, and preliminary biological evaluation of new isoform-selective f-current blockers.
AID406947	Reversal of ischemia-induced ST segment elevation in anesthetized New Zealand white rabbit at 2.5 mg/kg, iv	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	Sodium late current blockers in ischemia reperfusion: is the bullet magic?
AID515585	Blockade of human HCN4 expressed in HEK293 cells at -120 f-current amplitude by patch-clamp electrophysiological assay	2010	Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18	Design, synthesis, and preliminary biological evaluation of new isoform-selective f-current blockers.
AID406943	Effect on heart rate in anesthetized New Zealand white rabbit myocardial ischemia model assessed as beats per minute at 0.16 mg/kg	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	Sodium late current blockers in ischemia reperfusion: is the bullet magic?
AID1391632	Reduction of cardiovascular events in patient with severe chronic heart failure assessed as reduction in heart rate at 7.5 mg, po bid for 14 days	2018	Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9	Next-generation small molecule therapies for heart failure: 2015 and beyond.
AID406944	Effect on heart rate in anesthetized New Zealand white rabbit myocardial ischemia model assessed as beats per minute at 0.63 mg/kg	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	Sodium late current blockers in ischemia reperfusion: is the bullet magic?
AID406942	Effect on heart rate in anesthetized New Zealand white rabbit myocardial ischemia model assessed as beats per minute at 0.04 mg/kg	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	Sodium late current blockers in ischemia reperfusion: is the bullet magic?
AID515584	Blockade of mouse HCN2 expressed in HEK293 cells at -120 f-current amplitude by patch-clamp electrophysiological assay	2010	Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18	Design, synthesis, and preliminary biological evaluation of new isoform-selective f-current blockers.
AID515582	Blockade of mouse HCN1 expressed in HEK293 cells at -120 f-current amplitude by patch-clamp electrophysiological assay	2010	Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18	Design, synthesis, and preliminary biological evaluation of new isoform-selective f-current blockers.
AID1391628	Reduction of cardiovascular events in patient with acute MI and coronary revascularization assessed as reduction in death at 7.5 mg, po bid	2018	Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9	Next-generation small molecule therapies for heart failure: 2015 and beyond.
AID406939	Reversal of ischemia-induced ST segment elevation in iv dosed anesthetized New Zealand white rabbit	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	Sodium late current blockers in ischemia reperfusion: is the bullet magic?
AID1391629	Reduction of cardiovascular events in patient with acute MI and coronary revascularization assessed as reduction in heart rate at 7.5 mg, po bid	2018	Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9	Next-generation small molecule therapies for heart failure: 2015 and beyond.
AID1391631	Reduction of cardiovascular events in patient with severe chronic heart failure assessed as reduction in death at 7.5 mg, po bid for 14 days	2018	Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9	Next-generation small molecule therapies for heart failure: 2015 and beyond.
AID1391627	Reduction of cardiovascular events in patient with coronary artery disease and left ventricular systolic dysfunction assessed as relative risk reduction at 7.5 mg, po bid	2018	Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9	Next-generation small molecule therapies for heart failure: 2015 and beyond.
AID406945	Effect on heart rate in anesthetized New Zealand white rabbit myocardial ischemia model assessed as beats per minute at 2.5 mg/kg	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	Sodium late current blockers in ischemia reperfusion: is the bullet magic?
AID515586	Blockade of HCN in guinea pig spontaneously beating atria assessed as reduction of heart rate measured for 15 mins	2010	Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18	Design, synthesis, and preliminary biological evaluation of new isoform-selective f-current blockers.
AID515583	Blockade of human HCN4 expressed in HEK293 cells at 5 uM at -120 f-current amplitude by patch-clamp electrophysiological assay relative to control	2010	Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18	Design, synthesis, and preliminary biological evaluation of new isoform-selective f-current blockers.
AID1391630	Reduction of cardiovascular events in patient with severe chronic heart failure and left ventricular systolic dysfunction assessed as relative risk reduction at 7.5 mg, po bid for 14 days	2018	Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9	Next-generation small molecule therapies for heart failure: 2015 and beyond.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	11 (1.02)	18.2507
2000's	173 (16.06)	29.6817
2010's	707 (65.65)	24.3611
2020's	186 (17.27)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	197 (17.24%)	5.53%
Reviews	257 (22.48%)	6.00%
Case Studies	100 (8.75%)	4.05%
Observational	24 (2.10%)	0.25%
Other	565 (49.43%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Description	Relationhip Strength	Studies	Trials	Classes	Roles
zatebradine	[no description available]	medium	7	0	benzazepine
cilobradine	[no description available]	medium	3	0
ranolazine	[no description available]	medium	28	0	aromatic amide; monocarboxylic acid amide; monomethoxybenzene; N-alkylpiperazine; secondary alcohol
ranolazine	[no description available]	medium	28	1	aromatic amide; monocarboxylic acid amide; monomethoxybenzene; N-alkylpiperazine; secondary alcohol
tetrodotoxin	[no description available]	medium	1	0
amiodarone	[no description available]	medium	8	1	1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound	cardiovascular drug
trimetazidine	[no description available]	medium	11	0	aromatic amine
cardiovascular agents	[no description available]	medium	388	73
natriuretic peptide, brain	[no description available]	medium	21	11	polypeptide
bisoprolol	[no description available]	medium	24	9	secondary alcohol; secondary amine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
carvedilol	[no description available]	medium	20	7	carbazoles; secondary alcohol; secondary amino compound	alpha-adrenergic antagonist; antihypertensive agent; beta-adrenergic antagonist; cardiovascular drug; vasodilator agent
felodipine	[no description available]	medium	1	0	dichlorobenzene; dihydropyridine; ethyl ester; methyl ester	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
neopterin	[no description available]	medium	1	1
metoprolol	[no description available]	medium	51	13	aromatic ether; propanolamine; secondary alcohol; secondary amino compound	antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; geroprotector; xenobiotic
nitrates	[no description available]	medium	17	3	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species
cesium	[no description available]	medium	3	0	alkali metal atom
aldosterone	[no description available]	medium	2	0	11beta-hydroxy steroid; 18-oxo steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; mineralocorticoid; primary alpha-hydroxy ketone; steroid aldehyde	human metabolite; mouse metabolite
valsartan	[no description available]	medium	31	3	biphenylyltetrazole; monocarboxylic acid amide; monocarboxylic acid	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
sacubitril	[no description available]	medium	1	0	biphenyls
losartan potassium	[no description available]	medium	4	0
fludrocortisone	[no description available]	medium	4	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; fluorinated steroid; mineralocorticoid	adrenergic agent; anti-inflammatory drug
midodrine	[no description available]	medium	3	0	amino acid amide; aromatic ether; secondary alcohol	alpha-adrenergic agonist; prodrug; sympathomimetic agent; vasoconstrictor agent
thioctic acid	[no description available]	medium	1	0	dithiolanes; heterocyclic fatty acid; thia fatty acid	fundamental metabolite; geroprotector
deamino arginine vasopressin	[no description available]	medium	1	0	heterodetic cyclic peptide	diagnostic agent; renal agent; vasopressin receptor agonist
congo red	[no description available]	medium	1	0	bis(azo) compound
scopolamine hydrobromide	[no description available]	medium	1	0
capsaicin	[no description available]	medium	1	1	capsaicinoid	non-narcotic analgesic; TRPV1 agonist; voltage-gated sodium channel blocker
isoproterenol	[no description available]	medium	6	0	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent
atenolol	[no description available]	medium	28	10	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic
digoxin	[no description available]	medium	19	3	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope
pancuronium	[no description available]	medium	1	0	acetate ester; steroid ester	cholinergic antagonist; muscle relaxant; nicotinic antagonist
fentanyl	[no description available]	medium	1	0	anilide; monocarboxylic acid amide; piperidines	adjuvant; anaesthesia adjuvant; anaesthetic; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
verapamil	[no description available]	medium	4	0	aromatic ether; nitrile; polyether; tertiary amino compound
bucindolol	[no description available]	medium	2	0
clonidine	[no description available]	medium	5	0	clonidine; imidazoline
methyldopa	[no description available]	medium	1	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	alpha-adrenergic agonist; antihypertensive agent; hapten; peripheral nervous system drug; sympatholytic agent
cellulose	[no description available]	medium	2	0	glycoside
nicorandil	[no description available]	medium	14	0	nitrate ester; pyridinecarboxamide	potassium channel opener; vasodilator agent
piperidines	[no description available]	medium	3	0
sq-11725	[no description available]	medium	2	0
flecainide	[no description available]	medium	2	0	aromatic ether; monocarboxylic acid amide; organofluorine compound; piperidines	anti-arrhythmia drug
calixarenes	[no description available]	medium	1	0
methane	[no description available]	medium	1	0	alkane; gas molecular entity; mononuclear parent hydride; one-carbon compound	bacterial metabolite; fossil fuel; greenhouse gas
regadenoson	[no description available]	medium	1	0	purine nucleoside
dipyridamole	[no description available]	medium	1	0	piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol	adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent
dobutamine	[no description available]	medium	11	2	catecholamine; secondary amine	beta-adrenergic agonist; cardiotonic drug; sympathomimetic agent
adenosine	[no description available]	medium	1	0	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
atropine	[no description available]	medium	3	0
nitroglycerin	[no description available]	medium	3	0	nitroglycerol	explosive; muscle relaxant; nitric oxide donor; prodrug; tocolytic agent; vasodilator agent; xenobiotic
esmolol	[no description available]	medium	4	0	aromatic ether; ethanolamines; methyl ester; secondary alcohol; secondary amino compound
yohimbine	[no description available]	medium	1	0	methyl 17-hydroxy-20xi-yohimban-16-carboxylate	alpha-adrenergic antagonist; dopamine receptor D2 antagonist; serotonergic antagonist
dexmedetomidine	[no description available]	medium	1	0	medetomidine	alpha-adrenergic agonist; analgesic; non-narcotic analgesic; sedative
ajmaline	[no description available]	medium	1	0
quinidine	[no description available]	medium	1	0	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
mexiletine	[no description available]	medium	1	0	aromatic ether; primary amino compound	anti-arrhythmia drug
periciazine	[no description available]	medium	2	0	hydroxypiperidine; nitrile; phenothiazines	adrenergic antagonist; first generation antipsychotic; sedative
magnesium sulfate	[no description available]	medium	2	0	magnesium salt; metal sulfate; organic magnesium salt	anaesthetic; analgesic; anti-arrhythmia drug; anticonvulsant; calcium channel blocker; cardiovascular drug; fertilizer; tocolytic agent
reserpine	[no description available]	medium	2	0	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic
propylthiouracil	[no description available]	medium	2	0	pyrimidinethione	antidote to paracetamol poisoning; antimetabolite; antioxidant; antithyroid drug; carcinogenic agent; EC 1.14.13.39 (nitric oxide synthase) inhibitor; hormone antagonist
diphenhydramine	[no description available]	medium	2	0	ether; tertiary amino compound	anti-allergic agent; antidyskinesia agent; antiemetic; antiparkinson drug; antipruritic drug; antitussive; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; oneirogen; sedative
propranolol	[no description available]	medium	7	1	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
sildenafil citrate	[no description available]	medium	2	0	citrate salt	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
uk 68798	[no description available]	medium	3	0	aromatic ether; sulfonamide; tertiary amino compound	anti-arrhythmia drug; potassium channel blocker
pimobendan	[no description available]	medium	1	0	benzimidazoles; pyridazinone	cardiotonic drug; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
lignans	[no description available]	medium	1	0
sesamin	[no description available]	medium	1	0	benzodioxoles; furofuran; lignan	antineoplastic agent; neuroprotective agent; plant metabolite
sorbitan monostearate	[no description available]	medium	1	0
phosphatidylcholines	[no description available]	medium	1	0	1,2-diacyl-sn-glycero-3-phosphocholine
galactose	[no description available]	medium	1	0
3-nitropropionic acid	[no description available]	medium	1	0	C-nitro compound	antimycobacterial drug; EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor; mycotoxin; neurotoxin
barium chloride	[no description available]	medium	1	0	barium salt; inorganic chloride	potassium channel blocker
chlorine	[no description available]	medium	3	0	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
hydralazine	[no description available]	medium	6	0	azaarene; hydrazines; ortho-fused heteroarene; phthalazines	antihypertensive agent; vasodilator agent
lamotrigine	[no description available]	medium	1	0	1,2,4-triazines; dichlorobenzene; primary arylamine	anticonvulsant; antidepressant; antimanic drug; calcium channel blocker; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; excitatory amino acid antagonist; geroprotector; non-narcotic analgesic; xenobiotic
lacosamide	[no description available]	medium	1	0	N-acyl-amino acid
pregabalin	[no description available]	medium	1	0	gamma-amino acid	anticonvulsant; calcium channel blocker
topiramate	[no description available]	medium	1	0	cyclic ketal; ketohexose derivative; sulfamate ester	anticonvulsant; sodium channel blocker
D-fructopyranose	[no description available]	medium	1	0	cyclic hemiketal; D-fructose; fructopyranose	sweetening agent
atrial natriuretic factor	[no description available]	medium	3	0	polypeptide
ularitide	[no description available]	medium	2	0
endothelin-1	[no description available]	medium	1	0
homocysteine	[no description available]	medium	1	0	amino acid zwitterion; homocysteine; serine family amino acid	fundamental metabolite; mouse metabolite
glucose, (beta-d)-isomer	[no description available]	medium	2	0	D-glucopyranose	epitope; mouse metabolite
urea	[no description available]	medium	3	0	isourea; monocarboxylic acid amide; one-carbon compound	Daphnia magna metabolite; Escherichia coli metabolite; fertilizer; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
omecamtiv mecarbil	[no description available]	medium	3	0	ureas
empagliflozin	[no description available]	medium	2	0	aromatic ether; C-glycosyl compound; monochlorobenzenes; tetrahydrofuryl ether	hypoglycemic agent; sodium-glucose transport protein subtype 2 inhibitor
thiazoles	[no description available]	medium	3	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
edoxaban	[no description available]	medium	3	0	chloropyridine; monocarboxylic acid amide; tertiary amino compound; thiazolopyridine	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor; platelet aggregation inhibitor
monocrotaline	[no description available]	medium	1	0	pyrrolizidine alkaloid
diltiazem	[no description available]	medium	4	0	5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate	antihypertensive agent; calcium channel blocker; vasodilator agent
ethyl cellulose	[no description available]	medium	1	0	glycoside
isosorbide dinitrate	[no description available]	medium	5	0	glucitol derivative; nitrate ester	nitric oxide donor; vasodilator agent
natriuretic peptide, c-type	[no description available]	medium	1	0
sotalol	[no description available]	medium	2	0	ethanolamines; secondary alcohol; secondary amino compound; sulfonamide	anti-arrhythmia drug; beta-adrenergic antagonist; environmental contaminant; xenobiotic
veratridine	[no description available]	medium	1	0
cj-023,423	[no description available]	medium	1	0
pentylenetetrazole	[no description available]	medium	1	0	organic heterobicyclic compound; organonitrogen heterocyclic compound
pilocarpine	[no description available]	medium	1	0	pilocarpine	antiglaucoma drug
furosemide	[no description available]	medium	2	0	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic
spironolactone	[no description available]	medium	10	1	3-oxo-Delta(4) steroid; oxaspiro compound; steroid lactone; thioester	aldosterone antagonist; antihypertensive agent; diuretic; environmental contaminant; xenobiotic
ng-nitroarginine methyl ester	[no description available]	medium	3	0	alpha-amino acid ester; L-arginine derivative; methyl ester; N-nitro compound	EC 1.14.13.39 (nitric oxide synthase) inhibitor
nifedipine	[no description available]	medium	1	0	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
xenon	[no description available]	medium	1	0	monoatomic xenon; noble gas atom; p-block element atom
sorbitol	[no description available]	medium	1	0	glucitol	cathartic; Escherichia coli metabolite; food humectant; human metabolite; laxative; metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite; sweetening agent
lidocaine	[no description available]	medium	1	0	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic
corticosterone	[no description available]	medium	2	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
lutetium lu 177 dotatate	[no description available]	medium	1	0
bay 63-2521	[no description available]	medium	1	0	aminopyrimidine; carbamate ester; organofluorine compound; pyrazolopyridine	antihypertensive agent; soluble guanylate cyclase activator
ethosuximide	[no description available]	medium	1	0	dicarboximide; pyrrolidinone	anticonvulsant; geroprotector; T-type calcium channel blocker
colforsin	[no description available]	medium	1	0	acetate ester; cyclic ketone; labdane diterpenoid; organic heterotricyclic compound; tertiary alpha-hydroxy ketone; triol	adenylate cyclase agonist; anti-HIV agent; antihypertensive agent; plant metabolite; platelet aggregation inhibitor; protein kinase A agonist
1-methyl-3-isobutylxanthine	[no description available]	medium	1	0	3-isobutyl-1-methylxanthine
zd 7288	[no description available]	medium	7	0
reboxetine	[no description available]	medium	2	1	aromatic ether
perindopril	[no description available]	medium	2	1	alpha-amino acid ester; dicarboxylic acid monoester; ethyl ester; organic heterobicyclic compound	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
dronedarone	[no description available]	medium	3	0	1-benzofurans; aromatic ether; aromatic ketone; sulfonamide; tertiary amino compound	anti-arrhythmia drug; environmental contaminant; xenobiotic
iodixanol	[no description available]	medium	1	0	organoiodine compound	radioopaque medium
mycophenolic acid	[no description available]	medium	1	0	2-benzofurans; gamma-lactone; monocarboxylic acid; phenols	anticoronaviral agent; antimicrobial agent; antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; environmental contaminant; immunosuppressive agent; mycotoxin; Penicillium metabolite; xenobiotic
acetovanillone	[no description available]	medium	1	0	acetophenones; aromatic ketone; methyl ketone	antirheumatic drug; EC 1.6.3.1. [NAD(P)H oxidase (H2O2-forming)] inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug; plant metabolite
ryanodine	[no description available]	medium	3	0
hydroxyzine	[no description available]	medium	1	0	hydroxyether; monochlorobenzenes; N-alkylpiperazine	anticoronaviral agent; antipruritic drug; anxiolytic drug; dermatologic drug; H1-receptor antagonist
incretins	[no description available]	medium	1	0
lisinopril	[no description available]	medium	1	0	dipeptide	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
zithromax	[no description available]	medium	1	0	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic
pyrroles	[no description available]	medium	1	1	pyrrole; secondary amine
atorvastatin	[no description available]	medium	1	1	aromatic amide; dihydroxy monocarboxylic acid; monofluorobenzenes; pyrroles; statin (synthetic)	environmental contaminant; xenobiotic
clopidogrel	[no description available]	medium	2	0	methyl ester; monochlorobenzenes; thienopyridine	anticoagulant; P2Y12 receptor antagonist; platelet aggregation inhibitor
ticlopidine	[no description available]	medium	2	0	monochlorobenzenes; thienopyridine	anticoagulant; fibrin modulating drug; hematologic agent; P2Y12 receptor antagonist; platelet aggregation inhibitor
darapladib	[no description available]	medium	1	0
enalapril	[no description available]	medium	1	0	dicarboxylic acid monoester; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; geroprotector; prodrug
sea 0400	[no description available]	medium	1	0
tetracaine	[no description available]	medium	1	0	benzoate ester; tertiary amino compound	local anaesthetic
caffeine	[no description available]	medium	1	0	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
sulfuric acid	[no description available]	medium	1	0	sulfur oxoacid	catalyst
hydrochloric acid	[no description available]	medium	1	0	chlorine molecular entity; gas molecular entity; hydrogen halide; mononuclear parent hydride	mouse metabolite
isosorbide-5-mononitrate	[no description available]	medium	1	0	glucitol derivative; nitrate ester	nitric oxide donor; vasodilator agent
xylazine	[no description available]	medium	1	0	1,3-thiazine; methylbenzene; secondary amino compound	alpha-adrenergic agonist; analgesic; emetic; muscle relaxant; sedative
ephedrine	[no description available]	medium	1	0	phenethylamine alkaloid; phenylethanolamines	bacterial metabolite; environmental contaminant; nasal decongestant; plant metabolite; sympathomimetic agent; vasoconstrictor agent; xenobiotic
ketamine	[no description available]	medium	1	0	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic
silybin	[no description available]	medium	1	0
loperamide	[no description available]	medium	1	0	monocarboxylic acid amide; monochlorobenzenes; piperidines; tertiary alcohol	anticoronaviral agent; antidiarrhoeal drug; mu-opioid receptor agonist
losartan	[no description available]	medium	1	0	biphenylyltetrazole; imidazoles	angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist
calcium gluconate	[no description available]	medium	1	0	calcium salt	nutraceutical
atazanavir sulfate	[no description available]	medium	2	0	organic sulfate salt
amlodipine	[no description available]	medium	2	1	dihydropyridine; ethyl ester; methyl ester; monochlorobenzenes; primary amino compound	antihypertensive agent; calcium channel blocker; vasodilator agent
liraglutide	[no description available]	medium	1	0	lipopeptide; polypeptide	glucagon-like peptide-1 receptor agonist; neuroprotective agent
cobicistat	[no description available]	medium	1	0	1,3-thiazoles; carbamate ester; monocarboxylic acid amide; morpholines; ureas	P450 inhibitor
simvastatin	[no description available]	medium	2	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; statin (semi-synthetic)	EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; ferroptosis inducer; geroprotector; prodrug
phosphoserine	[no description available]	medium	1	0	non-proteinogenic alpha-amino acid; O-phosphoamino acid; serine derivative	human metabolite
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one	[no description available]	medium	1	0	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
triazoles	[no description available]	medium	1	0	1,2,3-triazole
suvorexant	[no description available]	medium	1	0	1,3-benzoxazoles; aromatic amide; diazepine; organochlorine compound; triazoles	central nervous system depressant; orexin receptor antagonist
naloxegol	[no description available]	medium	1	0	aromatic ether; organic heteropentacyclic compound; phenols; polyether; tertiary alcohol	cathartic; mu-opioid receptor antagonist
morphinans	[no description available]	medium	1	0	isoquinoline alkaloid fundamental parent; morphinane alkaloid
emtricitabine	[no description available]	medium	1	0	monothioacetal; nucleoside analogue; organofluorine compound; pyrimidone	antiviral drug; HIV-1 reverse transcriptase inhibitor
tenofovir	[no description available]	medium	1	0	nucleoside analogue; phosphonic acids	antiviral drug; drug metabolite; HIV-1 reverse transcriptase inhibitor
ritonavir	[no description available]	medium	1	0	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic
cesium chloride	[no description available]	medium	2	0	inorganic caesium salt; inorganic chloride	phase-transfer catalyst; vasoconstrictor agent
aliskiren	[no description available]	medium	2	0	monocarboxylic acid amide; monomethoxybenzene	antihypertensive agent
fumarates	[no description available]	medium	2	0	butenedioate; C4-dicarboxylate	human metabolite; metabolite; Saccharomyces cerevisiae metabolite
acebutolol	[no description available]	medium	1	0	alpha-D-glucosyl-(1->4)-D-mannopyranose
ferric carboxymaltose	[no description available]	medium	1	0
cisapride	[no description available]	medium	1	0	benzamides
melatonin	[no description available]	medium	1	0	acetamides; tryptamines	anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger
captopril	[no description available]	medium	1	0	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
quinapril	[no description available]	medium	1	0	dicarboxylic acid monoester; ethyl ester; isoquinolines; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
perhexiline	[no description available]	medium	1	0	piperidines	cardiovascular drug
fasudil	[no description available]	medium	1	0	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent
1-(5-isoquinolinesulfonyl)-2-methylpiperazine	[no description available]	medium	1	0	isoquinolines; N-sulfonylpiperazine	EC 2.7.11.13 (protein kinase C) inhibitor
bosentan anhydrous	[no description available]	medium	1	0	primary alcohol; pyrimidines; sulfonamide	antihypertensive agent; endothelin receptor antagonist
fluorobenzenes	[no description available]	medium	2	0	monofluorobenzenes	NMR chemical shift reference compound
angiotensin ii	[no description available]	medium	3	0	amino acid zwitterion; angiotensin II	human metabolite
bradykinin	[no description available]	medium	1	0	oligopeptide	human blood serum metabolite; vasodilator agent
benzofurans	[no description available]	medium	1	0
vernakalant	[no description available]	medium	1	0	alcohol; phenols
celivarone	[no description available]	medium	1	0
simendan	[no description available]	medium	1	1
aspirin	[no description available]	medium	1	0	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
pyridostigmine bromide	[no description available]	medium	1	0	pyridinium salt
carbamazepine	[no description available]	medium	1	0	dibenzoazepine; ureas	analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic
eplerenone	[no description available]	medium	3	0	3-oxo-Delta(4) steroid; epoxy steroid; gamma-lactone; methyl ester; organic heteropentacyclic compound; oxaspiro compound; steroid acid ester	aldosterone antagonist; antihypertensive agent
malondialdehyde	[no description available]	medium	1	0	dialdehyde	biomarker
3-hydroxy-3-methylglutaryl-coenzyme a	[no description available]	medium	1	0	3-hydroxy-3-methylglutaryl-CoA; 3-hydroxy fatty acyl-CoA	human metabolite; mouse metabolite
phenytoin	[no description available]	medium	1	1	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent
glycerol	[no description available]	medium	1	0	alditol; triol	algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent
thyroxine	[no description available]	medium	1	0	2-halophenol; iodophenol; L-phenylalanine derivative; non-proteinogenic L-alpha-amino acid; thyroxine zwitterion; thyroxine	antithyroid drug; human metabolite; mouse metabolite; thyroid hormone
falipamil	[no description available]	medium	2	0
alinidine	[no description available]	medium	3	0
arginine	[no description available]	medium	1	0	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
perylene	[no description available]	medium	1	1	ortho- and peri-fused polycyclic arene; perylenes
hypericin	[no description available]	medium	1	1
6 beta-hydroxycortisol	[no description available]	medium	1	1	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; 6beta-hydroxy steroid; C21-steroid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	human metabolite; mammalian metabolite; probe
lansoprazole	[no description available]	medium	1	1	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
omeprazole	[no description available]	medium	1	1	aromatic ether; benzimidazoles; pyridines; sulfoxide
candesartan	[no description available]	medium	1	0	benzimidazolecarboxylic acid; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
niacinamide	[no description available]	medium	1	0	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
rome	[no description available]	medium	1	1	2-amino-2-(methoxymethyl)-4-(4-octylphenyl)butan-1-ol	EC 2.7.1.91 (sphingosine kinase) inhibitor
eye	[no description available]	medium	1	0
hypericum	[no description available]	medium	1	1	penicillanic acids
diazoxide	[no description available]	low	0	0	benzothiadiazine; organochlorine compound; sulfone	antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent
milrinone	[no description available]	low	0	0	bipyridines; nitrile; pyridone	cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; platelet aggregation inhibitor; vasodilator agent
sulmazole	[no description available]	low	0	0	imidazopyridine; sulfoxide	adenosine A1 receptor antagonist; cardiotonic drug; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
carbachol	[no description available]	low	0	0	ammonium salt; carbamate ester	cardiotonic drug; miotic; muscarinic agonist; nicotinic acetylcholine receptor agonist; non-narcotic analgesic
phenylephrine	[no description available]	low	0	0	phenols; phenylethanolamines; secondary amino compound	alpha-adrenergic agonist; cardiotonic drug; mydriatic agent; nasal decongestant; protective agent; sympathomimetic agent; vasoconstrictor agent
aminophylline	[no description available]	low	0	0	mixture	bronchodilator agent; cardiotonic drug
bucladesine	[no description available]	low	0	0	3',5'-cyclic purine nucleotide; butanamides; butyrate ester	agonist; cardiotonic drug; vasodilator agent
deslanoside	[no description available]	low	0	0	12beta-hydroxy steroid; 14beta-hydroxy steroid; cardenolide glycoside; tetrasaccharide derivative	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; metabolite
arbutamine	[no description available]	low	0	0	catecholamine	beta-adrenergic agonist; cardiotonic drug
dobutamine hydrochloride	[no description available]	low	0	0	hydrochloride	beta-adrenergic agonist; cardiotonic drug; sympathomimetic agent
propionylcarnitine	[no description available]	low	0	0	O-acylcarnitine	analgesic; antirheumatic drug; cardiotonic drug; human metabolite; peripheral nervous system drug
ouabain	[no description available]	low	0	0	11alpha-hydroxy steroid; 14beta-hydroxy steroid; 5beta-hydroxy steroid; alpha-L-rhamnoside; cardenolide glycoside; steroid hormone	anti-arrhythmia drug; cardiotonic drug; EC 2.3.3.1 [citrate (Si)-synthase] inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; ion transport inhibitor; plant metabolite
neriifolin	[no description available]	low	0	0	cardenolide glycoside	cardiotonic drug; neuroprotective agent; toxin
solasodine	[no description available]	low	0	0	alkaloid antibiotic; azaspiro compound; hemiaminal ether; oxaspiro compound; sapogenin; steroid alkaloid	anticonvulsant; antifungal agent; antiinfective agent; antioxidant; antipyretic; antispermatogenic agent; apoptosis inducer; cardiotonic drug; central nervous system depressant; diuretic; immunomodulator; plant metabolite; teratogenic agent
colforsin daropate	[no description available]	medium	0	0	acetate ester; carboxylic ester; cyclic ketone; diol; organic heterotricyclic compound; tertiary amino compound	adenylate cyclase agonist; antihypertensive agent; cardiotonic drug; vasodilator agent
or 1259	[no description available]	low	0	0	hydrazone; nitrile; pyridazinone	anti-arrhythmia drug; cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; vasodilator agent
corlanor	[no description available]	low	0	0	hydrochloride	cardiotonic drug
cassaine	[no description available]	medium	0	0	enoate ester; organic hydroxy compound; tertiary amino compound; tricyclic diterpenoid	antihypertensive agent; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; local anaesthetic; plant metabolite; poison
acetyldigitoxin	[no description available]	low	0	0	cardenolide glycoside	anti-arrhythmia drug; cardiotonic drug; enzyme inhibitor
bufalin	[no description available]	low	0	0	14beta-hydroxy steroid; 3beta-hydroxy steroid	animal metabolite; anti-inflammatory agent; antineoplastic agent; cardiotonic drug
sk&f 81297	[no description available]	low	0	0	benzazepine
sk&f 82958	[no description available]	low	0	0	benzazepine
sk&f 77434	[no description available]	low	0	0	benzazepine; catechols; tertiary amino compound	dopamine agonist
sk&f-38393	[no description available]	low	0	0	benzazepine; catechols; secondary amino compound
1h-3-benzazepin-7-ol, 8-bromo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-	[no description available]	low	0	0	benzazepine
epinastine	[no description available]	low	0	0	benzazepine; guanidines	anti-allergic agent; H1-receptor antagonist; histamine antagonist; ophthalmology drug
fenoldopam	[no description available]	low	0	0	benzazepine	alpha-adrenergic agonist; antihypertensive agent; dopamine agonist; dopaminergic antagonist; vasodilator agent
mirtazapine	[no description available]	low	0	0	benzazepine; tetracyclic antidepressant	alpha-adrenergic antagonist; anxiolytic drug; H1-receptor antagonist; histamine antagonist; oneirogen; serotonergic antagonist
7-chloro-3-methyl-1-phenyl-1,2,4,5-tetrahydro-3-benzazepin-8-ol	[no description available]	low	0	0	benzazepine; organochlorine compound; tertiary amino compound	dopaminergic antagonist
azapetine	[no description available]	low	0	0	benzazepine
fluperlapine	[no description available]	low	0	0	benzazepine
fenoldopam mesylate	[no description available]	low	0	0	benzazepine
ecopipam	[no description available]	low	0	0	benzazepine
sk&f 104078	[no description available]	low	0	0	benzazepine
sk&f 86466	[no description available]	low	0	0	benzazepine
nnc 112	[no description available]	low	0	0	benzazepine
sk&f 83959	[no description available]	low	0	0	benzazepine; catechols; organochlorine compound; tertiary amino compound	dopamine agonist
conivaptan	[no description available]	low	0	0	benzazepine	aquaretic; vasopressin receptor antagonist
tolvaptan	[no description available]	low	0	0	benzazepine; benzenedicarboxamide	aquaretic; vasopressin receptor antagonist
sanguinine	[no description available]	low	0	0	benzazepine
lycoramine	[no description available]	low	0	0	benzazepine
7,8-dimethoxy-1,3-dihydro-3-benzazepin-2-one	[no description available]	low	0	0	benzazepine
5-Methyl-8-nitro-3-spirocyclohexyl-2,3,4,5-tetrahydro-1H-2-benzazepine	[no description available]	low	0	0	benzazepine
capsazepine	[no description available]	low	0	0	benzazepine; catechols; monochlorobenzenes; thioureas	capsaicin receptor antagonist
sch 23390	[no description available]	low	0	0	benzazepine
ru 42173	[no description available]	low	0	0	benzazepine
benazepril	[no description available]	low	0	0	benzazepine; dicarboxylic acid monoester; ethyl ester; lactam	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
benazeprilat	[no description available]	low	0	0	benzazepine; dicarboxylic acid; lactam	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
(5R)-9-bromo-5-phenyl-3-prop-2-enyl-1,2,4,5-tetrahydro-3-benzazepine-7,8-diol	[no description available]	low	0	0	benzazepine
demethylmirtazapine	[no description available]	low	0	0	benzazepine; tetracyclic antidepressant	alpha-adrenergic antagonist; anxiolytic drug; H1-receptor antagonist; histamine antagonist; human xenobiotic metabolite; serotonergic antagonist
lorcaserin	[no description available]	low	0	0	benzazepine; organochlorine compound	anti-obesity agent; appetite depressant
mln8054	[no description available]	low	0	0	benzazepine
mln 8237	[no description available]	low	0	0	benzazepine
evacetrapib	[no description available]	low	0	0	benzazepine
quinacrine	[no description available]	low	0	0	acridines; aromatic ether; organochlorine compound; tertiary amino compound	antimalarial; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
8-hydroxy-2-(di-n-propylamino)tetralin	[no description available]	low	0	0	phenols; tertiary amino compound; tetralins	serotonergic antagonist
pd 173074	[no description available]	low	0	0	aromatic amine; biaryl; dimethoxybenzene; pyridopyrimidine; tertiary amino compound; ureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist
ethylisopropylamiloride	[no description available]	low	0	0	aromatic amine; guanidines; monocarboxylic acid amide; organochlorine compound; pyrazines; tertiary amino compound	anti-arrhythmia drug; neuroprotective agent; sodium channel blocker
methylbufotenin	[no description available]	low	0	0	aromatic ether; tertiary amino compound; tryptamine alkaloid	hallucinogen; plant metabolite
ro 48-8071	[no description available]	low	0	0	aromatic ether; aromatic ketone; bromobenzenes; monofluorobenzenes; olefinic compound; tertiary amino compound	antineoplastic agent; EC 5.4.99.7 (lanosterol synthase) inhibitor
amodiaquine	[no description available]	low	0	0	aminoquinoline; organochlorine compound; phenols; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; drug allergen; EC 2.1.1.8 (histamine N-methyltransferase) inhibitor; non-steroidal anti-inflammatory drug; prodrug
antazoline	[no description available]	low	0	0	aromatic amine; imidazolines; tertiary amino compound	cholinergic antagonist; H1-receptor antagonist; xenobiotic
azelastine	[no description available]	low	0	0	monochlorobenzenes; phthalazines; tertiary amino compound	anti-allergic agent; anti-asthmatic drug; bronchodilator agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; H1-receptor antagonist; platelet aggregation inhibitor
benefin	[no description available]	low	0	0	C-nitro compound; organofluorine compound; substituted aniline; tertiary amino compound	agrochemical; herbicide
biperiden	[no description available]	low	0	0	piperidines; tertiary alcohol; tertiary amino compound	antidote to sarin poisoning; antidyskinesia agent; antiparkinson drug; muscarinic antagonist; parasympatholytic
bromhexine	[no description available]	low	0	0	organobromine compound; substituted aniline; tertiary amino compound	mucolytic
bromodiphenhydramine	[no description available]	low	0	0	organobromine compound; tertiary amino compound	antimicrobial agent; H1-receptor antagonist; muscarinic antagonist
bupivacaine	[no description available]	low	0	0	aromatic amide; piperidinecarboxamide; tertiary amino compound
carbinoxamine	[no description available]	low	0	0	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antiparkinson drug; H1-receptor antagonist; muscarinic antagonist
chlorambucil	[no description available]	low	0	0	aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
chloroquine	[no description available]	low	0	0	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
chlorpheniramine	[no description available]	low	0	0	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antidepressant; antipruritic drug; H1-receptor antagonist; histamine antagonist; serotonin uptake inhibitor
citalopram	[no description available]	low	0	0	2-benzofurans; cyclic ether; nitrile; organofluorine compound; tertiary amino compound
clofedanol	[no description available]	low	0	0	diarylmethane; tertiary amino compound	antitussive
cyclopentolate	[no description available]	low	0	0	carboxylic ester; tertiary alcohol; tertiary amino compound	diagnostic agent; muscarinic antagonist; mydriatic agent; parasympatholytic
cycrimine	[no description available]	low	0	0	piperidines; tertiary alcohol; tertiary amino compound	antidyskinesia agent; antiparkinson drug; muscarinic antagonist
dibucaine	[no description available]	low	0	0	aromatic ether; monocarboxylic acid amide; tertiary amino compound	topical anaesthetic
dilacor xr	[no description available]	low	0	0	acetate ester; aromatic ether; benzothiazepine; lactam; tertiary amino compound
disopyramide	[no description available]	low	0	0	monocarboxylic acid amide; pyridines; tertiary amino compound	anti-arrhythmia drug
1-phenyl-2-palmitoylamino-3-morpholino-1-propanol	[no description available]	low	0	0	benzyl alcohols; fatty amide; morpholines; secondary alcohol; tertiary amino compound
doxepin	[no description available]	low	0	0	dibenzooxepine; tertiary amino compound	antidepressant
profenamine	[no description available]	low	0	0	phenothiazines; tertiary amino compound	adrenergic antagonist; antidyskinesia agent; antiparkinson drug; histamine antagonist; muscarinic antagonist
flavoxate	[no description available]	low	0	0	carboxylic ester; flavones; piperidines; tertiary amino compound	antispasmodic drug; muscarinic antagonist; parasympatholytic
flurazepam	[no description available]	low	0	0	1,4-benzodiazepinone; monofluorobenzenes; organochlorine compound; tertiary amino compound	anticonvulsant; anxiolytic drug; GABAA receptor agonist; sedative
vanoxerine	[no description available]	low	0	0	ether; N-alkylpiperazine; organofluorine compound; tertiary amino compound	dopamine uptake inhibitor
gbr 12935	[no description available]	low	0	0	ether; N-alkylpiperazine; tertiary amino compound	dopamine uptake inhibitor
hydroxychloroquine	[no description available]	low	0	0	aminoquinoline; organochlorine compound; primary alcohol; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; dermatologic drug
isothipendyl	[no description available]	low	0	0	aromatic amine; tertiary amino compound
ketotifen	[no description available]	low	0	0	cyclic ketone; olefinic compound; organic heterotricyclic compound; organosulfur heterocyclic compound; piperidines; tertiary amino compound	anti-asthmatic drug; H1-receptor antagonist
lofepramine	[no description available]	low	0	0	aromatic ketone; dibenzoazepine; monochlorobenzenes; tertiary amino compound	antidepressant
4-(dimethylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)benzamide	[no description available]	low	0	0	benzamides; hydroxamic acid; secondary carboxamide; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
meperidine	[no description available]	low	0	0	ethyl ester; piperidinecarboxylate ester; tertiary amino compound	antispasmodic drug; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic
mesoridazine	[no description available]	low	0	0	phenothiazines; sulfoxide; tertiary amino compound	dopaminergic antagonist; first generation antipsychotic
methadone	[no description available]	low	0	0	benzenes; diarylmethane; ketone; tertiary amino compound
methiothepin	[no description available]	low	0	0	aryl sulfide; dibenzothiepine; N-alkylpiperazine; tertiary amino compound	antipsychotic agent; dopaminergic antagonist; geroprotector; serotonergic antagonist
metoclopramide	[no description available]	low	0	0	benzamides; monochlorobenzenes; substituted aniline; tertiary amino compound	antiemetic; dopaminergic antagonist; environmental contaminant; gastrointestinal drug; xenobiotic
minoxidil	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
monodansylcadaverine	[no description available]	low	0	0	aminonaphthalene; primary amino compound; sulfonamide; tertiary amino compound	EC 2.3.2.13 (protein-glutamine gamma-glutamyltransferase) inhibitor; fluorochrome; protective agent
mosapramine	[no description available]	low	0	0	azaspiro compound; dibenzoazepine; organochlorine compound; tertiary amino compound
clorgyline	[no description available]	low	0	0	aromatic ether; dichlorobenzene; terminal acetylenic compound; tertiary amino compound	antidepressant; EC 1.4.3.4 (monoamine oxidase) inhibitor
nefopam	[no description available]	low	0	0	benzoxazocine; tertiary amino compound
nicardipine	[no description available]	low	0	0	benzenes; C-nitro compound; diester; dihydropyridine; methyl ester; tertiary amino compound
nizatidine	[no description available]	low	0	0	1,3-thiazoles; C-nitro compound; carboxamidine; organic sulfide; tertiary amino compound	anti-ulcer drug; cholinergic drug; H2-receptor antagonist
orphenadrine	[no description available]	low	0	0	ether; tertiary amino compound	antidyskinesia agent; antiparkinson drug; H1-receptor antagonist; muscarinic antagonist; muscle relaxant; NMDA receptor antagonist; parasympatholytic
benoxinate	[no description available]	low	0	0	amino acid ester; benzoate ester; substituted aniline; tertiary amino compound	drug allergen; local anaesthetic; topical anaesthetic
oxybutynin	[no description available]	low	0	0	acetylenic compound; carboxylic ester; racemate; tertiary alcohol; tertiary amino compound	antispasmodic drug; calcium channel blocker; local anaesthetic; muscarinic antagonist; muscle relaxant; parasympatholytic
pheniramine	[no description available]	low	0	0	pyridines; tertiary amino compound
pipamperone	[no description available]	low	0	0	aromatic ketone; bipiperidines; monocarboxylic acid amide; organofluorine compound; tertiary amino compound	dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
piromidic acid	[no description available]	low	0	0	monocarboxylic acid; pyridopyrimidine; pyrrolidines; quinolone antibiotic; tertiary amino compound	antibacterial drug; DNA synthesis inhibitor
pj-34	[no description available]	low	0	0	phenanthridines; secondary carboxamide; tertiary amino compound	angiogenesis inhibitor; anti-inflammatory agent; antiatherosclerotic agent; antineoplastic agent; apoptosis inducer; cardioprotective agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; neuroprotective agent
procaine	[no description available]	low	0	0	benzoate ester; substituted aniline; tertiary amino compound	central nervous system depressant; drug allergen; local anaesthetic; peripheral nervous system drug
propiomazine	[no description available]	low	0	0	aromatic ketone; phenothiazines; tertiary amino compound	dopaminergic antagonist; histamine antagonist; muscarinic antagonist; phenothiazine antipsychotic drug; sedative; serotonergic antagonist
psilocin	[no description available]	low	0	0	hydroxyindoles; phenols; tertiary amino compound; tryptamine alkaloid	drug metabolite; fungal metabolite; hallucinogen; human xenobiotic metabolite; serotonergic agonist
setiptiline	[no description available]	low	0	0	tertiary amino compound; tetracyclic antidepressant	alpha-adrenergic antagonist; serotonergic antagonist
sibutramine	[no description available]	low	0	0	organochlorine compound; tertiary amino compound	anti-obesity agent; serotonin uptake inhibitor
spiperone	[no description available]	low	0	0	aromatic ketone; azaspiro compound; organofluorine compound; piperidines; tertiary amino compound	alpha-adrenergic antagonist; antipsychotic agent; dopaminergic antagonist; psychotropic drug; serotonergic antagonist
tilorone	[no description available]	low	0	0	aromatic ether; diether; fluoren-9-ones; tertiary amino compound	anti-inflammatory agent; antineoplastic agent; antiviral agent; interferon inducer; nicotinic acetylcholine receptor agonist
tosufloxacin	[no description available]	low	0	0	1,8-naphthyridine derivative; amino acid; aminopyrrolidine; monocarboxylic acid; organofluorine compound; primary amino compound; quinolone antibiotic; tertiary amino compound
n,n,n',n'-tetrakis(2-pyridylmethyl)ethylenediamine	[no description available]	low	0	0	N-substituted diamine; pyridines; tertiary amino compound	apoptosis inducer; chelator; copper chelator
ultram	[no description available]	low	0	0	aromatic ether; tertiary alcohol; tertiary amino compound
trimethobenzamide	[no description available]	low	0	0	benzamides; tertiary amino compound	antiemetic
trimipramine	[no description available]	low	0	0	dibenzoazepine; tertiary amino compound	antidepressant; environmental contaminant; xenobiotic
venlafaxine	[no description available]	low	0	0	cyclohexanols; monomethoxybenzene; tertiary alcohol; tertiary amino compound	adrenergic uptake inhibitor; analgesic; antidepressant; dopamine uptake inhibitor; environmental contaminant; serotonin uptake inhibitor; xenobiotic
zotepine	[no description available]	low	0	0	dibenzothiepine; tertiary amino compound	alpha-adrenergic drug; second generation antipsychotic; serotonergic drug
phentolamine	[no description available]	low	0	0	imidazoles; phenols; substituted aniline; tertiary amino compound	alpha-adrenergic antagonist; vasodilator agent
vincristine	[no description available]	low	0	0	acetate ester; formamides; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
aminopyrine	[no description available]	low	0	0	pyrazolone; tertiary amino compound	antipyretic; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
tetrabenazine	[no description available]	low	0	0	benzoquinolizine; cyclic ketone; tertiary amino compound
acepromazine	[no description available]	low	0	0	aromatic ketone; methyl ketone; phenothiazines; tertiary amino compound	phenothiazine antipsychotic drug
egtazic acid	[no description available]	low	0	0	diether; tertiary amino compound; tetracarboxylic acid	chelator
gramine	[no description available]	low	0	0	aminoalkylindole; indole alkaloid; tertiary amino compound	antibacterial agent; antiviral agent; plant metabolite; serotonergic antagonist
thenyldiamine	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
4-(dimethylamino)benzaldehyde	[no description available]	low	0	0	benzaldehydes; substituted aniline; tertiary amino compound	chromogenic compound
2-diethylaminoethanol	[no description available]	low	0	0	ethanolamines; primary alcohol; tertiary amino compound
triethanolamine	[no description available]	low	0	0	amino alcohol; tertiary amino compound; triol	buffer; surfactant
4-nitrosodimethylaniline	[no description available]	low	0	0	dimethylaniline; nitroso compound; tertiary amino compound
triethylenediamine	[no description available]	low	0	0	bridged compound; diamine; saturated organic heterobicyclic parent; tertiary amino compound	antioxidant; catalyst; reagent
galantamine	[no description available]	low	0	0	benzazepine alkaloid fundamental parent; benzazepine alkaloid; organic heterotetracyclic compound; tertiary amino compound	antidote to curare poisoning; cholinergic drug; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; plant metabolite
beta-erythroidine	[no description available]	low	0	0	delta-lactone; indole alkaloid; organic heterotetracyclic compound; tertiary amino compound	muscle relaxant; plant metabolite
psilocybin	[no description available]	low	0	0	organic phosphate; tertiary amino compound; tryptamine alkaloid	fungal metabolite; hallucinogen; prodrug; serotonergic agonist
neutral red base	[no description available]	low	0	0	aromatic amine; phenazines; primary amino compound; tertiary amino compound	acid-base indicator; dye; two-colour indicator
benzydamine	[no description available]	low	0	0	aromatic ether; indazoles; tertiary amino compound	analgesic; central nervous system stimulant; hallucinogen; local anaesthetic; non-steroidal anti-inflammatory drug
4-dimethylaminopyridine	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
prothipendyl	[no description available]	low	0	0	aromatic amine; tertiary amino compound
dymanthine	[no description available]	low	0	0	tertiary amino compound
azaperone	[no description available]	low	0	0	aminopyridine; aromatic ketone; monofluorobenzenes; N-alkylpiperazine; N-arylpiperazine; tertiary amino compound	antipsychotic agent; dopaminergic antagonist
glaucine	[no description available]	low	0	0	aporphine alkaloid; organic heterotetracyclic compound; polyether; tertiary amino compound	antibacterial agent; antineoplastic agent; antitussive; muscle relaxant; NF-kappaB inhibitor; plant metabolite; platelet aggregation inhibitor; rat metabolite
glyphosphine	[no description available]	low	0	0	glycine derivative; phosphonic acids; tertiary amino compound	plant growth retardant
c.i. solvent yellow 56	[no description available]	low	0	0	azobenzenes; substituted aniline; tertiary amino compound	dye; mutagen
4-dimethylaminophenol	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
ethyl 4-dimethylaminobenzoate	[no description available]	low	0	0	benzoate ester; ethyl ester; tertiary amino compound
mopidamol	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
thenalidine	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
oryzalin	[no description available]	low	0	0	aromatic amine; C-nitro compound; sulfonamide; tertiary amino compound	agrochemical; antimitotic; herbicide
pirimicarb	[no description available]	low	0	0	aminopyrimidine; carbamate ester; tertiary amino compound	agrochemical; carbamate insecticide; EC 3.1.1.7 (acetylcholinesterase) inhibitor; environmental contaminant; insecticide; xenobiotic
dihydro-beta-erythroidine	[no description available]	low	0	0	delta-lactone; organic heterotetracyclic compound; tertiary amino compound	nicotinic antagonist
propamocarb	[no description available]	low	0	0	carbamate ester; carbamate fungicide; tertiary amino compound	antifungal agrochemical; environmental contaminant; xenobiotic
tridemorph	[no description available]	low	0	0	morpholines; tertiary amino compound	antifungal agrochemical
amitraz	[no description available]	low	0	0	formamidines; tertiary amino compound	acaricide; environmental contaminant; insecticide; xenobiotic
butaclamol	[no description available]	low	0	0	amino alcohol; organic heteropentacyclic compound; tertiary alcohol; tertiary amino compound	dopaminergic antagonist
2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline	[no description available]	low	0	0	isoquinolinol; tertiary amino compound	human metabolite; neurotoxin; rat metabolite
vx	[no description available]	low	0	0	organic thiophosphate; tertiary amino compound	EC 3.1.1.7 (acetylcholinesterase) inhibitor; neurotoxin
vindesine	[no description available]	low	0	0	methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; primary carboxamide; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent
miglustat	[no description available]	low	0	0	piperidines; tertiary amino compound	anti-HIV agent; EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor
loceryl	[no description available]	low	0	0	morpholine antifungal drug; tertiary amino compound	EC 1.14.13.132 (squalene monooxygenase) inhibitor; EC 1.3.1.70 (Delta(14)-sterol reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor
mifepristone	[no description available]	low	0	0	3-oxo-Delta(4) steroid; acetylenic compound; tertiary amino compound	abortifacient; contraceptive drug; hormone antagonist; synthetic oral contraceptive
carmoxirole	[no description available]	low	0	0	indolecarboxylic acid; tertiary amino compound; tetrahydropyridine	antihypertensive agent; dopamine agonist; platelet aggregation inhibitor
naxagolide	[no description available]	low	0	0	organic heterotricyclic compound; phenols; tertiary amino compound	anticonvulsant; antiparkinson drug; dopamine agonist
temafloxacin	[no description available]	low	0	0	amino acid; monocarboxylic acid; N-arylpiperazine; organofluorine compound; quinolone antibiotic; quinolone; secondary amino compound; tertiary amino compound
tiagabine	[no description available]	low	0	0	beta-amino acid; piperidinemonocarboxylic acid; tertiary amino compound; thiophenes	anticonvulsant; GABA reuptake inhibitor
eliprodil	[no description available]	low	0	0	monochlorobenzenes; monofluorobenzenes; piperidines; secondary alcohol; tertiary amino compound
irinotecan	[no description available]	low	0	0	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
carfentanil	[no description available]	low	0	0	methyl ester; piperidines; tertiary amino compound; tertiary carboxamide	mu-opioid receptor agonist; opioid analgesic; tranquilizing drug
acridine orange	[no description available]	low	0	0	aminoacridines; aromatic amine; tertiary amino compound	fluorochrome; histological dye
tenocyclidine	[no description available]	low	0	0	piperidines; tertiary amino compound; thiophenes	central nervous system stimulant; hallucinogen; neuroprotective agent; NMDA receptor antagonist
nelfinavir	[no description available]	low	0	0	aryl sulfide; benzamides; organic heterobicyclic compound; phenols; secondary alcohol; tertiary amino compound	antineoplastic agent; HIV protease inhibitor
plerixafor	[no description available]	low	0	0	azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound	anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant
nile red	[no description available]	low	0	0	aromatic amine; cyclic ketone; organic heterotetracyclic compound; tertiary amino compound	fluorochrome; histological dye
cephalotaxine	[no description available]	low	0	0	benzazepine alkaloid fundamental parent; benzazepine alkaloid; cyclic acetal; enol ether; organic heteropentacyclic compound; secondary alcohol; tertiary amino compound
d 888	[no description available]	low	0	0	aromatic ether; nitrile; tertiary amino compound	anti-arrhythmia drug; calcium channel blocker; vasodilator agent
4-(diethylamino)benzaldehyde	[no description available]	low	0	0	aromatic amine; benzaldehydes; tertiary amino compound	EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor
spiramide	[no description available]	low	0	0	aromatic ether; azaspiro compound; organofluorine compound; piperidines; tertiary amino compound	dopaminergic antagonist; serotonergic antagonist
propildazine	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
hp 873	[no description available]	low	0	0	1,2-benzoxazoles; aromatic ether; aromatic ketone; methyl ketone; monoamine; organofluorine compound; piperidines; tertiary amino compound	dopaminergic antagonist; second generation antipsychotic; serotonergic antagonist
tubulosine	[no description available]	low	0	0	beta-carbolines; isoquinoline alkaloid; isoquinolines; phenols; secondary amino compound; tertiary amino compound
voacamine	[no description available]	low	0	0	alkaloid ester; methyl ester; monoterpenoid indole alkaloid; organic heteropentacyclic compound; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; plant metabolite
dauricine	[no description available]	low	0	0	aromatic ether; bisbenzylisoquinoline alkaloid; isoquinolines; phenols; tertiary amino compound	plant metabolite
rivastigmine	[no description available]	low	0	0	carbamate ester; tertiary amino compound	cholinergic drug; EC 3.1.1.8 (cholinesterase) inhibitor; neuroprotective agent
dimethylformamide-dimethylacetal	[no description available]	low	0	0	acetal; tertiary amino compound	chromatographic reagent
n-(3-(dimethylamino)propyl)methacrylamide	[no description available]	low	0	0	tertiary amino compound
n,n-diisopropylethylamine	[no description available]	low	0	0	tertiary amino compound
spiroxamine	[no description available]	low	0	0	dioxolane; spiroketal; tertiary amino compound	antifungal agrochemical; environmental contaminant; sterol biosynthesis inhibitor; xenobiotic
mor-14	[no description available]	low	0	0	hydroxypiperidine; piperidine alkaloid; tertiary amino compound	anti-HIV agent; cardioprotective agent; EC 3.2.1.20 (alpha-glucosidase) inhibitor; plant metabolite
triflusulfuron-methyl	[no description available]	low	0	0	1,3,5-triazines; aromatic ether; benzoate ester; methyl ester; N-sulfonylurea; organofluorine compound; tertiary amino compound	agrochemical; EC 2.2.1.6 (acetolactate synthase) inhibitor; proherbicide
allocryptopine	[no description available]	low	0	0	aromatic ether; cyclic acetal; cyclic ketone; dibenzazecine alkaloid; organic heterotetracyclic compound; tertiary amino compound
sporidesmin	[no description available]	low	0	0	aromatic ether; cyclic ketone; diketone; organic disulfide; organic heteropentacyclic compound; organochlorine compound; secondary alcohol; tertiary alcohol; tertiary amino compound	mycotoxin; Wnt signalling activator
ecgonine methyl ester	[no description available]	low	0	0	methyl ester; tertiary amino compound; tropane alkaloid	analgesic; central nervous system depressant; metabolite; mouse metabolite; opioid analgesic; peripheral nervous system drug
ecteinascidin 743	[no description available]	low	0	0	acetate ester; azaspiro compound; bridged compound; hemiaminal; isoquinoline alkaloid; lactone; organic heteropolycyclic compound; organic sulfide; oxaspiro compound; polyphenol; tertiary amino compound	alkylating agent; angiogenesis modulating agent; anti-inflammatory agent; antineoplastic agent; marine metabolite
aporphine	[no description available]	low	0	0	aporphine alkaloid; isoquinoline alkaloid fundamental parent; tertiary amino compound
efonidipine	[no description available]	low	0	0	C-nitro compound; carboxylic ester; dihydropyridine; tertiary amino compound
mosapride	[no description available]	low	0	0	aromatic ether; benzamides; monochlorobenzenes; monofluorobenzenes; morpholines; secondary carboxamide; substituted aniline; tertiary amino compound
n-(4-(7-diethylamino-4-methylcoumarin-3-yl)phenyl)maleimide	[no description available]	low	0	0	benzenes; coumarins; maleimides; tertiary amino compound	fluorescent dye
gefitinib	[no description available]	low	0	0	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
lofentanil	[no description available]	low	0	0	methyl ester; piperidines; tertiary amino compound; tertiary carboxamide	mu-opioid receptor agonist; opioid analgesic
1-(1-(2-benzo(b)thienyl)cyclohexyl)piperidine	[no description available]	low	0	0	1-benzothiophenes; piperidines; tertiary amino compound	dopamine uptake inhibitor
desvenlafaxine	[no description available]	low	0	0	cyclohexanols; phenols; tertiary amino compound	antidepressant; drug metabolite; marine xenobiotic metabolite
xaliproden	[no description available]	low	0	0	(trifluoromethyl)benzenes; naphthalenes; tertiary amino compound; tetrahydropyridine	serotonergic agonist
ulipristal acetate	[no description available]	low	0	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; steroid ester; tertiary amino compound	contraceptive drug; progesterone receptor modulator; progestin
sr 57227a	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
2,8-dinitroimipramine	[no description available]	low	0	0	C-nitro compound; dibenzoazepine; tertiary amino compound
corytuberine	[no description available]	low	0	0	aporphine alkaloid; aromatic ether; organic heterotetracyclic compound; polyphenol; tertiary amino compound	plant metabolite
5,6-didehydrosparteine	[no description available]	low	0	0	organic heterotetracyclic compound; quinolizidine alkaloid; tertiary amino compound	human xenobiotic metabolite
stephenanthrine	[no description available]	low	0	0	cyclic acetal; organic heterotetracyclic compound; tertiary amino compound
hydromethylthionine	[no description available]	low	0	0	aromatic amine; phenothiazines; tertiary amino compound	bacterial xenobiotic metabolite; fluorochrome; mouse metabolite; rat metabolite
nbi 27914	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
top 53	[no description available]	low	0	0	furonaphthodioxole; gamma-lactone; organic heterotetracyclic compound; phenols; tertiary amino compound	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
antalarmin	[no description available]	low	0	0	pyrrolopyrimidine; tertiary amino compound	corticotropin-releasing factor receptor antagonist
alpha-putrescinylthymine	[no description available]	low	0	0	N-substituted putrescine; pyrimidine nucleobase; pyrimidone; secondary amino compound; tertiary amino compound
2-(4-morpholinoanilino)-6-cyclohexylaminopurine	[no description available]	low	0	0	morpholines; purines; secondary amino compound; tertiary amino compound	adenosine A3 receptor antagonist; antineoplastic agent; Aurora kinase inhibitor; cell dedifferentiation agent
l 778,123	[no description available]	low	0	0	imidazoles; monochlorobenzenes; nitrile; piperazinone; tertiary amino compound	antineoplastic agent; EC 2.5.1.58 (protein farnesyltransferase) inhibitor; EC 2.5.1.59 (protein geranylgeranyltransferase type I) inhibitor
vincaleukoblastine	[no description available]	low	0	0	acetate ester; indole alkaloid fundamental parent; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; immunosuppressive agent; microtubule-destabilising agent; plant metabolite
noscapine	[no description available]	low	0	0	aromatic ether; benzylisoquinoline alkaloid; cyclic acetal; isobenzofuranone; organic heterobicyclic compound; organic heterotricyclic compound; tertiary amino compound	antineoplastic agent; antitussive; apoptosis inducer; plant metabolite
azaleucine	[no description available]	low	0	0	alanine derivative; leucine derivative; non-proteinogenic alpha-amino acid; tertiary amino compound
nsc 23766	[no description available]	low	0	0	aminopyrimidine; aminoquinoline; primary amino compound; secondary amino compound; tertiary amino compound	antiviral agent; apoptosis inducer; EC 3.6.5.2 (small monomeric GTPase) inhibitor; muscarinic antagonist
gant 61	[no description available]	low	0	0	aminal; dialkylarylamine; pyridines; substituted aniline; tertiary amino compound	antineoplastic agent; apoptosis inducer; glioma-associated oncogene inhibitor; Hedgehog signaling pathway inhibitor
conessine	[no description available]	low	0	0	steroid alkaloid; tertiary amino compound	antibacterial agent; antimalarial; H3-receptor antagonist; plant metabolite
rocuronium	[no description available]	low	0	0	3alpha-hydroxy steroid; acetate ester; androstane; morpholines; quaternary ammonium ion; tertiary amino compound	drug allergen; muscle relaxant; neuromuscular agent
deltaline	[no description available]	low	0	0	acetate ester; cyclic acetal; diterpene alkaloid; organic polycyclic compound; tertiary alcohol; tertiary amino compound
oxyacanthine	[no description available]	low	0	0	bisbenzylisoquinoline alkaloid; isoquinolines; macrocycle; phenols; tertiary amino compound
ergonovine	[no description available]	low	0	0	ergot alkaloid; monocarboxylic acid amide; organic heterotetracyclic compound; primary alcohol; secondary amino compound; tertiary amino compound	diagnostic agent; fungal metabolite; oxytocic; toxin
cocaine	[no description available]	low	0	0	benzoate ester; methyl ester; tertiary amino compound; tropane alkaloid	adrenergic uptake inhibitor; central nervous system stimulant; dopamine uptake inhibitor; environmental contaminant; local anaesthetic; mouse metabolite; plant metabolite; serotonin uptake inhibitor; sodium channel blocker; sympathomimetic agent; vasoconstrictor agent; xenobiotic
afimoxifene	[no description available]	low	0	0	phenols; tertiary amino compound	antineoplastic agent; estrogen receptor antagonist; metabolite
efinaconazole	[no description available]	low	0	0	conazole antifungal drug; olefinic compound; organofluorine compound; piperidines; tertiary alcohol; tertiary amino compound; triazole antifungal drug	EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor
n-nonyl-1-deoxynojirimycin	[no description available]	low	0	0	hydroxypiperidine; tertiary amino compound	antiviral agent; EC 3.2.1.20 (alpha-glucosidase) inhibitor; EC 3.2.1.45 (glucosylceramidase) inhibitor
3-(4-chlorophenyl)-6-(1-pyrrolidinyl)-1,2,4,5-tetrazine	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
n-methylproline	[no description available]	low	0	0	L-alpha-amino acid zwitterion; L-proline derivative; tertiary amino compound	human metabolite; plant metabolite
5-[3-(dimethylamino)phenyl]-N-methyl-1,3,4-thiadiazol-2-amine	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
N4-(2-furanylmethyl)-N2-(3-methylphenyl)-6-(4-morpholinyl)-1,3,5-triazine-2,4-diamine	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
7-(2-methyl-2,3-dihydroindol-1-yl)-3-(phenylmethyl)triazolo[4,5-d]pyrimidine	[no description available]	low	0	0	aromatic amine; tertiary amino compound
tiamulin	[no description available]	low	0	0	carbotricyclic compound; carboxylic ester; cyclic ketone; organic sulfide; secondary alcohol; semisynthetic derivative; tertiary amino compound; tetracyclic diterpenoid	antibacterial drug
2-amino-4-(cyanomethyl)-6-(N-methylanilino)pyridine-3,5-dicarbonitrile	[no description available]	low	0	0	aromatic amine; tertiary amino compound
N-[4-(diethylamino)phenyl]-N'-phenylurea	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
4-bromo-2-phenyl-5-(1-piperidinyl)-3-pyridazinone	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
N4,N4-dimethyl-N1-(4-nitro-1,1-dioxo-2,5-dihydrothiophen-3-yl)benzene-1,4-diamine	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
N-methyl-2-(4-methylphenyl)-N-(1-methylpiperidin-4-yl)quinazolin-4-amine	[no description available]	low	0	0	piperidines; quinazolines; tertiary amino compound; toluenes
4-(2,3-dihydro-1H-indol-1-yl)-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine	[no description available]	low	0	0	aromatic amine; tertiary amino compound
4-[methyl-(4-thiophen-2-yl-2-thiazolyl)amino]phenol	[no description available]	low	0	0	aromatic amine; tertiary amino compound
4-[[4-bromo-5-(4-morpholinyl)-2-furanyl]methylideneamino]phenol	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
4-chloro-5-(dimethylamino)-2-(4-methylphenyl)-3-pyridazinone	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
N,N-dibutyl-2-(pyridin-4-yl)quinazolin-4-amine	[no description available]	low	0	0	pyridines; quinazolines; tertiary amino compound
2-[5-(4-chlorophenyl)-1,3,5-dithiazinan-2-ylidene]-2-diethoxyphosphorylacetonitrile	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
2-[[4-(4-chloroanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
2-(2,4-dioxo-1H-pyrimidin-6-yl)-N-[2-(4-morpholinyl)ethyl]acetamide	[no description available]	low	0	0	morpholines; pyrimidone; secondary carboxamide; tertiary amino compound
2-chloro-N-[4-(N-propan-2-ylanilino)phenyl]acetamide	[no description available]	low	0	0	aromatic amine; tertiary amino compound
tamoxifen	[no description available]	low	0	0	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
3-(1-pyrrolidinyl)-5-(trifluoromethyl)pyridine-2-carbothioamide	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
wiskostatin	[no description available]	low	0	0	carbazoles; organobromine compound; secondary alcohol; tertiary amino compound
2-[[2-oxo-2-[4-[5-(trifluoromethyl)-2-pyridinyl]-1,4-diazepan-1-yl]ethyl]thio]acetic acid	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
3-(4-ethyl-1-piperazinyl)-5-methylpyridazino[3,4-b][1,4]benzoxazine	[no description available]	low	0	0	aromatic amine; tertiary amino compound
4-(5,6-diphenyl-1,2,4-triazin-3-yl)morpholine	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
3-[[5,5-dimethyl-3-(4-morpholinyl)-1-cyclohex-2-enylidene]amino]-N,N-dimethylaniline	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
ranitidine	[no description available]	low	0	0	C-nitro compound; furans; organic sulfide; tertiary amino compound	anti-ulcer drug; drug allergen; environmental contaminant; H2-receptor antagonist; xenobiotic
stenusin	[no description available]	low	0	0	piperidine alkaloid; tertiary amino compound
tandutinib	[no description available]	low	0	0	aromatic ether; N-arylpiperazine; N-carbamoylpiperazine; phenylureas; piperidines; quinazolines; tertiary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
dasatinib	[no description available]	low	0	0	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
noribogaine	[no description available]	low	0	0	monoterpenoid indole alkaloid; organic heteropentacyclic compound; secondary amino compound; tertiary amino compound	kappa-opioid receptor agonist; NMDA receptor antagonist; psychotropic drug; serotonin uptake inhibitor
2-[[4-(3-methylanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
2-(N-ethylanilino)-4-thieno[3,2-d][1,3]thiazinone	[no description available]	low	0	0	aromatic amine; tertiary amino compound
N-[3-(N-ethylanilino)propyl]-2,4-dimethyl-6-oxo-3-pyrancarboxamide	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
5-(1-azepanyl)-1,3,4-thiadiazol-2-amine	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
3-(5-chloro-2-methylphenyl)-6-(2,6-dimethyl-4-morpholinyl)-1H-pyrimidine-2,4-dione	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
nafadotride	[no description available]	low	0	0	aromatic ether; naphthalenecarboxamide; nitrile; pyrrolidines; tertiary amino compound	dopaminergic antagonist
N4-ethyl-N6,1,2-trimethyl-N4-phenylpyrimidin-1-ium-4,6-diamine	[no description available]	low	0	0	aromatic amine; tertiary amino compound
clopidogrel carboxylic acid	[no description available]	low	0	0	monocarboxylic acid; monochlorobenzenes; tertiary amino compound; thienopyridine	drug metabolite; marine xenobiotic metabolite
LY-310762	[no description available]	low	0	0	aromatic ketone; monofluorobenzenes; oxindoles; piperidines; tertiary amino compound	receptor modulator; serotonergic antagonist
ly 367265	[no description available]	low	0	0	dihydropyridine; fluoroindole; tertiary amino compound; thiadiazoloquinoline	antidepressant; geroprotector; serotonergic antagonist; serotonin uptake inhibitor
N-(1-benzylpiperidin-4-yl)-2-(pyridin-3-yl)quinazolin-4-amine	[no description available]	low	0	0	aromatic amine; piperidines; pyridines; quinazolines; secondary amino compound; tertiary amino compound
3-[4-(dimethylamino)phenyl]-N-methyl-5-(4-methylphenyl)-3,4-dihydropyrazole-2-carbothioamide	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
mycophenolate mofetil	[no description available]	low	0	0	carboxylic ester; ether; gamma-lactone; phenols; tertiary amino compound	anticoronaviral agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; immunosuppressive agent; prodrug
josamycin	[no description available]	low	0	0	acetate ester; aldehyde; disaccharide derivative; glycoside; macrolide antibiotic; tertiary alcohol; tertiary amino compound	antibacterial drug; metabolite
acetylspiramycin	[no description available]	low	0	0	acetate ester; aldehyde; disaccharide derivative; ether; macrolide; tertiary amino compound	antibacterial drug; antimicrobial agent; bacterial metabolite
n,n-dimethylsphingenine	[no description available]	low	0	0	aminodiol; sphingoid; tertiary amino compound	EC 2.7.1.91 (sphingosine kinase) inhibitor; metabolite
alvocidib	[no description available]	low	0	0	dihydroxyflavone; hydroxypiperidine; monochlorobenzenes; tertiary amino compound	antineoplastic agent; antirheumatic drug; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin	[no description available]	low	0	0	1,4-benzoquinones; ansamycin; carbamate ester; secondary amino compound; tertiary amino compound	Hsp90 inhibitor
morphine	[no description available]	low	0	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
kn 93	[no description available]	low	0	0	monochlorobenzenes; monomethoxybenzene; primary alcohol; sulfonamide; tertiary amino compound	EC 2.7.11.17 (Ca(2+)/calmodulin-dependent protein kinase) inhibitor; geroprotector
bosutinib	[no description available]	low	0	0	aminoquinoline; aromatic ether; dichlorobenzene; N-methylpiperazine; nitrile; tertiary amino compound	antineoplastic agent; tyrosine kinase inhibitor
su 11652	[no description available]	low	0	0	olefinic compound; organochlorine compound; oxindoles; pyrrolecarboxamide; tertiary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor
palbociclib	[no description available]	low	0	0	aminopyridine; aromatic ketone; cyclopentanes; piperidines; pyridopyrimidine; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
bedaquiline	[no description available]	low	0	0	aromatic ether; naphthalenes; organobromine compound; quinolines; tertiary alcohol; tertiary amino compound	antitubercular agent; ATP synthase inhibitor
catharanthine	[no description available]	low	0	0	alkaloid ester; bridged compound; methyl ester; monoterpenoid indole alkaloid; organic heteropentacyclic compound; tertiary amino compound
oripavine	[no description available]	low	0	0	ether; morphinane alkaloid; organic heteropentacyclic compound; organic hydroxy compound; tertiary amino compound	bacterial xenobiotic metabolite; opioid analgesic
cinanserin	[no description available]	low	0	0	aryl sulfide; cinnamamides; secondary carboxamide; tertiary amino compound	anticoronaviral agent; antiviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
DPI2	[no description available]	low	0	0	benzenes; morpholines; secondary carboxamide; tertiary amino compound; thiazolidinone	ferroptosis inducer
7-hydroxy-2-(n-n-propyl-n-(3-iodo-2'-propenyl)-amino)tetralin	[no description available]	low	0	0	organoiodine compound; phenols; tertiary amino compound; tetralins	dopamine agonist
sdz eaa 494	[no description available]	low	0	0	monocarboxylic acid; olefinic compound; phosphonic acids; piperazinecarboxylic acid; tertiary amino compound	anticonvulsant; neuroprotective agent; NMDA receptor antagonist
demycarosylturimycin h	[no description available]	low	0	0	aldehyde; disaccharide derivative; ether; macrolide; tertiary amino compound	antibacterial drug; antimicrobial agent; bacterial metabolite
ro 25-6981	[no description available]	low	0	0	benzenes; phenols; piperidines; secondary alcohol; tertiary amino compound	anticonvulsant; antidepressant; neuroprotective agent; NMDA receptor antagonist
yunaconitine	[no description available]	low	0	0	acetate ester; aromatic ether; benzoate ester; bridged compound; diterpene alkaloid; organic heteropolycyclic compound; polyether; secondary alcohol; tertiary alcohol; tertiary amino compound	antifeedant; human urinary metabolite; phytotoxin; plant metabolite; xenobiotic
eaa-090	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
prasugrel	[no description available]	low	0	0	acetate ester; cyclopropanes; ketone; monofluorobenzenes; tertiary amino compound; thienopyridine
bay 58-2667	[no description available]	low	0	0	aromatic ether; benzoic acids; dicarboxylic acid; tertiary amino compound	antihypertensive agent; soluble guanylate cyclase activator; vasodilator agent
muromonab-cd3	[no description available]	low	0	0	alkaloid; macrocycle; organic heteropentacyclic compound; organonitrogen heterocyclic compound; oxacycle; tertiary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; IP3 receptor antagonist; marine metabolite
px-866	[no description available]	low	0	0	acetate ester; delta-lactone; organic heterotetracyclic compound; tertiary amino compound	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
pi103	[no description available]	low	0	0	aromatic amine; morpholines; organic heterotricyclic compound; phenols; tertiary amino compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
selexipag	[no description available]	low	0	0	aromatic amine; ether; monocarboxylic acid amide; N-sulfonylcarboxamide; pyrazines; tertiary amino compound	orphan drug; platelet aggregation inhibitor; prodrug; prostacyclin receptor agonist; vasodilator agent
zm 447439	[no description available]	low	0	0	aromatic ether; benzamides; morpholines; polyether; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; apoptosis inducer; Aurora kinase inhibitor
tofacitinib	[no description available]	low	0	0	N-acylpiperidine; nitrile; pyrrolopyrimidine; tertiary amino compound	antirheumatic drug; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
mre 269	[no description available]	low	0	0	aromatic amine; ether; monocarboxylic acid; pyrazines; sulfonamide; tertiary amino compound	drug metabolite; orphan drug; platelet aggregation inhibitor; prostacyclin receptor agonist; vasodilator agent
n,n-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride	[no description available]	low	0	0	aromatic ether; hydrochloride; methoxybenzenes; tertiary amino compound	antipsychotic agent; receptor modulator
NNC 55-0396 (free base)	[no description available]	low	0	0	benzimidazoles; cyclopropanecarboxylate ester; organofluorine compound; tertiary amino compound; tetralins	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; neuroprotective agent; potassium channel blocker; T-type calcium channel blocker
pateamine a	[no description available]	low	0	0	1,3-thiazoles; macrodiolide; olefinic compound; primary amino compound; tertiary amino compound	antineoplastic agent; antiviral agent; eukaryotic initiation factor 4F inhibitor; marine metabolite
pimavanserin	[no description available]	low	0	0	aromatic ether; monofluorobenzenes; piperidines; tertiary amino compound; ureas	5-hydroxytryptamine 2A receptor inverse agonist; antipsychotic agent; serotonergic antagonist
bibw 2992	[no description available]	low	0	0	aromatic ether; enamide; furans; monochlorobenzenes; organofluorine compound; quinazolines; secondary carboxamide; tertiary amino compound	antineoplastic agent; tyrosine kinase inhibitor
akuammicine	[no description available]	low	0	0	methyl ester; monoterpenoid indole alkaloid; organic heteropentacyclic compound; tertiary amino compound	plant metabolite
crenolanib	[no description available]	low	0	0	aminopiperidine; aromatic ether; benzimidazoles; oxetanes; quinolines; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
PDGF receptor tyrosine kinase inhibitor III	[no description available]	low	0	0	aromatic ether; N-arylpiperazine; N-carbamoylpiperazine; phenylureas; quinazolines; tertiary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
abt-737	[no description available]	low	0	0	aromatic amine; aryl sulfide; biphenyls; C-nitro compound; monochlorobenzenes; N-arylpiperazine; N-sulfonylcarboxamide; secondary amino compound; tertiary amino compound	anti-allergic agent; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
azd 8931	[no description available]	low	0	0	aromatic ether; monochlorobenzenes; monofluorobenzenes; piperidines; quinazolines; secondary amino compound; tertiary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist
azd 1152	[no description available]	low	0	0	anilide; monoalkyl phosphate; monofluorobenzenes; pyrazoles; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; Aurora kinase inhibitor; prodrug
pf 00299804	[no description available]	low	0	0	enamide; monochlorobenzenes; monofluorobenzenes; piperidines; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
finafloxacin	[no description available]	low	0	0	cyclopropanes; monocarboxylic acid; nitrile; organofluorine compound; quinolone; secondary amino compound; tertiary amino compound	antibacterial drug; antimicrobial agent
sarpagine	[no description available]	low	0	0	indole alkaloid; phenols; primary alcohol; secondary amino compound; tertiary amino compound
5,7-dihydroxy-2-methyl-8-(4-(3-hydroxy-1-methyl)-piperidinyl)-4h-1-benzopyran-4-one	[no description available]	low	0	0	alkaloid; chromones; hydroxypiperidine; resorcinols; tertiary amino compound	anti-inflammatory agent; anti-ulcer drug; anticholesteremic drug; antileishmanial agent; antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; fungal metabolite; plant metabolite
azd 1152-hqpa	[no description available]	low	0	0	anilide; monofluorobenzenes; primary alcohol; pyrazoles; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; Aurora kinase inhibitor
ku 0063794	[no description available]	low	0	0	benzyl alcohols; monomethoxybenzene; morpholines; pyridopyrimidine; tertiary amino compound	antineoplastic agent; mTOR inhibitor
8-{1-[4-(dimethylamino)phenyl]-3-(pyrrolidin-1-yl)propyl}-5,7-dimethoxy-4-pentyl-2H-chromen-2-one	[no description available]	low	0	0	aromatic ether; coumarins; pyrrolidines; tertiary amino compound
flupyradifurone	[no description available]	low	0	0	butenolide; enamine; monochloropyridine; organofluorine insecticide; tertiary amino compound	insecticide; nicotinic acetylcholine receptor agonist
alcaftadine	[no description available]	low	0	0	aldehyde; imidazobenzazepine; piperidines; tertiary amino compound	anti-allergic agent; H1-receptor antagonist
benzoylaconine	[no description available]	low	0	0	benzoate ester; bridged compound; diterpene alkaloid; organic heteropolycyclic compound; polyether; secondary alcohol; tertiary alcohol; tertiary amino compound; tetrol	phytotoxin; plant metabolite
deoxyaconitine	[no description available]	low	0	0	acetate ester; benzoate ester; bridged compound; diol; diterpene alkaloid; organic heteropolycyclic compound; polyether; secondary alcohol; tertiary amino compound	plant metabolite
2-[[4-(4-methylanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
2-[[4-(2-chloroanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
2-[[4-(2-hydroxyethylamino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]phenol	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
vindolinine	[no description available]	low	0	0	methyl ester; monoterpenoid indole alkaloid; organic heteropentacyclic compound; tertiary amino compound	plant metabolite
tenovin-6	[no description available]	low	0	0	monocarboxylic acid amide; tertiary amino compound; thioureas	antineoplastic agent; p53 activator; Sir2 inhibitor
lde225	[no description available]	low	0	0	aminopyridine; aromatic ether; benzamides; biphenyls; morpholines; organofluorine compound; tertiary amino compound	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist
benzoylmesaconine	[no description available]	low	0	0	benzoate ester; bridged compound; diterpene alkaloid; organic heteropolycyclic compound; polyether; secondary alcohol; tertiary alcohol; tertiary amino compound; tetrol	analgesic; antiinfective agent; plant metabolite
sch772984	[no description available]	low	0	0	biaryl; indazoles; N-acylpiperazine; N-alkylpyrrolidine; N-arylpiperazine; pyridines; pyrimidines; pyrrolidinecarboxamide; secondary carboxamide; tertiary amino compound; tertiary carboxamide	analgesic; antineoplastic agent; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
navitoclax	[no description available]	low	0	0	aryl sulfide; monochlorobenzenes; morpholines; N-sulfonylcarboxamide; organofluorine compound; piperazines; secondary amino compound; sulfone; tertiary amino compound	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	[no description available]	low	0	0	aminopyrimidine; benzamides; morpholines; nitrile; secondary amino compound; tertiary amino compound	anti-anaemic agent; antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
(5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol	[no description available]	low	0	0	benzyl alcohols; morpholines; pyridopyrimidine; tertiary amino compound	antineoplastic agent; apoptosis inducer; mTOR inhibitor
N-[[(2R,3S)-10-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-N-methylmethanesulfonamide	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
(2S,3R)-8-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
N-[[(2S,3S)-10-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-N,3,5-trimethyl-4-isoxazolesulfonamide	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
(2S,3S)-10-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
3-cyclohexyl-1-[[(2S,3S)-10-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methylurea	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
1-[[(2S,3S)-10-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-propan-2-ylurea	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
cblc137	[no description available]	low	0	0	aromatic ketone; carbazoles; methyl ketone; secondary amino compound; tertiary amino compound	antineoplastic agent; apoptosis inducer; NF-kappaB inhibitor; p53 activator
1-[3-[(5-bromo-2-pyridinyl)-butylamino]propyl]-3-[3-(1H-imidazol-5-yl)propyl]thiourea	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
lrrk2-in1	[no description available]	low	0	0	aromatic amine; aromatic ether; N-acylpiperidine; N-alkylpiperazine; pyrimidobenzodiazepine; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
tubastatin a	[no description available]	low	0	0	hydroxamic acid; pyridoindole; tertiary amino compound	EC 3.5.1.98 (histone deacetylase) inhibitor
pracinostat	[no description available]	low	0	0	benzimidazole; hydroxamic acid; olefinic compound; tertiary amino compound	antimalarial; antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
delgocitinib	[no description available]	low	0	0	azaspiro compound; N-acylazetidine; nitrile; pyrrolopyrimidine; tertiary amino compound; tertiary carboxamide	anti-inflammatory drug; antipsoriatic; antiseborrheic; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
pf 956980	[no description available]	low	0	0	N-acylpiperidine; N-acylpyrrolidine; pyrrolopyrimidine; tertiary amino compound	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
AZD3463	[no description available]	low	0	0	aminopiperidine; aminopyrimidine; indoles; monomethoxybenzene; organochlorine compound; secondary amino compound; tertiary amino compound	antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
gsk2879552	[no description available]	low	0	0	benzenes; benzoic acids; cyclopropanes; monocarboxylic acid; piperidines; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 1.14.99.66 (lysine-specific histone demethylase 1A) inhibitor
osimertinib	[no description available]	low	0	0	acrylamides; aminopyrimidine; biaryl; indoles; monomethoxybenzene; secondary amino compound; secondary carboxamide; substituted aniline; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
as 1842856	[no description available]	low	0	0	organofluorine compound; primary amino compound; quinolinemonocarboxylic acid; quinolone; secondary amino compound; tertiary amino compound	anti-obesity agent; antineoplastic agent; apoptosis inducer; autophagy inhibitor; forkhead box protein O1 inhibitor; hypoglycemic agent
MLI-2	[no description available]	low	0	0	aromatic ether; cyclopropanes; indazoles; morpholines; pyrimidines; tertiary amino compound	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
ap20187	[no description available]	low	0	0	aromatic ether; carboxylic ester; N-acylpiperidine; tertiary amino compound	ligand
BDA-366	[no description available]	low	0	0	anthraquinone; epoxide; secondary alcohol; secondary amino compound; tertiary amino compound	antineoplastic agent; apoptosis inducer
5-(2-chloro-6-fluorobenzyl)-6-methyl-2-morpholinopyrimidin-4-ol	[no description available]	low	0	0	dialkylarylamine; tertiary amino compound
2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1h-indole-5-carbonitrile	[no description available]	low	0	0	hydroxyindoles; morpholines; nitrile; pyridines; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; tau aggregation inhibitor
sb-590885	[no description available]	low	0	0	aromatic ether; imidazoles; ketoxime; pyridines; tertiary amino compound
sotorasib	[no description available]	low	0	0	acrylamides; methylpyridines; monofluorobenzenes; N-acylpiperazine; phenols; pyridopyrimidine; tertiary amino compound; tertiary carboxamide	antineoplastic agent
camphene	[no description available]	low	0	0	carbobicyclic compound; monoterpene	fragrance; plant metabolite
pinane	[no description available]	low	0	0	carbobicyclic compound; monoterpene; terpenoid fundamental parent	plant metabolite
fenchone, (+-)-isomer	[no description available]	low	0	0	carbobicyclic compound; cyclic terpene ketone; fenchane monoterpenoid	plant metabolite
camphoroquinone	[no description available]	low	0	0	bornane monoterpenoid; carbobicyclic compound
verbenone	[no description available]	low	0	0	carbobicyclic compound; cyclic ketone; enone
pravastatin	[no description available]	low	0	0	3-hydroxy carboxylic acid; carbobicyclic compound; carboxylic ester; hydroxy monocarboxylic acid; secondary alcohol; statin (semi-synthetic)	anticholesteremic drug; environmental contaminant; metabolite; xenobiotic
l 154819	[no description available]	low	0	0	carbobicyclic compound; dihydroxy monocarboxylic acid; fatty acid ester; polyketide	Aspergillus metabolite; drug metabolite; EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; teratogenic agent
benzocyclobutene	[no description available]	low	0	0	carbobicyclic compound	metabolite
carane	[no description available]	low	0	0	carbobicyclic compound; monoterpene; terpenoid fundamental parent
beta-eudesmol	[no description available]	low	0	0	carbobicyclic compound; eudesmane sesquiterpenoid; tertiary alcohol	volatile oil component
6,6-dimethyl-2-methylenebicyclo(3.1.1)heptan-3-ol	[no description available]	low	0	0	carbobicyclic compound; pinane monoterpenoid; secondary alcohol	GABA modulator; mouse metabolite; plant metabolite; volatile oil component
t-cadinol	[no description available]	low	0	0	cadinane sesquiterpenoid; carbobicyclic compound; octahydronaphthalenes; tertiary alcohol	plant metabolite; volatile oil component
albicanol	[no description available]	low	0	0	carbobicyclic compound; homoallylic alcohol; primary alcohol; sesquiterpenoid	antifeedant; antifungal agent; antineoplastic agent; fungal metabolite; mammalian metabolite; marine metabolite; plant metabolite
ml 236a	[no description available]	low	0	0	2-pyranones; carbobicyclic compound; hexahydronaphthalenes; polyketide; secondary alcohol	antiatherosclerotic agent; anticholesteremic drug; antilipemic drug; antimicrobial agent; EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; fungal metabolite
(north)-methanocarbathymidine	[no description available]	low	0	0	C-glycosyl pyrimidine; carbobicyclic compound; primary alcohol; pyrimidone; secondary alcohol
bicyclo(2.2.1)heptene	[no description available]	low	0	0	bridged compound; carbobicyclic compound; cyclic olefin
nootkatone	[no description available]	low	0	0	carbobicyclic compound; enone; sesquiterpenoid	fragrance; insect repellent; plant metabolite
t-muurolol	[no description available]	low	0	0	cadinane sesquiterpenoid; carbobicyclic compound; octahydronaphthalenes; tertiary alcohol	bacterial metabolite; fungicide; marine metabolite; plant metabolite; volatile oil component
australifungin	[no description available]	low	0	0	carbobicyclic compound; enol; enone; secondary alcohol	antifungal agent; EC 2.3.1.24 (sphingosine N-acyltransferase) inhibitor; HIV-1 integrase inhibitor; metabolite
iloprost	[no description available]	low	0	0	carbobicyclic compound; monocarboxylic acid; secondary alcohol	platelet aggregation inhibitor; vasodilator agent
andrographolide	[no description available]	low	0	0	carbobicyclic compound; gamma-lactone; labdane diterpenoid; primary alcohol; secondary alcohol	anti-HIV agent; anti-inflammatory drug; antineoplastic agent; metabolite
valerenic acid	[no description available]	low	0	0	carbobicyclic compound; monocarboxylic acid; sesquiterpenoid	GABA modulator; plant metabolite; sedative; volatile oil component
valencene	[no description available]	low	0	0	carbobicyclic compound; polycyclic olefin; sesquiterpene
monacolin j	[no description available]	low	0	0	2-pyranones; carbobicyclic compound; hexahydronaphthalenes; polyketide; secondary alcohol	antimicrobial agent; EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; fungal metabolite
alpha-cadinol	[no description available]	low	0	0	cadinane sesquiterpenoid; carbobicyclic compound; octahydronaphthalenes; tertiary alcohol	fungicide; plant metabolite; volatile oil component
artemisic acid	[no description available]	low	0	0	carbobicyclic compound; monocarboxylic acid; octahydronaphthalenes; sesquiterpenoid	metabolite
dihydroartemisinic acid	[no description available]	low	0	0	carbobicyclic compound; monocarboxylic acid; octahydronaphthalenes; sesquiterpenoid	plant metabolite
benzobicyclon	[no description available]	low	0	0	aromatic ketone; carbobicyclic compound; cyclic ketone; monochlorobenzenes; organic sulfide; sulfone
spiculoic acid a	[no description available]	low	0	0	carbobicyclic compound; cyclic ketone; oxo monocarboxylic acid; styrenes	antineoplastic agent; metabolite
hu 308	[no description available]	low	0	0	aromatic ether; bridged compound; carbobicyclic compound; primary allylic alcohol; synthetic cannabinoid	anti-inflammatory agent; antihypertensive agent; apoptosis inhibitor; bone density conservation agent; CB2 receptor agonist
oplodiol	[no description available]	low	0	0	carbobicyclic compound; octahydronaphthalenes; secondary alcohol; sesquiterpenoid; tertiary alcohol	plant metabolite
ilicicolin h	[no description available]	low	0	0	aromatic ketone; carbobicyclic compound; ilicicolin; monohydroxypyridine; octahydronaphthalenes; phenols; pyridone	antimicrobial agent; mitochondrial respiratory-chain inhibitor
vanilmandelic acid	[no description available]	low	0	0	2-hydroxy monocarboxylic acid; aromatic ether; phenols	human metabolite
4-(2,4-dichlorophenoxy)butyric acid	[no description available]	low	0	0	aromatic ether; monocarboxylic acid; organochlorine compound	agrochemical; phenoxy herbicide; synthetic auxin
win 52035	[no description available]	low	0	0	aromatic ether
win 52084	[no description available]	low	0	0	aromatic ether
5-(nonyloxy)tryptamine	[no description available]	low	0	0	aromatic ether; primary amino compound; tryptamines	serotonergic agonist
5-methoxytryptamine	[no description available]	low	0	0	aromatic ether; primary amino compound; tryptamines	5-hydroxytryptamine 2A receptor agonist; 5-hydroxytryptamine 2B receptor agonist; 5-hydroxytryptamine 2C receptor agonist; antioxidant; cardioprotective agent; human metabolite; mouse metabolite; neuroprotective agent; radiation protective agent; serotonergic agonist
rtki cpd	[no description available]	low	0	0	aromatic ether; monochlorobenzenes; quinazolines	antineoplastic agent; antiviral agent; epidermal growth factor receptor antagonist; geroprotector
amsacrine	[no description available]	low	0	0	acridines; aromatic ether; sulfonamide	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
aristolochic acid i	[no description available]	low	0	0	aristolochic acids; aromatic ether; C-nitro compound; cyclic acetal; monocarboxylic acid; organic heterotetracyclic compound	carcinogenic agent; metabolite; mutagen; nephrotoxin; toxin
2,4-dihydroxy-7-methoxy-1,4-benzoxazin-3-one	[no description available]	low	0	0	aromatic ether; benzoxazine; cyclic hydroxamic acid; lactol	allelochemical; plant metabolite
bufetolol	[no description available]	low	0	0	aromatic ether
bufexamac	[no description available]	low	0	0	aromatic ether; hydroxamic acid	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug
bunitrolol	[no description available]	low	0	0	aromatic ether
bupranolol	[no description available]	low	0	0	aromatic ether
cgp 12177	[no description available]	low	0	0	aromatic ether; benzimidazoles; secondary alcohol; secondary amino compound	beta-adrenergic antagonist
ciglitazone	[no description available]	low	0	0	aromatic ether; thiazolidinone	antineoplastic agent; insulin-sensitizing drug
cirazoline	[no description available]	low	0	0	aromatic ether
clofibrate	[no description available]	low	0	0	aromatic ether; ethyl ester; monochlorobenzenes	anticholesteremic drug; antilipemic drug; geroprotector; PPARalpha agonist
clofibric acid	[no description available]	low	0	0	aromatic ether; monocarboxylic acid; monochlorobenzenes	anticholesteremic drug; antilipemic drug; antineoplastic agent; herbicide; marine xenobiotic metabolite; PPARalpha agonist
colchicine, (+-)-isomer	[no description available]	low	0	0	acetamides; alkaloid; aromatic ether; carbotricyclic compound	microtubule-destabilising agent; plant metabolite
croconazole	[no description available]	low	0	0	aromatic ether; conazole antifungal drug; imidazole antifungal drug; monochlorobenzenes
cypermethrin	[no description available]	low	0	0	aromatic ether; cyclopropanecarboxylate ester; nitrile; organochlorine compound	agrochemical; molluscicide; pyrethroid ester acaricide; pyrethroid ester insecticide
racemethorphan	[no description available]	low	0	0	aromatic ether; morphinane alkaloid; morphinane-like compound; organic heterotetracyclic compound
domiphen	[no description available]	low	0	0	aromatic ether
donepezil	[no description available]	low	0	0	aromatic ether; indanones; piperidines; racemate	EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; nootropic agent
epirizole	[no description available]	low	0	0	aromatic ether
ethacrynic acid	[no description available]	low	0	0	aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid	EC 2.5.1.18 (glutathione transferase) inhibitor; ion transport inhibitor; loop diuretic
ethoxyquin	[no description available]	low	0	0	aromatic ether; quinolines	antifungal agrochemical; food antioxidant; genotoxin; geroprotector; herbicide; Hsp90 inhibitor; neuroprotective agent; UDP-glucuronosyltransferase activator
ethoxzolamide	[no description available]	low	0	0	aromatic ether; benzothiazoles; sulfonamide	antiglaucoma drug; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
2-hexyloxybenzamide	[no description available]	low	0	0	aromatic ether; benzamides	antifungal agent
carbonyl cyanide p-trifluoromethoxyphenylhydrazone	[no description available]	low	0	0	aromatic ether; hydrazone; nitrile; organofluorine compound	ATP synthase inhibitor; geroprotector; ionophore
fenofibrate	[no description available]	low	0	0	aromatic ether; chlorobenzophenone; isopropyl ester; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
fenvalerate	[no description available]	low	0	0	aromatic ether; carboxylic ester; monochlorobenzenes	pyrethroid ester acaricide; pyrethroid ester insecticide
fluoxetine	[no description available]	low	0	0	(trifluoromethyl)benzenes; aromatic ether; secondary amino compound
gallamine triethiodide	[no description available]	low	0	0	aromatic ether
gemfibrozil	[no description available]	low	0	0	aromatic ether	antilipemic drug
haloprogin	[no description available]	low	0	0	aromatic ether
indomethacin	[no description available]	low	0	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
ipriflavone	[no description available]	low	0	0	aromatic ether; isoflavones	bone density conservation agent
ly 171883	[no description available]	low	0	0	acetophenones; aromatic ether; phenols; tetrazoles	anti-asthmatic drug; leukotriene antagonist
mephenesin	[no description available]	low	0	0	aromatic ether; glycerol ether
methocarbamol	[no description available]	low	0	0	aromatic ether; carbamate ester; secondary alcohol
methoctramine	[no description available]	low	0	0	aromatic ether; tetramine	muscarinic antagonist
methoxsalen	[no description available]	low	0	0	aromatic ether; psoralens	antineoplastic agent; cross-linking reagent; dermatologic drug; photosensitizing agent; plant metabolite
nefazodone	[no description available]	low	0	0	aromatic ether; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazoles	alpha-adrenergic antagonist; analgesic; antidepressant; serotonergic antagonist; serotonin uptake inhibitor
nimesulide	[no description available]	low	0	0	aromatic ether; C-nitro compound; sulfonamide	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
nisoxetine	[no description available]	low	0	0	aromatic ether; secondary amino compound	adrenergic uptake inhibitor; antidepressant
n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	[no description available]	low	0	0	aromatic ether; C-nitro compound; sulfonamide	antineoplastic agent; cyclooxygenase 2 inhibitor
oxprenolol	[no description available]	low	0	0	aromatic ether
pantoprazole	[no description available]	low	0	0	aromatic ether; benzimidazoles; organofluorine compound; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; environmental contaminant; xenobiotic
pd 153035	[no description available]	low	0	0	aromatic amine; aromatic ether; bromobenzenes; quinazolines; secondary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist
pentamidine	[no description available]	low	0	0	aromatic ether; carboxamidine; diether	anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic
phenacetin	[no description available]	low	0	0	acetamides; aromatic ether	cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug
pioglitazone	[no description available]	low	0	0	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic
piretanide	[no description available]	low	0	0	aromatic ether
pramoxine	[no description available]	low	0	0	aromatic ether; morpholines	local anaesthetic
prazosin	[no description available]	low	0	0	aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
primaquine	[no description available]	low	0	0	aminoquinoline; aromatic ether; N-substituted diamine	antimalarial
proglumetacin	[no description available]	low	0	0	aromatic ether; benzamides; carboxylic ester; monochlorobenzenes; N-acylindole; N-alkylpiperazine	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; lipoxygenase inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug
propoxur	[no description available]	low	0	0	aromatic ether; carbamate ester	acaricide; agrochemical; carbamate insecticide; EC 3.1.1.7 (acetylcholinesterase) inhibitor
pyrilamine	[no description available]	low	0	0	aromatic ether; ethylenediamine derivative	H1-receptor antagonist
sulfadimethoxine	[no description available]	low	0	0	aromatic ether; pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; drug allergen; environmental contaminant; xenobiotic
tetrahydropapaverine	[no description available]	low	0	0	aromatic ether; benzylisoquinoline alkaloid; benzyltetrahydroisoquinoline; polyether; secondary amino compound
triclosan	[no description available]	low	0	0	aromatic ether; dichlorobenzene; monochlorobenzenes; phenols	antibacterial agent; antimalarial; drug allergen; EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; fungicide; persistent organic pollutant; xenobiotic
viloxazine	[no description available]	low	0	0	aromatic ether
wb 4101	[no description available]	low	0	0	aromatic ether; benzodioxine; secondary amino compound	alpha-adrenergic antagonist
3,3',5-triiodothyropropionic acid	[no description available]	low	0	0	aromatic ether
methacetin	[no description available]	low	0	0	acetamides; aromatic ether
mestranol	[no description available]	low	0	0	17beta-hydroxy steroid; aromatic ether; terminal acetylenic compound	prodrug; xenoestrogen
visnagin	[no description available]	low	0	0	aromatic ether; furanochromone; polyketide	anti-inflammatory agent; antihypertensive agent; EC 1.1.1.37 (malate dehydrogenase) inhibitor; phytotoxin; plant metabolite; vasodilator agent
2-tert-butyl-4-hydroxyanisole	[no description available]	low	0	0	aromatic ether; phenols
mecoprop	[no description available]	low	0	0	aromatic ether; monocarboxylic acid; monochlorobenzenes
phenetidine	[no description available]	low	0	0	aromatic ether; substituted aniline
2-methyl-4-chlorophenoxy gamma-butyric acid	[no description available]	low	0	0	aromatic ether; monocarboxylic acid; monochlorobenzenes	environmental contaminant; phenoxy herbicide; xenobiotic
4-bromophenyl phenyl ether	[no description available]	low	0	0	aromatic ether; organobromine compound
di-(4-aminophenyl)ether	[no description available]	low	0	0	aromatic ether
phenyl ether	[no description available]	low	0	0	aromatic ether	plant metabolite
diglycidyl resorcinol ether	[no description available]	low	0	0	aromatic ether
phenetole	[no description available]	low	0	0	aromatic ether
scoparone	[no description available]	low	0	0	aromatic ether; coumarins	anti-allergic agent; anti-inflammatory agent; antihypertensive agent; antilipemic drug; immunosuppressive agent; plant metabolite
dimethoxyphenylethylamine	[no description available]	low	0	0	alkaloid; aromatic ether; phenylethylamine	allergen; plant metabolite
dichlorprop	[no description available]	low	0	0	aromatic ether; dichlorobenzene; monocarboxylic acid
3-tert-butyl-4-hydroxyanisole	[no description available]	low	0	0	aromatic ether; phenols	antioxidant; human xenobiotic metabolite
ethyl vanillin	[no description available]	low	0	0	aromatic ether; benzaldehydes; phenols	antioxidant; flavouring agent
benzethonium chloride	[no description available]	low	0	0	aromatic ether; chloride salt; quaternary ammonium salt	antibacterial agent; antifungal agent; antiseptic drug; antiviral agent; disinfectant
peucedanin	[no description available]	low	0	0	aromatic ether; furanocoumarin; lactone	plant metabolite
phenetidine	[no description available]	low	0	0	aromatic ether; primary amino compound; substituted aniline	drug metabolite
6-methoxybenzoxazolinone	[no description available]	low	0	0	aromatic ether; benzoxazole	antibacterial agent; anticonvulsant; antifungal agent; muscle relaxant; plant metabolite
3-anisidine	[no description available]	low	0	0	aromatic ether; substituted aniline
domiphen bromide	[no description available]	low	0	0	aromatic ether
dibrompropamidine	[no description available]	low	0	0	aromatic ether
4-Ethoxyphenol	[no description available]	low	0	0	aromatic ether; phenols
bulbocapnine	[no description available]	low	0	0	aporphine alkaloid; aromatic ether; oxacycle; phenols	EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor; EC 1.4.3.22 (diamine oxidase) inhibitor; plant metabolite
xylocholine	[no description available]	low	0	0	aromatic ether
3-methoxycatechol	[no description available]	low	0	0	aromatic ether; catechols	G-protein-coupled receptor agonist
2-phenoxypropanoic acid	[no description available]	low	0	0	aromatic ether; carboxylic acid
6-methoxyquinoline	[no description available]	low	0	0	aromatic ether; quinolines
metaxalone	[no description available]	low	0	0	aromatic ether
heliamine	[no description available]	low	0	0	aromatic ether; diether; isoquinoline alkaloid; isoquinolines	plant metabolite
2,4,6-trichlorophenyl 4-nitrophenyl ether	[no description available]	low	0	0	aromatic ether; C-nitro compound; chlorobenzenes	EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor; herbicide
etridiazol	[no description available]	low	0	0	aromatic ether; organochlorine compound; thiadiazole antifungal agent; thiadiazoles	antifungal agrochemical; nitrification inhibitor
toliprolol	[no description available]	low	0	0	aromatic ether
5-methoxyindoleacetic acid	[no description available]	low	0	0	aromatic ether; indole-3-acetic acids	antibacterial agent; Brassica napus metabolite; carcinogenic agent; human urinary metabolite; marine xenobiotic metabolite; rat metabolite
iproclozide	[no description available]	low	0	0	aromatic ether
phenoxyacetic acid	[no description available]	low	0	0	aromatic ether; monocarboxylic acid	allergen; Aspergillus metabolite; human xenobiotic metabolite; plant growth retardant
nafenopin	[no description available]	low	0	0	aromatic ether; monocarboxylic acid
methyl vanillate	[no description available]	low	0	0	aromatic ether; benzoate ester; phenols	antioxidant; plant metabolite
5-methoxyindole-2-carboxylic acid	[no description available]	low	0	0	aromatic ether; indolecarboxylic acid	EC 1.8.1.4 (dihydrolipoyl dehydrogenase) inhibitor; hypoglycemic agent; plant metabolite
2-isopropoxyphenol	[no description available]	low	0	0	aromatic ether; phenols
dehydroemetine	[no description available]	low	0	0	aromatic ether; isoquinolines; pyridoisoquinoline	antileishmanial agent; antimalarial; antiprotozoal drug
1,2-epoxy-3-(p-nitrophenoxy)propane	[no description available]	low	0	0	aromatic ether; C-nitro compound; epoxide
laurolitsine	[no description available]	low	0	0	aporphine alkaloid; aromatic ether; phenols	HIV-1 integrase inhibitor; metabolite
metocurine iodide	[no description available]	low	0	0	aromatic ether
ac 45594	[no description available]	low	0	0	aromatic ether
3-phenoxybenzylalcohol	[no description available]	low	0	0	aromatic ether; benzyl alcohols	marine xenobiotic metabolite
devrinol	[no description available]	low	0	0	aromatic ether; monocarboxylic acid amide; naphthalenes
fluorodifen	[no description available]	low	0	0	aromatic ether
acridine half-mustard	[no description available]	low	0	0	aminoacridines; aromatic ether; organochlorine compound; secondary amino compound	mutagen
precocene i	[no description available]	low	0	0	aromatic ether; chromenes	plant metabolite; precocenes
oxadiazon	[no description available]	low	0	0	aromatic ether
lofexidine	[no description available]	low	0	0	aromatic ether; carboxamidine; dichlorobenzene; imidazoles	alpha-adrenergic agonist; antihypertensive agent
alclofenac	[no description available]	low	0	0	aromatic ether; monocarboxylic acid; monochlorobenzenes	drug allergen; non-narcotic analgesic; non-steroidal anti-inflammatory drug
phenylglycidyl ether	[no description available]	low	0	0	aromatic ether
phenoxyethanol	[no description available]	low	0	0	aromatic ether; glycol ether; primary alcohol	antiinfective agent; central nervous system depressant
metipranolol	[no description available]	low	0	0	acetate ester; aromatic ether; propanolamine; secondary amino compound	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
silybin	[no description available]	low	0	0	aromatic ether; benzodioxine; flavonolignan; polyphenol; secondary alpha-hydroxy ketone	antineoplastic agent; antioxidant; hepatoprotective agent; plant metabolite
oxamethacin	[no description available]	low	0	0	aromatic ether; hydroxamic acid; N-acylindole; organochlorine compound	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
canadine	[no description available]	low	0	0	aromatic ether; berberine alkaloid; organic heteropentacyclic compound; oxacycle
7-ethoxycoumarin	[no description available]	low	0	0	aromatic ether; coumarins
medifoxamine	[no description available]	low	0	0	aromatic ether
chlormethoxynil	[no description available]	low	0	0	aromatic ether
climbazole	[no description available]	low	0	0	aromatic ether; hemiaminal ether; imidazoles; ketone; monochlorobenzenes
4-hexyloxyaniline	[no description available]	low	0	0	aromatic ether; substituted aniline
ticrynafen	[no description available]	low	0	0	aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid; thiophenes	antihypertensive agent; hepatotoxic agent; loop diuretic
2-(4-(2,4-dichlorophenoxy)phenoxy)propionic acid	[no description available]	low	0	0	aromatic ether; dichlorobenzene; diether; monocarboxylic acid
bezafibrate	[no description available]	low	0	0	aromatic ether; monocarboxylic acid amide; monocarboxylic acid; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
oxyfluorofen	[no description available]	low	0	0	aromatic ether	EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor; herbicide
triadimefon	[no description available]	low	0	0	aromatic ether; hemiaminal ether; ketone; monochlorobenzenes; triazoles
levobunolol	[no description available]	low	0	0	aromatic ether; cyclic ketone; propanolamine	antiglaucoma drug; beta-adrenergic antagonist
dichlorfop-methyl	[no description available]	low	0	0	aromatic ether; dichlorobenzene; diether; methyl ester
decamethrin	[no description available]	low	0	0	aromatic ether; cyclopropanecarboxylate ester; nitrile; organobromine compound	agrochemical; antifeedant; calcium channel agonist; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; pyrethroid ester insecticide
triadimenol	[no description available]	low	0	0	aromatic ether; conazole fungicide; hemiaminal ether; monochlorobenzenes; secondary alcohol; triazole fungicide	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; xenobiotic metabolite
triclopyr	[no description available]	low	0	0	aromatic ether; chloropyridine; monocarboxylic acid	agrochemical; environmental contaminant; herbicide; xenobiotic
prenalterol	[no description available]	low	0	0	aromatic ether
st 1059	[no description available]	low	0	0	aromatic ether; primary amino compound; secondary alcohol	alpha-adrenergic agonist; sympathomimetic agent; vasoconstrictor agent
paroxetine	[no description available]	low	0	0	aromatic ether; benzodioxoles; organofluorine compound; piperidines	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
acifluorfen	[no description available]	low	0	0	aromatic ether; benzoic acids; C-nitro compound; monocarboxylic acid; organochlorine compound; organofluorine compound	agrochemical; EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor; herbicide
bopindolol	[no description available]	low	0	0	aromatic ether; benzoate ester; methylindole; secondary amino compound
fenpropathrin, (+-)-isomer	[no description available]	low	0	0	aromatic ether; cyclopropanecarboxylate ester	agrochemical; pyrethroid ester acaricide; pyrethroid ester insecticide
triflumuron	[no description available]	low	0	0	aromatic ether; benzoylurea insecticide; monochlorobenzenes; organofluorine compound
flutolanil	[no description available]	low	0	0	(trifluoromethyl)benzenes; aromatic ether; benzamides; benzanilide fungicide	antifungal agrochemical; EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor
fenoxaprop ethyl	[no description available]	low	0	0	aromatic ether
triclabendazole	[no description available]	low	0	0	aromatic ether
4,5-amino-3,5-dichloro-6-fluoro-2-pyridinyloxyacetic acid	[no description available]	low	0	0	aminopyridine; aromatic ether; monocarboxylic acid; organochlorine compound; organofluorine compound	environmental contaminant; herbicide; xenobiotic
fluvalinate	[no description available]	low	0	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; nitrile; organochlorine acaricide; organochlorine insecticide; organofluorine acaricide; organofluorine insecticide	agrochemical; pyrethroid ester acaricide; pyrethroid ester insecticide
haloxyfop	[no description available]	low	0	0	aromatic ether; monocarboxylic acid; organochlorine compound; organofluorine compound; pyridines
fluazifop-butyl	[no description available]	low	0	0	aromatic ether; carboxylic ester; organofluorine compound; pyridines
fomesafen	[no description available]	low	0	0	aromatic ether; C-nitro compound; monochlorobenzenes; N-sulfonylcarboxamide; organofluorine compound; phenols	agrochemical; EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor; herbicide
fenoxycarb	[no description available]	low	0	0	aromatic ether; carbamate ester	environmental contaminant; insecticide; juvenile hormone mimic; xenobiotic
quizalofop-ethyl	[no description available]	low	0	0	aromatic ether; ethyl ester; organochlorine compound; quinoxaline derivative
cetamolol	[no description available]	low	0	0	aromatic ether
atomoxetine	[no description available]	low	0	0	aromatic ether; secondary amino compound; toluenes	adrenergic uptake inhibitor; antidepressant; environmental contaminant; xenobiotic
methyl bensulfuron	[no description available]	low	0	0	aromatic ether; methyl ester; N-sulfonylurea; pyrimidines	agrochemical; EC 2.2.1.6 (acetolactate synthase) inhibitor; herbicide
itraconazole	[no description available]	low	0	0	aromatic ether; conazole antifungal drug; cyclic ketal; dichlorobenzene; dioxolane; N-arylpiperazine; triazole antifungal drug; triazoles	EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; Hedgehog signaling pathway inhibitor; P450 inhibitor
loxtidine	[no description available]	low	0	0	aromatic ether; piperidines; primary alcohol; triazoles	H2-receptor antagonist
disoxaril	[no description available]	low	0	0	aromatic ether
chlorimuron ethyl	[no description available]	low	0	0	aromatic ether; ethyl ester; N-sulfonylurea; organochlorine pesticide; pyrimidines; sulfamoylbenzoate	agrochemical; EC 2.2.1.6 (acetolactate synthase) inhibitor; proherbicide
tepoxalin	[no description available]	low	0	0	aromatic ether; hydroxamic acid; monochlorobenzenes; pyrazoles	antipyretic; apoptosis inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; immunomodulator; lipoxygenase inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
pioglitazone hydrochloride	[no description available]	low	0	0	aromatic ether
aripiprazole	[no description available]	low	0	0	aromatic ether; delta-lactam; dichlorobenzene; N-alkylpiperazine; N-arylpiperazine; quinolone	drug metabolite; H1-receptor antagonist; second generation antipsychotic; serotonergic agonist
sulfametrole	[no description available]	low	0	0	aromatic ether; substituted aniline; sulfonamide antibiotic; thiadiazoles
propamidine	[no description available]	low	0	0	aromatic ether; guanidines; polyether	antimicrobial agent; antiseptic drug
hexamidine	[no description available]	low	0	0	aromatic ether; guanidines; polyether	antimicrobial agent; antiseptic drug
o-4-methylthymine	[no description available]	low	0	0	aromatic ether; methylthymine	human metabolite
fenclofenac	[no description available]	low	0	0	aromatic ether
tetraiodothyroacetic acid	[no description available]	low	0	0	2-halophenol; aromatic ether; iodophenol; monocarboxylic acid	apoptosis inducer; human metabolite; thyroid hormone
fluazuron	[no description available]	low	0	0	aromatic ether; chloropyridine; monochlorobenzenes; N-acylurea; organochlorine acaricide; organofluorine acaricide; phenylureas	acaricide; mite growth regulator
etiroxate	[no description available]	low	0	0	aromatic ether
etofamide	[no description available]	low	0	0	aromatic ether
esreboxetine	[no description available]	low	0	0	aromatic ether
guaethol	[no description available]	low	0	0	aromatic ether; phenols; volatile organic compound	flavouring agent
5'-nitro-2'-propoxyacetanilide	[no description available]	low	0	0	aromatic ether; C-nitro compound
suberosin	[no description available]	low	0	0	aromatic ether; coumarins	anticoagulant; plant metabolite
4-methoxyestradiol	[no description available]	low	0	0	17beta-hydroxy steroid; 3-hydroxy steroid; aromatic ether; phenols	estrogen; human metabolite; rat metabolite
toltrazuril	[no description available]	low	0	0	aromatic ether
plafibride	[no description available]	low	0	0	aromatic ether
cinitapride	[no description available]	low	0	0	aromatic ether; C-nitro compound
isoscopoletin	[no description available]	low	0	0	aromatic ether; hydroxycoumarin	plant metabolite
ethofenprox	[no description available]	low	0	0	aromatic ether	pyrethroid ether insecticide
fenoxypropazine	[no description available]	low	0	0	aromatic ether
fluphenacur	[no description available]	low	0	0	aromatic ether; benzoylurea insecticide; dichlorobenzene; N-acylurea; organofluorine compound
amezinium	[no description available]	low	0	0	aromatic ether; primary arylamine; pyridazinium ion	adrenergic uptake inhibitor; antihypotensive agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; sympathomimetic agent
rubrofusarin	[no description available]	low	0	0	aromatic ether; benzochromenone; phenols; polyketide	biological pigment; EC 1.14.18.1 (tyrosinase) inhibitor; fungal metabolite
triasulfuron	[no description available]	low	0	0	1,3,5-triazines; aromatic ether; N-sulfonylurea; organochlorine compound	agrochemical; herbicide
uvaretin	[no description available]	low	0	0	aromatic ether; dihydrochalcones; polyketide; resorcinol	antineoplastic agent; plant metabolite
fangchinoline	[no description available]	low	0	0	aromatic ether; bisbenzylisoquinoline alkaloid; macrocycle	anti-HIV-1 agent; anti-inflammatory agent; antineoplastic agent; antioxidant; neuroprotective agent; plant metabolite
prochloraz	[no description available]	low	0	0	amide fungicide; aromatic ether; conazole fungicide; imidazole fungicide; imidazoles; trichlorobenzene; ureas	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; environmental contaminant; xenobiotic
stictic acid	[no description available]	low	0	0	aromatic ether
pramoxine hydrochloride	[no description available]	low	0	0	aromatic ether
4-methoxybenzylamine	[no description available]	low	0	0	aralkylamino compound; aromatic ether; primary amino compound
xanthurenic acid 8-methyl ether	[no description available]	low	0	0	aromatic ether; monohydroxyquinoline; quinolinemonocarboxylic acid	carcinogenic agent; metabolite; mouse metabolite
adriamycinol	[no description available]	low	0	0	aminoglycoside; anthracycline antibiotic; aromatic ether; deoxy hexoside; p-quinones; phenols; polyol; tetracenequinones	cardiotoxic agent; drug metabolite
difenoconazole	[no description available]	low	0	0	aromatic ether; conazole fungicide; cyclic ketal; dioxolane; triazole fungicide; triazoles	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; environmental contaminant; xenobiotic
a 8947	[no description available]	low	0	0	aromatic ether; biaryl; N-sulfonylurea; pyrazole pesticide; tetrazoles	EC 2.2.1.6 (acetolactate synthase) inhibitor; herbicide
thifluzamide	[no description available]	low	0	0	1,3-thiazoles; anilide fungicide; aromatic amide; aromatic ether; dibromobenzene; organofluorine compound	antifungal agrochemical; EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor
ethylhydrocupreine	[no description available]	low	0	0	aromatic ether; cinchona alkaloid	EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
7,8-dihydromethysticin	[no description available]	low	0	0	2-pyranones; aromatic ether
4,5-dimethoxy-2-nitrobenzaldehyde	[no description available]	low	0	0	aromatic ether; C-nitro compound
bisphenol f diglycidyl ether	[no description available]	low	0	0	aromatic ether; diarylmethane; epoxide
oryzemate	[no description available]	low	0	0	1,2-benzisothiazole; aromatic ether; benzothiazole fungicide; sulfone	antifungal agrochemical; plant activator
bitertanol	[no description available]	low	0	0	aromatic ether; biphenyls; secondary alcohol; triazoles
fluazifop	[no description available]	low	0	0	aromatic ether; monocarboxylic acid; organofluorine compound; pyridines
diflufenican	[no description available]	low	0	0	(trifluoromethyl)benzenes; aromatic ether; pyridinecarboxamide	carotenoid biosynthesis inhibitor; environmental contaminant; herbicide; xenobiotic
hexafluoron	[no description available]	low	0	0	aromatic ether; benzoylurea insecticide; dichlorobenzene; N-acylurea; organochlorine insecticide; organofluorine insecticide
diethofencarb	[no description available]	low	0	0	aromatic ether; carbamate ester; carbanilate fungicide	antifungal agrochemical
pyriproxyfen	[no description available]	low	0	0	aromatic ether; pyridines	juvenile hormone mimic
methyl 2-(((((4-ethoxy-6-(methylamino)-1,3,5-triazin-2-yl)amino)carbonyl)amino)sulfonyl)benzoate	[no description available]	low	0	0	aromatic ether; benzoate ester; diamino-1,3,5-triazine; methyl ester; N-sulfonylurea	EC 2.2.1.6 (acetolactate synthase) inhibitor; herbicide
dpx e9636	[no description available]	low	0	0	aromatic ether; N-sulfonylurea; pyridines; pyrimidines; sulfone	environmental contaminant; herbicide; xenobiotic
aclonifen	[no description available]	low	0	0	aromatic ether; C-nitro compound; monochlorobenzenes; primary amino compound; substituted aniline	agrochemical; carotenoid biosynthesis inhibitor; EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor; herbicide
cinosulfuron	[no description available]	low	0	0	aromatic ether
clodinafop-propargyl	[no description available]	low	0	0	aromatic ether; carboxylic ester; organochlorine compound; organofluorine compound; propyzamide; pyridines	agrochemical; EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor; herbicide
vestitol	[no description available]	low	0	0	aromatic ether; hydroxyisoflavans; methoxyisoflavan	anti-inflammatory agent; phytoalexin; plant metabolite
laudanine	[no description available]	low	0	0	aromatic ether; benzylisoquinoline alkaloid; benzyltetrahydroisoquinoline; phenols; racemate
cryptopleurine	[no description available]	low	0	0	alkaloid antibiotic; alkaloid; aromatic ether; organic heteropentacyclic compound	antineoplastic agent; antiviral agent; protein synthesis inhibitor
6-hydroxymethylmexiletine	[no description available]	low	0	0	aromatic ether
4-hydroxymexiletine	[no description available]	low	0	0	aromatic ether; phenols
cloquintocet-mexyl	[no description available]	low	0	0	aromatic ether; carboxylic ester; organochlorine compound; quinolines
novaluron	[no description available]	low	0	0	aromatic ether; benzoylurea insecticide; monochlorobenzenes; organofluorine compound
bursehernin	[no description available]	low	0	0	aromatic ether; benzodioxoles; butan-4-olide; lignan	plant metabolite
2,2',4,4'-tetrabromodiphenyl ether	[no description available]	low	0	0	aromatic ether; organobromine compound
syringaresinol	[no description available]	low	0	0	aromatic ether; furofuran; lignan; polyether; polyphenol	plant metabolite
p-methoxy-n-methylphenethylamine	[no description available]	low	0	0	aromatic ether; secondary amino compound	metabolite
aflatoxin q1	[no description available]	low	0	0	aflatoxin; aromatic ether; aromatic ketone	carcinogenic agent; human xenobiotic metabolite
u 73122	[no description available]	low	0	0	aromatic ether; aza-steroid; maleimides	EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor
cyfluthrin	[no description available]	low	0	0	aromatic ether; cyclopropanecarboxylate ester; nitrile; organochlorine compound; organofluorine compound	agrochemical; pyrethroid ester insecticide
norverapamil	[no description available]	low	0	0	aromatic ether; nitrile; polyether; secondary amino compound
fumitremorgin a	[no description available]	low	0	0	aromatic ether; diol; indole alkaloid; organic heterohexacyclic compound; organic peroxide	mycotoxin
deguelin	[no description available]	low	0	0	aromatic ether; diether; organic heteropentacyclic compound; rotenones	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; mitochondrial NADH:ubiquinone reductase inhibitor; plant metabolite
aristolochic acid ii	[no description available]	low	0	0	aristolochic acids; aromatic ether; C-nitro compound; cyclic acetal; monocarboxylic acid; organic heterotetracyclic compound	carcinogenic agent; metabolite; mutagen; nephrotoxin; toxin
tephrosin	[no description available]	low	0	0	aromatic ether; cyclic ketone; organic heteropentacyclic compound; rotenones	antineoplastic agent; metabolite; pesticide
alpha-hydroxymetoprolol	[no description available]	low	0	0	aromatic ether
5-(tetradecyloxy)-2-furancarboxylic acid	[no description available]	low	0	0	aromatic ether; furoic acid	antineoplastic agent; apoptosis inducer; EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor; PPARalpha agonist
tafenoquine	[no description available]	low	0	0	(trifluoromethyl)benzenes; aminoquinoline; aromatic ether; primary amino compound; secondary amino compound
5-hydroxymethylomeprazole	[no description available]	low	0	0	aromatic ether; benzimidazoles; pyridines; sulfoxide	drug metabolite
ym 12617	[no description available]	low	0	0	aromatic ether; secondary amino compound; sulfonamide
cgp 28392	[no description available]	low	0	0	aromatic ether
sodium-binding benzofuran isophthalate	[no description available]	low	0	0	1-benzofurans; aromatic ether; crown compound; tetracarboxylic acid	fluorochrome
garenoxacin	[no description available]	low	0	0	aromatic ether; cyclopropanes; isoindoles; organofluorine compound; quinolinemonocarboxylic acid; quinolone antibiotic	antibacterial drug; non-steroidal anti-inflammatory drug
ay 25545	[no description available]	low	0	0	acetate ester; aromatic ether; C-glycosyl compound; naphthoisochromene; olefinic compound; phenols; tertiary amine	antimicrobial agent; antineoplastic agent; bacterial metabolite
b 823-08	[no description available]	low	0	0	aromatic ether
cyclazosin	[no description available]	low	0	0	aromatic amide; aromatic ether; furans; monocarboxylic acid amide; quinazolines; quinoxaline derivative	adenosine A2A receptor antagonist
febuxostat	[no description available]	low	0	0	1,3-thiazolemonocarboxylic acid; aromatic ether; nitrile	EC 1.17.3.2 (xanthine oxidase) inhibitor
marsupsin	[no description available]	low	0	0	1-benzofurans; aromatic ether; polyphenol	antilipemic drug; hypoglycemic agent; metabolite
6,6'-bieckol	[no description available]	low	0	0	aromatic ether; oxacycle; phlorotannin	anti-HIV-1 agent; metabolite; radical scavenger
xibenolol	[no description available]	low	0	0	aromatic ether
cicloprolol	[no description available]	low	0	0	aromatic ether
chs 828	[no description available]	low	0	0	aromatic ether
2-(4-methoxyphenoxy)propanoic acid	[no description available]	low	0	0	aromatic ether; carboxylic acid
moxifloxacin	[no description available]	low	0	0	aromatic ether; cyclopropanes; fluoroquinolone antibiotic; pyrrolidinopiperidine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug
rp 73401	[no description available]	low	0	0	aromatic ether; benzamides; chloropyridine; monocarboxylic acid amide	anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; phosphodiesterase IV inhibitor
2,2',4,4',5,5'-hexabrominated diphenyl ether	[no description available]	low	0	0	aromatic ether; organobromine compound
varespladib	[no description available]	low	0	0	aromatic ether; benzenes; dicarboxylic acid monoamide; indoles; monocarboxylic acid; primary carboxamide	anti-inflammatory drug; antidote; EC 3.1.1.4 (phospholipase A2) inhibitor
birb 796	[no description available]	low	0	0	aromatic ether; morpholines; naphthalenes; pyrazoles; ureas	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; immunomodulator
schizandrin b	[no description available]	low	0	0	aromatic ether; cyclic acetal; organic heterotetracyclic compound; oxacycle; tannin	anti-asthmatic agent; anti-inflammatory agent; antilipemic drug; antioxidant; apoptosis inhibitor; hepatoprotective agent; nephroprotective agent; neuroprotective agent; plant metabolite
s 23121	[no description available]	low	0	0	aromatic ether; dicarboximide; monochlorobenzenes; monofluorobenzenes; pyrroline; terminal acetylenic compound
acrovestone	[no description available]	low	0	0	acetophenones; aromatic ether; olefinic compound; polyphenol	antioxidant; EC 1.14.18.1 (tyrosinase) inhibitor; plant metabolite
actinodaphine	[no description available]	low	0	0	aporphine alkaloid; aromatic ether; organic heteropentacyclic compound; phenols; secondary amino compound	antibacterial agent; antifungal agent; antineoplastic agent; apoptosis inducer; plant metabolite; platelet aggregation inhibitor; topoisomerase inhibitor
isohomovanillic acid	[no description available]	low	0	0	aromatic ether; phenols; phenylacetic acids	metabolite
3,5-diiodothyropropionic acid	[no description available]	low	0	0	aromatic ether; monocarboxylic acid; organoiodine compound; phenols
7,8-dihydro-5,6-dehydrokawain	[no description available]	low	0	0	2-pyranones; aromatic ether
4-amino-2-methoxypyrimidine	[no description available]	low	0	0	aminopyrimidine; aromatic ether; methylcytosine	metabolite
aristolochic acid D	[no description available]	low	0	0	aristolochic acids; aromatic ether; C-nitro compound; cyclic acetal; monocarboxylic acid; organic heterotetracyclic compound	carcinogenic agent; metabolite; nephrotoxin; toxin
myricanone	[no description available]	low	0	0	aromatic ether; cyclic ketone; diarylheptanoid; methoxybenzenes; phenols	antineoplastic agent; plant metabolite
pannarin	[no description available]	low	0	0	aldehyde; aromatic ether; depsidones; organic heterotricyclic compound; organochlorine compound; phenols	antimicrobial agent; antineoplastic agent; apoptosis inducer; lichen metabolite
aminopotentidine	[no description available]	low	0	0	aromatic ether; benzamides; guanidines; nitrile; piperidines; substituted aniline	H2-receptor antagonist
aristolochic acid c	[no description available]	low	0	0	aristolochic acids; aromatic ether; C-nitro compound; cyclic acetal; monocarboxylic acid; organic heterotetracyclic compound	carcinogenic agent; metabolite; mutagen; nephrotoxin; toxin
pluviatolide	[no description available]	low	0	0	aromatic ether; benzodioxoles; butan-4-olide; lignan; phenols	plant metabolite
erysodine	[no description available]	low	0	0	aromatic ether; diether; Erythrina alkaloid; organic heterotetracyclic compound; phenols	antiparasitic agent; nicotinic antagonist; phytogenic insecticide
erlotinib	[no description available]	low	0	0	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor
rubrofusarin B	[no description available]	low	0	0	aromatic ether; benzochromenone; naphtho-gamma-pyrone; phenols; polyketide	Aspergillus metabolite
ly 293111	[no description available]	low	0	0	aromatic ether
enrasentan	[no description available]	low	0	0	aromatic ether; benzodioxoles; indanes; monocarboxylic acid; monomethoxybenzene; primary alcohol	antihypertensive agent; endothelin receptor antagonist
quizalofop	[no description available]	low	0	0	aromatic ether; monocarboxylic acid; organochlorine compound; quinoxaline derivative
cyhalofop-butyl	[no description available]	low	0	0	aromatic ether
cyperin	[no description available]	low	0	0	aromatic ether
aflatoxin b1	[no description available]	low	0	0	aflatoxin; aromatic ether; aromatic ketone	carcinogenic agent; human metabolite
etravirine	[no description available]	low	0	0	aminopyrimidine; aromatic ether; dinitrile; organobromine compound	antiviral agent; HIV-1 reverse transcriptase inhibitor
5-o-methyllicoricidin	[no description available]	low	0	0	aromatic ether; hydroxyisoflavans; methoxyisoflavan	antibacterial agent; plant metabolite
pronuciferine	[no description available]	low	0	0	aromatic ether; cyclic ketone; isoquinoline alkaloid; isoquinolines; organic heterotetracyclic compound	plant metabolite
famoxadone	[no description available]	low	0	0	aromatic ether; carbohydrazide; oxazolidinone
cimicoxib	[no description available]	low	0	0	aromatic ether; imidazoles; organochlorine compound; organofluorine compound; sulfonamide	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
sorafenib	[no description available]	low	0	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
dabuzalgron	[no description available]	low	0	0	aromatic ether; imidazoles; monochlorobenzenes; sulfonamide	alpha-adrenergic agonist
fonsecin	[no description available]	low	0	0	aromatic ether; cyclic hemiketal; heptaketide; naphtho-gamma-pyrone; phenols	Aspergillus metabolite; marine metabolite
lasofoxifene	[no description available]	low	0	0	aromatic ether; N-alkylpyrrolidine; naphthols; tetralins	antineoplastic agent; bone density conservation agent; cardioprotective agent; estrogen receptor agonist; estrogen receptor antagonist
(+-)-Dihydromethysticin	[no description available]	low	0	0	2-pyranones; aromatic ether
2-[2-[2-(2-aminophenoxy)ethoxy]ethoxy]aniline	[no description available]	low	0	0	aromatic ether; substituted aniline
chondocurine (1beta)-(+-)-isomer	[no description available]	low	0	0	aromatic ether
1-methyl-4-prop-2-enoxy-2-pyrimidinone	[no description available]	low	0	0	aromatic ether; pyrimidone
4-[4-(3-methyl-4-nitrophenoxy)butoxy]benzonitrile	[no description available]	low	0	0	aromatic ether; C-nitro compound
lariciresinol	[no description available]	low	0	0	aromatic ether; lignan; oxolanes; phenols; primary alcohol	antifungal agent; plant metabolite
tryptoquivaline	[no description available]	low	0	0	aromatic ether; indole alkaloid; organic heteropentacyclic compound	breast cancer resistance protein inhibitor; mycotoxin
2-methoxyestrone	[no description available]	low	0	0	17-oxo steroid; 3-hydroxy steroid; alicyclic ketone; aromatic ether; phenolic steroid; phenols	human metabolite; mouse metabolite
win 54954	[no description available]	low	0	0	aromatic ether
silychristin	[no description available]	low	0	0	1-benzofurans; aromatic ether; flavonolignan; polyphenol; secondary alpha-hydroxy ketone	lipoxygenase inhibitor; metabolite; prostaglandin antagonist; radical scavenger
cleomiscosin a	[no description available]	low	0	0	aromatic ether; delta-lactone; organic heterotricyclic compound; phenols; primary alcohol	anti-inflammatory agent; metabolite
bispyribac	[no description available]	low	0	0	aromatic ether; benzoic acids; monocarboxylic acid; pyrimidines	herbicide
petunidin-3-glucoside	[no description available]	low	0	0	anthocyanin cation; aromatic ether; beta-D-glucoside	antioxidant; metabolite
malvidin-3-glucoside	[no description available]	low	0	0	anthocyanin cation; aromatic ether; beta-D-glucoside	metabolite
dioncophylline c	[no description available]	low	0	0	aromatic ether; biaryl; isoquinoline alkaloid; isoquinolines; methoxynaphthalene; methylnaphthalenes; naphthols	antimalarial; antiplasmodial drug; metabolite
stigmatellin	[no description available]	low	0	0	aromatic ether; chromones; olefinic compound; phenols	bacterial metabolite; quinol oxidation site inhibitor
roflumilast	[no description available]	low	0	0	aromatic ether; benzamides; chloropyridine; cyclopropanes; organofluorine compound	anti-asthmatic drug; phosphodiesterase IV inhibitor
teniposide	[no description available]	low	0	0	aromatic ether; beta-D-glucoside; cyclic acetal; furonaphthodioxole; gamma-lactone; monosaccharide derivative; phenols; thiophenes	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
prinomastat	[no description available]	low	0	0	aromatic ether; hydroxamic acid; pyridines; sulfonamide; thiomorpholines	antineoplastic agent; EC 3.4.24.35 (gelatinase B) inhibitor; matrix metalloproteinase inhibitor
posaconazole	[no description available]	low	0	0	aromatic ether; conazole antifungal drug; N-arylpiperazine; organofluorine compound; oxolanes; triazole antifungal drug; triazoles	trypanocidal drug
gancaonin I	[no description available]	low	0	0	1-benzofurans; aromatic ether; resorcinols	antibacterial agent; plant metabolite
glycyrin	[no description available]	low	0	0	aromatic ether; coumarins; hydroxyisoflavans	antibacterial agent; metabolite; plant metabolite
glyasperin D	[no description available]	low	0	0	aromatic ether; hydroxyisoflavans; methoxyisoflavan	plant metabolite
licoricidin	[no description available]	low	0	0	aromatic ether; hydroxyisoflavans; methoxyisoflavan	antibacterial agent; plant metabolite
egonol	[no description available]	low	0	0	1-benzofurans; aromatic ether; benzodioxoles; primary alcohol	plant metabolite
N-ethylharmine	[no description available]	low	0	0	aromatic ether; beta-carbolines; semisynthetic derivative	anti-HIV agent
pf 1163a	[no description available]	low	0	0	aromatic ether; lactam; macrolide antibiotic; secondary alcohol	antifungal agent; Penicillium metabolite
pf 1163b	[no description available]	low	0	0	aromatic ether; lactam; macrolide antibiotic	antifungal agent; Penicillium metabolite
licocoumarone	[no description available]	low	0	0	1-benzofurans; aromatic ether; resorcinols	antibacterial agent; apoptosis inducer; EC 1.4.3.4 (monoamine oxidase) inhibitor; plant metabolite
4-(4-chloro-2-methylphenoxy)-n-hydroxybutanamide	[no description available]	low	0	0	aromatic ether
LSM-22807	[no description available]	low	0	0	aromatic ether
N-[2-(3-methylphenoxy)ethyl]-1H-1,2,4-triazole-5-carboxamide	[no description available]	low	0	0	aromatic ether
piperlactam s	[no description available]	low	0	0	alkaloid; aromatic ether; gamma-lactam; organic heterotetracyclic compound; phenols	anti-inflammatory agent; antioxidant; plant metabolite
5,5-dioxo-1-(4-phenoxyphenyl)-3a,4,6,6a-tetrahydro-3H-thieno[3,4-b]pyrrol-2-one	[no description available]	low	0	0	aromatic ether
antofine	[no description available]	low	0	0	alkaloid antibiotic; alkaloid; aromatic ether; organic heteropentacyclic compound	angiogenesis inhibitor; anti-inflammatory agent; antimicrobial agent; antineoplastic agent; antiviral agent; phytotoxin; plant metabolite
xanthohumol	[no description available]	low	0	0	aromatic ether; chalcones; polyphenol	anti-HIV-1 agent; antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.3.1.20 (diacylglycerol O-acyltransferase) inhibitor; metabolite
2-phenoxy-N-(2-pyridinyl)butanamide	[no description available]	low	0	0	aromatic ether
6-amino-4-(2-ethoxyphenyl)-3-propyl-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile	[no description available]	low	0	0	aromatic ether; pyranopyrazole
N-[4-[4-[[1-oxo-2-(1-pyrrolidinyl)ethyl]amino]phenoxy]phenyl]-2-(1-pyrrolidinyl)acetamide	[no description available]	low	0	0	aromatic ether
2-(3,4-diethoxyphenyl)-5-(2-furanyl)-1,3,4-oxadiazole	[no description available]	low	0	0	aromatic ether
2-[[5-(phenoxymethyl)-4-(2-phenylethyl)-1,2,4-triazol-3-yl]thio]acetamide	[no description available]	low	0	0	aromatic ether
1-(8-methyl-2,5,11,14-tetraoxa-8-azabicyclo[13.4.0]nonadeca-1(15),16,18-trien-17-yl)ethanol	[no description available]	low	0	0	aromatic ether
3-[2-(3-phenoxypropyl)-5-tetrazolyl]pyridine	[no description available]	low	0	0	aromatic ether
1-cyclohexyl-5-(2-phenoxyethylthio)tetrazole	[no description available]	low	0	0	aromatic ether
N-(5-ethyl-1,3,4-thiadiazol-2-yl)-2-[[5-[(3-methylphenoxy)methyl]-1,3,4-oxadiazol-2-yl]thio]acetamide	[no description available]	low	0	0	aromatic ether
6-amino-4-[3-ethoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]-3-ethyl-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile	[no description available]	low	0	0	aromatic ether; pyranopyrazole
2-[[5-[(2,3-dimethylphenoxy)methyl]-4-methyl-1,2,4-triazol-3-yl]thio]-1-thiophen-2-ylethanone	[no description available]	low	0	0	aromatic ether
(1-methyl-2-imidazolyl)-(4-phenylmethoxyphenyl)methanol	[no description available]	low	0	0	aromatic ether
5-(3-butoxyphenyl)-1,3,4-thiadiazol-2-amine	[no description available]	low	0	0	aromatic ether
3-(2-ethoxy-6-methyl-3-pyridinyl)-5-(2-pyridinyl)-1,2,4-oxadiazole	[no description available]	low	0	0	aromatic ether
6-(3,4,5-triethoxyphenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole	[no description available]	low	0	0	aromatic ether; triazolothiadiazole
4-(1-benzotriazolyl)-5-(2-methoxyphenoxy)benzene-1,2-dicarbonitrile	[no description available]	low	0	0	aromatic ether
4-cyclohexyl-3-[(3-methylphenoxy)methyl]-1H-1,2,4-triazole-5-thione	[no description available]	low	0	0	aromatic ether
7-ethoxy-9-nitro-5H-benzo[b][1,4]benzoxazepin-6-one	[no description available]	low	0	0	aromatic ether
4-[4-(2-quinoxalinyl)phenoxy]benzene-1,2-dicarbonitrile	[no description available]	low	0	0	aromatic ether
1-(4-amino-1,2,5-oxadiazol-3-yl)-5-(phenoxymethyl)-4-triazolecarboxylic acid ethyl ester	[no description available]	low	0	0	aromatic ether
2-(4-ethylphenoxy)-N-(1H-1,2,4-triazol-5-yl)acetamide	[no description available]	low	0	0	aromatic ether
2-(4-chloro-3-methylphenoxy)-N-(1H-1,2,4-triazol-5-yl)acetamide	[no description available]	low	0	0	aromatic ether
5-[(4-ethylphenoxy)methyl]-N-(2-pyridinylmethyl)-2-furancarboxamide	[no description available]	low	0	0	aromatic ether
7-methoxy-3,5-dimethyl-2-thiazolo[4,5-d]pyrimidinethione	[no description available]	low	0	0	aromatic ether
N-[4-(4-ethylphenyl)-2-thiazolyl]carbamic acid phenyl ester	[no description available]	low	0	0	aromatic ether
2-(2-bromo-4-methylphenoxy)-N-(2-pyridinylmethyl)acetamide	[no description available]	low	0	0	aromatic ether
1-[[3-(4-chlorophenoxy)phenyl]methyl]-4-ethylpiperazine	[no description available]	low	0	0	aromatic ether
2-methoxy-4-[(4-methyl-1,4-diazepan-1-yl)methyl]-6-nitrophenol	[no description available]	low	0	0	aromatic ether; C-nitro compound
4-[[4-(ethylamino)-6-(methylthio)-1,3,5-triazin-2-yl]oxy]benzoic acid ethyl ester	[no description available]	low	0	0	aromatic ether
5-ethyl-3-[[4-(2-methylpropoxy)phenyl]methylthio]-1H-1,2,4-triazole	[no description available]	low	0	0	aromatic ether
[4-[(2-fluorophenyl)methoxy]phenyl]-(1-pyrrolidinyl)methanethione	[no description available]	low	0	0	aromatic ether
5-[(2-chlorophenoxy)methyl]-3-pyridin-4-yl-1,2,4-oxadiazole	[no description available]	low	0	0	aromatic ether
4-(4-phenylmethoxyphenyl)thiadiazole	[no description available]	low	0	0	aromatic ether
N-methyl-2-[[4-methyl-5-[(4-nitrophenoxy)methyl]-1,2,4-triazol-3-yl]thio]acetamide	[no description available]	low	0	0	aromatic ether; C-nitro compound
2-[[5-(4-ethoxyphenyl)-1,3,4-oxadiazol-2-yl]thio]-1-(4-morpholinyl)ethanone	[no description available]	low	0	0	aromatic ether
4-(3-pyridinyloxy)benzene-1,2-dicarbonitrile	[no description available]	low	0	0	aromatic ether
N-tert-butyl-2-(4-chloro-3-methylphenoxy)acetamide	[no description available]	low	0	0	aromatic ether
1-(2-furanylmethyl)-3-(4-phenoxyphenyl)thiourea	[no description available]	low	0	0	aromatic ether
1-(2-methylpropyl)-3-(4-phenoxyphenyl)thiourea	[no description available]	low	0	0	aromatic ether
1-cyclopentyl-3-(4-phenoxyphenyl)thiourea	[no description available]	low	0	0	aromatic ether
5-[(4-ethoxyphenoxy)methyl]-N-(3-pyridinyl)-2-furancarboxamide	[no description available]	low	0	0	aromatic ether
2-(2,3-dimethylphenoxy)-N-pyridin-4-ylacetamide	[no description available]	low	0	0	aromatic ether
5-[(2-chlorophenoxy)methyl]-N-(2-thiazolyl)-2-furancarboxamide	[no description available]	low	0	0	aromatic ether
N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]-2-furancarboxamide	[no description available]	low	0	0	aromatic ether
N-(4,5-dihydrothiazol-2-yl)-2-(2-methylphenoxy)acetamide	[no description available]	low	0	0	aromatic ether
5-(2-fluorophenoxy)-1-methyl-3-nitro-1,2,4-triazole	[no description available]	low	0	0	aromatic ether
1-methyl-5-(1-naphthalenyloxy)-4-nitroimidazole	[no description available]	low	0	0	aromatic ether
curcumin	[no description available]	low	0	0	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
1-(3,4-dimethoxyphenyl)-3-(2-methoxy-5-nitrophenyl)urea	[no description available]	low	0	0	aromatic ether; C-nitro compound
1-cyclopentyl-3-(2-phenoxyphenyl)thiourea	[no description available]	low	0	0	aromatic ether
N-(1-ethyl-2-benzimidazolyl)-5-[(4-methyl-2-nitrophenoxy)methyl]-2-furancarboxamide	[no description available]	low	0	0	aromatic ether; C-nitro compound
2-chloro-12-(4-methoxyphenyl)sulfonylquinoxalino[2,3-b][1,4]benzoxazine	[no description available]	low	0	0	aromatic ether
1-(3-methoxy-5-nitrophenyl)-3-(4-methylphenyl)urea	[no description available]	low	0	0	aromatic ether; C-nitro compound
2-(2-bromo-4-chlorophenoxy)-N-cyclohexyl-N-methylacetamide	[no description available]	low	0	0	aromatic ether
2-furanyl-[4-(4-phenoxyphenyl)sulfonyl-1-piperazinyl]methanone	[no description available]	low	0	0	aromatic ether
4-(2-methoxyphenoxy)-N-(3-pyridinyl)benzenesulfonamide	[no description available]	low	0	0	aromatic ether
1-(3-chlorophenyl)-3-(2-phenoxyphenyl)thiourea	[no description available]	low	0	0	aromatic ether
N-[3-[2-(1-azepanyl)-4,5-dicyanophenoxy]phenyl]acetamide	[no description available]	low	0	0	aromatic ether
2,5-dimethoxy-N-(4-phenoxyphenyl)benzenesulfonamide	[no description available]	low	0	0	aromatic ether
4-[[4-(dimethylamino)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]oxy]benzoic acid methyl ester	[no description available]	low	0	0	aromatic ether
N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]-5-methyl-3-phenyl-4-isoxazolecarboxamide	[no description available]	low	0	0	aromatic ether
1-[4-[[4-(2-chloro-6-nitrophenoxy)phenyl]methoxy]phenyl]ethanone	[no description available]	low	0	0	aromatic ether
N-[4-[[2-(4-hydroxyphenyl)-1,3-dioxo-5-isoindolyl]oxy]phenyl]-2,2-dimethylpropanamide	[no description available]	low	0	0	aromatic ether
N-[[4-(4-chlorophenoxy)anilino]-sulfanylidenemethyl]benzamide	[no description available]	low	0	0	aromatic ether
2-(4-fluorophenoxy)-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)acetamide	[no description available]	low	0	0	aromatic ether
4-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]oxy]-N-propan-2-ylbenzenesulfonamide	[no description available]	low	0	0	aromatic ether
4-(4-tert-butylphenoxy)-5-methoxy-2-phenylpyrimidine	[no description available]	low	0	0	aromatic ether
4-phenoxy-2-phenyl-5-pyrimidinecarboxylic acid ethyl ester	[no description available]	low	0	0	aromatic ether
Src Inhibitor-1	[no description available]	low	0	0	aromatic ether; polyether; quinazolines; secondary amino compound	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
N-[2,5-dioxo-6-(4-phenoxyphenyl)-3-pyrano[3,2-c]pyridinyl]benzamide	[no description available]	low	0	0	aromatic ether
2-(4-chlorophenoxy)-4-(dimethylamino)-3-pyridinecarbonitrile	[no description available]	low	0	0	aromatic ether
6-methyl-5-[2-(2-methylphenoxy)ethyl]-2-sulfanylidene-1H-pyrimidin-4-one	[no description available]	low	0	0	aromatic ether
4-(4-chlorophenoxy)-1-(4-morpholinyl)-1-butanone	[no description available]	low	0	0	aromatic ether
N4-ethyl-6-[2-(4-methylphenoxy)ethylthio]-N2-propan-2-yl-1,3,5-triazine-2,4-diamine	[no description available]	low	0	0	aromatic ether
4-(phenylmethyl)-3-[2-(4-propoxyphenyl)ethyl]-1H-1,2,4-triazole-5-thione	[no description available]	low	0	0	aromatic ether
1-[[1-oxo-3-(4-propan-2-yloxyphenyl)propyl]amino]-3-(phenylmethyl)thiourea	[no description available]	low	0	0	aromatic ether
N-[3-(3-methylphenoxy)-5-nitrophenyl]-2-(3-nitro-1,2,4-triazol-1-yl)acetamide	[no description available]	low	0	0	aromatic ether
N-bis(2-fluorophenoxy)phosphoryl-3,4-dimethylaniline	[no description available]	low	0	0	aromatic ether
2-[[4-(2-ethoxyanilino)-6-(4-ethoxyanilino)-2-pyrimidinyl]methylidene]propanedinitrile	[no description available]	low	0	0	aromatic ether
5-methyl-3-[(4-pentoxyphenyl)methylthio]-1H-1,2,4-triazole	[no description available]	low	0	0	aromatic ether
4,5-dichloro-1-[2-(4-chlorophenoxy)ethyl]imidazole	[no description available]	low	0	0	aromatic ether
1-butyl-3-(4-phenoxyphenyl)thiourea	[no description available]	low	0	0	aromatic ether
N-(3-cyano-2-thiophenyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenoxy]acetamide	[no description available]	low	0	0	aromatic ether
2-(2-bromophenyl)-5-[(2-chlorophenoxy)methyl]-1,3,4-oxadiazole	[no description available]	low	0	0	aromatic ether
5-(4-ethoxyphenyl)-N-(3,4,5,6-tetrahydro-2H-azepin-7-yl)-1,3,4-oxadiazol-2-amine	[no description available]	low	0	0	aromatic ether
4-(4-chloro-2-methylphenoxy)-1-(4-morpholinyl)-1-butanone	[no description available]	low	0	0	aromatic ether
N9-(4-butoxyphenyl)-6,8,10-triazaspiro[4.5]deca-6,9-diene-7,9-diamine	[no description available]	low	0	0	aromatic ether
2-[2-(4-chlorophenoxy)ethylthio]pyrimidine	[no description available]	low	0	0	aromatic ether
5-(3-phenoxypropyl)-3-(3-pyridinyl)-1,2,4-oxadiazole	[no description available]	low	0	0	aromatic ether
N-[(3-ethoxy-2-prop-2-enoxyphenyl)methyl]-2-thiazolamine	[no description available]	low	0	0	aromatic ether
2-(2-bromophenoxy)-N-(2-pyridinylmethyl)acetamide	[no description available]	low	0	0	aromatic ether
4-[2-[(4-chlorophenyl)thio]ethoxy]-3-ethoxybenzaldehyde	[no description available]	low	0	0	aromatic ether
1-(3-fluorophenyl)-4-(4-hydroxy-3-methoxy-5-nitrophenyl)-4H-pyridine-3,5-dicarboxylic acid diethyl ester	[no description available]	low	0	0	aromatic ether; C-nitro compound
5-(2-ethoxyphenyl)-3H-1,3,4-oxadiazole-2-thione	[no description available]	low	0	0	aromatic ether
N-tert-butyl-4-(2-fluorophenoxy)-1-butanamine	[no description available]	low	0	0	aromatic ether
N-butyl-4-phenoxy-1-butanamine	[no description available]	low	0	0	aromatic ether
N-[3-[[diethylamino(sulfanylidene)methyl]thio]-1-oxopropyl]carbamic acid (4-methylphenyl) ester	[no description available]	low	0	0	aromatic ether
1,3-dimethyl-5-[[2-[2-(4-nitrophenoxy)ethoxy]phenyl]methylidene]-1,3-diazinane-2,4,6-trione	[no description available]	low	0	0	aromatic ether; C-nitro compound
4-[2-[2-(4-bromo-2-chlorophenoxy)ethoxy]ethyl]morpholine	[no description available]	low	0	0	aromatic ether
2-[2-(3-ethylphenoxy)ethyl]propanedioic acid diethyl ester	[no description available]	low	0	0	aromatic ether
2,3-dihydro-1,4-dioxin-5-carboxylic acid [2-[4-[4-(2-methylbutan-2-yl)phenoxy]anilino]-2-oxoethyl] ester	[no description available]	low	0	0	aromatic ether
1-[3-(2-bromo-4-chlorophenoxy)propyl]-4-methylpiperidine	[no description available]	low	0	0	aromatic ether
N4-(2-methoxyphenyl)benzene-1,4-diamine	[no description available]	low	0	0	aromatic ether; substituted aniline
4-(1H-benzimidazol-2-ylthio)butanoic acid [2-oxo-2-(4-phenoxyanilino)ethyl] ester	[no description available]	low	0	0	aromatic ether
2-phenoxybenzoic acid [2-(2-furanylmethylamino)-2-oxoethyl] ester	[no description available]	low	0	0	aromatic ether
1-[2,5-dimethyl-1-(phenylmethyl)-3-pyrrolyl]-2-[4-(1,3,4-oxadiazol-2-yl)phenoxy]ethanone	[no description available]	low	0	0	aromatic ether
N-[6-amino-1-(2-methylpropyl)-2,4-dioxo-5-pyrimidinyl]-2-(2-methylphenoxy)-N-(2-methylpropyl)acetamide	[no description available]	low	0	0	aromatic ether
4-[[6-[(2-methyl-5-thieno[2,3-e][1,3]benzothiazolyl)oxy]-3-pyridinyl]sulfonyl]morpholine	[no description available]	low	0	0	aromatic ether
5-(3-fluorophenoxy)-8-nitroisoquinoline	[no description available]	low	0	0	aromatic ether
1-[4-(2-prop-2-enylphenoxy)butyl]pyrrolidine	[no description available]	low	0	0	aromatic ether
2-(2,4-dibromophenoxy)-N-[oxo-(propan-2-ylamino)methyl]acetamide	[no description available]	low	0	0	aromatic ether
4-phenoxyphenyl 4-hydroxypiperidine-1-carboxylate	[no description available]	low	0	0	aromatic ether
N'-benzoyl-5-(3,5-dichlorophenoxy)-2-furancarbohydrazide	[no description available]	low	0	0	aromatic ether
1-[2-[(4-chlorophenoxy)methyl]-4-thiazolyl]ethanone	[no description available]	low	0	0	aromatic ether
5-(benzyloxy)-2-(hydroxymethyl)-1,4-dihydropyridin-4-one	[no description available]	low	0	0	aromatic ether
2-(4-aminophenoxy)isophthalonitrile	[no description available]	low	0	0	aromatic ether
N5-(2-chloro-6-phenoxybenzyl)-1H-1,2,4-triazole-3,5-diamine	[no description available]	low	0	0	aromatic ether
N-[(2-chloro-6-phenoxyphenyl)methyl]benzenesulfonamide	[no description available]	low	0	0	aromatic ether
N-[5-(tert-butyl)-3-isoxazolyl]-N'-[2-(trifluoromethoxy)phenyl]urea	[no description available]	low	0	0	aromatic ether
6-(4-methoxyphenoxy)-2-imidazo[1,2-b]pyridazinecarboxylic acid ethyl ester	[no description available]	low	0	0	aromatic ether
2-fluoro-N-[2,2,2-trichloro-1-[[(4-methoxy-2-nitroanilino)-sulfanylidenemethyl]amino]ethyl]acetamide	[no description available]	low	0	0	aromatic ether; C-nitro compound
2-amino-4-(4,5-dimethoxy-2-nitrophenyl)-7,7-dimethyl-5-oxo-6,8-dihydro-4H-1-benzopyran-3-carbonitrile	[no description available]	low	0	0	aromatic ether; C-nitro compound
2,4-dichloro-N-[2,2,2-trichloro-1-[[(4-methoxy-2-nitroanilino)-sulfanylidenemethyl]amino]ethyl]benzamide	[no description available]	low	0	0	aromatic ether; C-nitro compound
1-anilino-3-[4-(3-anilino-2-hydroxypropoxy)phenoxy]-2-propanol	[no description available]	low	0	0	aromatic ether
1-[4-(3-ethoxyphenoxy)butyl]imidazole	[no description available]	low	0	0	aromatic ether
N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]-2-oxolanecarboxamide	[no description available]	low	0	0	aromatic ether
1-[[2-(2,4-difluorophenoxy)-1-oxopropyl]amino]-3-(2-oxolanylmethyl)thiourea	[no description available]	low	0	0	aromatic ether
N-[[(5-bromo-6-methyl-2-pyridinyl)amino]-sulfanylidenemethyl]-2-(2-chlorophenoxy)acetamide	[no description available]	low	0	0	aromatic ether
2-[(4-chlorophenyl)sulfonyl-methylamino]-N-(4-methoxy-2-nitrophenyl)acetamide	[no description available]	low	0	0	aromatic ether; C-nitro compound
4-oxido-3-(4-phenoxyphenyl)-4a,5,6,7,8,8a-hexahydroquinoxalin-1-ium 1-oxide	[no description available]	low	0	0	aromatic ether
1-(2-fluorophenyl)-3-(4-methoxy-2-nitrophenyl)urea	[no description available]	low	0	0	aromatic ether; C-nitro compound
2-[[5-[(2-fluorophenoxy)methyl]-4-prop-2-enyl-1,2,4-triazol-3-yl]thio]-N-[(2-furanylmethylamino)-oxomethyl]acetamide	[no description available]	low	0	0	aromatic ether
cyclopropanecarboxylic acid [2-oxo-2-(4-phenoxyanilino)ethyl] ester	[no description available]	low	0	0	aromatic ether
toremifene	[no description available]	low	0	0	aromatic ether; organochlorine compound; tertiary amine	antineoplastic agent; bone density conservation agent; estrogen antagonist; estrogen receptor modulator
dieckol	[no description available]	low	0	0	aromatic ether; oxacycle; phlorotannin	anticoagulant; EC 3.2.1.20 (alpha-glucosidase) inhibitor; hepatoprotective agent; metabolite; radical scavenger
2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine	[no description available]	low	0	0	aromatic ether
naproxol	[no description available]	low	0	0	aromatic ether	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug
tamoxifen n-oxide	[no description available]	low	0	0	aromatic ether; tertiary amine oxide	anti-estrogen; metabolite
diafenthiuron	[no description available]	low	0	0	aromatic ether; thiourea acaricide; thiourea insecticide	oxidative phosphorylation inhibitor; proinsecticide
ospemifene	[no description available]	low	0	0	aromatic ether; organochlorine compound; primary alcohol	anti-inflammatory agent; antineoplastic agent; estrogen receptor modulator
zd 6474	[no description available]	low	0	0	aromatic ether; organobromine compound; organofluorine compound; piperidines; quinazolines; secondary amine	antineoplastic agent; tyrosine kinase inhibitor
adefovir	[no description available]	low	0	0	aromatic ether; aromatic ketone; biaryl; cyclic ketone; naphtho-gamma-pyrone; organooxygen heterocyclic antibiotic; polyphenol	antimalarial; Aspergillus metabolite; marine metabolite
3-chloro-N-[2,2,2-trichloro-1-[[(4-methoxy-2-nitroanilino)-sulfanylidenemethyl]amino]ethyl]benzamide	[no description available]	low	0	0	aromatic ether; C-nitro compound
N-(2-hydroxyethyl)-4-[2-nitro-4-(trifluoromethyl)phenoxy]benzamide	[no description available]	low	0	0	aromatic ether
N'-[2-[(4-amino-5-cyano-2-pyrimidinyl)thio]-1-oxoethyl]-2-(4-methylphenoxy)acetohydrazide	[no description available]	low	0	0	aromatic ether
N-[(2-methyl-4-thiazolyl)methyl]-4-phenoxybenzenesulfonamide	[no description available]	low	0	0	aromatic ether
6-amino-4-(2-ethoxy-4-hydroxyphenyl)-3-propyl-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile	[no description available]	low	0	0	aromatic ether; pyranopyrazole
1-[(2-ethoxyphenyl)methyl]-3-thiophen-2-ylurea	[no description available]	low	0	0	aromatic ether
quinoxyfen	[no description available]	low	0	0	aromatic ether; monofluorobenzenes; organochlorine compound; quinolines	antifungal agrochemical
1-(1-naphthalenyl)-3-[[2-(2-nitrophenoxy)-1-oxoethyl]amino]urea	[no description available]	low	0	0	aromatic ether; C-nitro compound
2-methyl-1,3-bis(phenylmethoxy)benzene	[no description available]	low	0	0	aromatic ether
1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-ethoxyphenoxysulfonyl)urea	[no description available]	low	0	0	aromatic ether
3-[(4-ethylphenoxy)methyl]-4-(6-methylheptan-2-yl)-1H-1,2,4-triazole-5-thione	[no description available]	low	0	0	aromatic ether
2-chloro-N-(2-methyl-6-oxo-5H-benzo[b][1,4]benzoxazepin-8-yl)acetamide	[no description available]	low	0	0	aromatic ether
5-(benzenesulfonyl)-4-(2,6-dimethylphenoxy)-2-phenylpyrimidine	[no description available]	low	0	0	aromatic ether
4-(2-methylphenoxy)-6-phenylfuro[2,3-d]pyrimidine	[no description available]	low	0	0	aromatic ether
1-[4-(2-chlorophenoxy)butyl]imidazole	[no description available]	low	0	0	aromatic ether; imidazoles; monochlorobenzenes
N-(2-chlorophenyl)-4-[[(2-methoxy-4-nitroanilino)-sulfanylidenemethyl]hydrazo]-4-oxobutanamide	[no description available]	low	0	0	aromatic ether; C-nitro compound
N-(2-methoxy-4-nitrophenyl)-2-[(1-methyl-2-imidazolyl)thio]acetamide	[no description available]	low	0	0	aromatic ether; C-nitro compound
N-[4-(phenoxymethyl)-2-thiazolyl]-1-adamantanecarboxamide	[no description available]	low	0	0	aromatic ether
hydroxypioglitazone	[no description available]	low	0	0	aromatic ether; pyridines; thiazolidinediones	human xenobiotic metabolite
sc 560	[no description available]	low	0	0	aromatic ether; monochlorobenzenes; organofluorine compound; pyrazoles	angiogenesis modulating agent; antineoplastic agent; apoptosis inducer; cyclooxygenase 1 inhibitor; non-steroidal anti-inflammatory drug
sc-19220	[no description available]	low	0	0	aromatic ether
5-methyl-4-(3-phenoxyphenyl)-2-sulfanylidene-3,4-dihydro-1H-pyrimidine-6-carboxylic acid ethyl ester	[no description available]	low	0	0	aromatic ether
8-[4-(4-fluorophenoxy)-3-nitrophenyl]-7-(2-hydroxyethyl)-3-(phenylmethyl)purine-2,6-dione	[no description available]	low	0	0	aromatic ether
2-phenoxybenzoic acid [2-oxo-2-(propan-2-ylamino)ethyl] ester	[no description available]	low	0	0	aromatic ether
2-(4-bromophenoxy)-N'-[2-[(4-methyl-1,2,4-triazol-3-yl)thio]-1-oxoethyl]acetohydrazide	[no description available]	low	0	0	aromatic ether
2-(2-methoxyanilino)-2-(2-phenylmethoxyphenyl)acetonitrile	[no description available]	low	0	0	aromatic ether; substituted aniline
N-(4-phenoxyphenyl)-2-(1,2,3,4-tetrahydroisoquinolin-1-yl)acetamide	[no description available]	low	0	0	aromatic ether
5-(3,4-dimethoxyphenyl)-3-(2-furanylmethyl)-4-imino-5H-[1]benzopyrano[2,3-d]pyrimidin-8-ol	[no description available]	low	0	0	aromatic ether
3,3-dimethyl-1,5-dinitro-6-phenoxy-3-azoniabicyclo[3.3.1]non-6-ene	[no description available]	low	0	0	aromatic ether
fraxin	[no description available]	low	0	0	aromatic ether; beta-D-glucoside; hydroxycoumarin	anti-inflammatory agent; hepatoprotective agent; plant metabolite
fraxetin	[no description available]	low	0	0	aromatic ether; hydroxycoumarin	anti-inflammatory agent; antibacterial agent; antimicrobial agent; antioxidant; apoptosis inducer; apoptosis inhibitor; Arabidopsis thaliana metabolite; hepatoprotective agent; hypoglycemic agent
5,6-dehydrokawain	[no description available]	low	0	0	2-pyranones; aromatic ether
jtk-303	[no description available]	low	0	0	aromatic ether; monochlorobenzenes; organofluorine compound; quinolinemonocarboxylic acid; quinolone	HIV-1 integrase inhibitor
coniferin	[no description available]	low	0	0	aromatic ether; cinnamyl alcohol beta-D-glucoside; monosaccharide derivative	plant metabolite
daphnoretin	[no description available]	low	0	0	aromatic ether; hydroxycoumarin	antineoplastic agent; antiviral agent; metabolite
kavain	[no description available]	low	0	0	2-pyranones; aromatic ether
methysticin	[no description available]	low	0	0	2-pyranones; aromatic ether
yangonin	[no description available]	low	0	0	2-pyranones; aromatic ether
hinokiflavone	[no description available]	low	0	0	aromatic ether; biflavonoid; hydroxyflavone	antineoplastic agent; metabolite; neuroprotective agent
gentiacaulein	[no description available]	low	0	0	aromatic ether; polyphenol; xanthones	plant metabolite
gentisin	[no description available]	low	0	0	aromatic ether; polyphenol; xanthones	plant metabolite
isogentisin	[no description available]	low	0	0	aromatic ether; polyphenol; xanthones	EC 1.4.3.4 (monoamine oxidase) inhibitor; plant metabolite
mangostin	[no description available]	low	0	0	aromatic ether; phenols; xanthones	antimicrobial agent; antineoplastic agent; antioxidant; plant metabolite
1,8-dihydroxy-3,7-dimethoxyxanthone	[no description available]	low	0	0	aromatic ether; polyphenol; xanthones	plant metabolite
swerchirin	[no description available]	low	0	0	aromatic ether; phenols; xanthones	hypoglycemic agent; metabolite
1,2,8-trihydroxy-6-methoxyxanthone	[no description available]	low	0	0	aromatic ether; polyphenol; xanthones	antioxidant; plant metabolite
wedelolactone	[no description available]	low	0	0	aromatic ether; coumestans; delta-lactone; polyphenol	antineoplastic agent; apoptosis inducer; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; hepatoprotective agent; metabolite
cyhalothrin	[no description available]	low	0	0	aromatic ether; cyclopropanecarboxylate ester; nitrile; organochlorine compound; organofluorine compound	agrochemical; pyrethroid ester acaricide; pyrethroid ester insecticide
sofalcone	[no description available]	low	0	0	aromatic ether; chalcones; monocarboxylic acid	anti-ulcer drug; antibacterial agent; gastrointestinal drug; plant metabolite
neticonazole	[no description available]	low	0	0	aromatic ether; benzenes; conazole antifungal drug; enamine; imidazole antifungal drug; imidazoles; methyl sulfide	antifungal drug; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor
pibutidine	[no description available]	low	0	0	aromatic ether; cyclobutenones; olefinic compound; piperidines; primary amino compound; pyridines; secondary amino compound	anti-ulcer drug; H2-receptor antagonist
purmorphamine	[no description available]	low	0	0	aromatic ether; morpholines; purines; secondary amino compound	osteogenesis regulator; SMO receptor agonist
8-(2-chlorophenyl)-3-(4-ethoxyphenyl)-6-oxo-2,4,7,8-tetrahydropyrido[2,1-b][1,3,5]thiadiazine-9-carbonitrile	[no description available]	low	0	0	aromatic ether
ro 41-5253	[no description available]	low	0	0	aromatic ether; benzoic acids; sulfone; thiochromane	apoptosis inducer; retinoic acid receptor alpha antagonist
glycycoumarin	[no description available]	low	0	0	aromatic ether; coumarins; resorcinols	antispasmodic drug; plant metabolite
isoginkgetin	[no description available]	low	0	0	aromatic ether; biflavonoid	antineoplastic agent; EC 3.4.24.35 (gelatinase B) inhibitor; plant metabolite
neoglycyrol	[no description available]	low	0	0	aromatic ether; coumestans; delta-lactone; polyphenol	antineoplastic agent; plant metabolite
rhamnazin	[no description available]	low	0	0	aromatic ether; dimethoxyflavone; phenols; trihydroxyflavone	antineoplastic agent; plant metabolite
bw b70c	[no description available]	low	0	0	aromatic ether; hydroxamic acid; organofluorine compound; ureas	EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor
lichexanthone	[no description available]	low	0	0	aromatic ether; phenols; xanthones	plant metabolite
alternariol monomethyl ether	[no description available]	low	0	0	aromatic ether; benzochromenone	antifungal agent; fungal metabolite; mycotoxin
decussatin	[no description available]	low	0	0	aromatic ether; phenols; xanthones	plant metabolite
dimethomorph	[no description available]	low	0	0	aromatic ether; enamide; monochlorobenzenes; morpholine fungicide; tertiary carboxamide
benanomicin b	[no description available]	low	0	0	aromatic ether; disaccharide derivative; L-alanine derivative; polyketide; polyphenol; pradimicin; secondary alcohol
pradimicin b	[no description available]	low	0	0	aromatic ether; L-alanine derivative; monosaccharide derivative; polyketide; polyphenol; pradimicin; secondary alcohol
1,7-dihydroxy-4-methoxyxanthone	[no description available]	low	0	0	aromatic ether; phenols; xanthones	metabolite; plant metabolite
pradimicin a	[no description available]	low	0	0	aromatic ether; carboxylic acid; disaccharide derivative; L-alanine derivative; p-quinones; polyphenol; pradimicin; secondary alcohol
clodinafop	[no description available]	low	0	0	aromatic ether; monocarboxylic acid; organochlorine compound; organofluorine compound; pyridines	EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor; phenoxy herbicide
ici 118551	[no description available]	low	0	0	aromatic ether; indanes; secondary alcohol; secondary amino compound	beta-adrenergic antagonist
ochnaflavone	[no description available]	low	0	0	aromatic ether; biflavonoid; hydroxyflavone	anti-inflammatory agent; antiatherogenic agent; antibacterial agent; EC 3.1.1.4 (phospholipase A2) inhibitor; leukotriene antagonist; plant metabolite
3-(4-fluorophenoxy)-6-methoxy-2-(4-methoxyphenyl)-1-benzothiophene 1-oxide	[no description available]	low	0	0	aromatic ether
flavasperone	[no description available]	low	0	0	aromatic ether; naphtho-gamma-pyrone; phenols	acyl-CoA:cholesterol acyltransferase 2 inhibitor; antiviral agent; Aspergillus metabolite; marine metabolite
4-hydroxycordoin	[no description available]	low	0	0	aromatic ether; chalcones; polyphenol	anti-inflammatory agent; antibacterial agent; plant metabolite
n-feruloylserotonin	[no description available]	low	0	0	aromatic ether; cinnamamides; hydroxyindoles; phenols; secondary carboxamide	plant metabolite
tyrphostin ag825	[no description available]	low	0	0	aromatic ether; benzothiazoles; enamide; nitrile; organic sulfide; phenols; primary carboxamide	epidermal growth factor receptor antagonist
kresoxim-methyl	[no description available]	low	0	0	aromatic ether; methoxyiminoacetate strobilurin antifungal agent; methyl ester; oxime O-ether	antifungal agrochemical; environmental contaminant; mitochondrial cytochrome-bc1 complex inhibitor; xenobiotic
5-methoxy-3,6-diphenyl-1,2,4-triazine	[no description available]	low	0	0	aromatic ether
pyrachlostrobin	[no description available]	low	0	0	aromatic ether; carbamate ester; carbanilate fungicide; methoxycarbanilate strobilurin antifungal agent; monochlorobenzenes; pyrazoles	antifungal agrochemical; environmental contaminant; mitochondrial cytochrome-bc1 complex inhibitor; xenobiotic
piericidin a	[no description available]	low	0	0	aromatic ether; methylpyridines; monohydroxypyridine; secondary allylic alcohol	antimicrobial agent; bacterial metabolite; EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor; mitochondrial respiratory-chain inhibitor
metrafenone	[no description available]	low	0	0	aromatic ether; aryl phenyl ketone fungicide; benzophenones; organobromine compound	antifungal agrochemical
2-(4-fluoro-3-(trifluoromethyl)phenoxy)-n-(phenylmethyl)butanamide	[no description available]	low	0	0	(trifluoromethyl)benzenes; aromatic ether; monocarboxylic acid amide; monofluorobenzenes
b 43	[no description available]	low	0	0	aromatic amine; aromatic ether; cyclopentanes; primary amino compound; pyrrolopyrimidine	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector
5-(4-phenylbutoxy)psoralen	[no description available]	low	0	0	aromatic ether; benzenes; psoralens	geroprotector; immunosuppressive agent; potassium channel blocker
5-ia-85380	[no description available]	low	0	0	aromatic ether
ru 58668	[no description available]	low	0	0	17beta-hydroxy steroid; 3-hydroxy steroid; aromatic ether; organofluorine compound; sulfone	anti-estrogen; antineoplastic agent; estrogen receptor antagonist
altenusin	[no description available]	low	0	0	aromatic ether; carboxybiphenyl; catechols; hydroxybiphenyls; polyphenol	antifungal agent; fungal metabolite
gw 501516	[no description available]	low	0	0	1,3-thiazoles; aromatic ether; aryl sulfide; monocarboxylic acid; organofluorine compound	carcinogenic agent; PPARbeta/delta agonist
camostat	[no description available]	low	0	0	aromatic ether; phenols
lenvatinib	[no description available]	low	0	0	aromatic amide; aromatic ether; cyclopropanes; monocarboxylic acid amide; monochlorobenzenes; phenylureas; quinolines	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist; orphan drug; vascular endothelial growth factor receptor antagonist
nsc 716970	[no description available]	low	0	0	aromatic amine; aromatic ether; indolecarboxamide; organochlorine compound	antineoplastic agent
lobeglitazone	[no description available]	low	0	0	aromatic ether
noviflumuron	[no description available]	low	0	0	aromatic ether; benzoylurea insecticide; dichlorobenzene; organofluorine compound
etomoxir	[no description available]	low	0	0	aromatic ether
fr 148083	[no description available]	low	0	0	aromatic ether; macrolide; phenols; secondary alcohol; secondary alpha-hydroxy ketone	antibacterial agent; antineoplastic agent; metabolite; NF-kappaB inhibitor
9-methoxycanthin-6-one	[no description available]	low	0	0	aromatic ether; indole alkaloid; organic heterotetracyclic compound	antineoplastic agent; antiplasmodial drug; metabolite
sb 3ct compound	[no description available]	low	0	0	aromatic ether
varespladib methyl	[no description available]	low	0	0	aromatic ether; benzenes; indoles; methyl ester; primary carboxamide	anti-inflammatory drug; antidote; EC 3.1.1.4 (phospholipase A2) inhibitor; prodrug
dapagliflozin	[no description available]	low	0	0	aromatic ether; C-glycosyl compound; monochlorobenzenes	hypoglycemic agent; sodium-glucose transport protein subtype 2 inhibitor
naveglitazar	[no description available]	low	0	0	aromatic ether
tivozanib	[no description available]	low	0	0	aromatic ether
ustiloxin b	[no description available]	low	0	0	aromatic ether; heterodetic cyclic peptide; macrocycle; phenols; secondary alcohol; secondary carboxamide; sulfoxide	Aspergillus metabolite; microtubule-destabilising agent; mycotoxin
hypothemycin	[no description available]	low	0	0	aromatic ether; diol; enone; epoxide; macrolide; phenols; polyketide; secondary alpha-hydroxy ketone	antifungal agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; fungal metabolite
tryprostatin a	[no description available]	low	0	0	aromatic ether; dipeptide; indole alkaloid; indoles; pyrrolopyrazine	breast cancer resistance protein inhibitor
cediranib	[no description available]	low	0	0	aromatic ether
3-iodothyronamine	[no description available]	low	0	0	aromatic ether
rubraxanthone	[no description available]	low	0	0	aromatic ether; polyphenol; xanthones	antibacterial agent; antineoplastic agent; metabolite
7,8-Dihydroyangonin	[no description available]	low	0	0	2-pyranones; aromatic ether
sch 51344	[no description available]	low	0	0	aromatic amine; aromatic ether; primary alcohol; pyrazoloquinoline; secondary amino compound	antineoplastic agent
ancistroealaine a	[no description available]	low	0	0	aromatic ether; biaryl; isoquinoline alkaloid; isoquinolines; methoxynaphthalene; methylnaphthalenes	antileishmanial agent; antiplasmodial drug; metabolite; trypanocidal drug
tolfenpyrad	[no description available]	low	0	0	aromatic amide; aromatic ether; organochlorine compound; pyrazole insecticide	agrochemical; antifungal agent; EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor; mitochondrial NADH:ubiquinone reductase inhibitor
SIS3 free base	[no description available]	low	0	0	aromatic ether; enamide; isoquinolines; monocarboxylic acid amide; pyrrolopyridine; tertiary carboxamide	Smad3 inhibitor
apixaban	[no description available]	low	0	0	aromatic ether; lactam; piperidones; pyrazolopyridine	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor
dihydrokavain	[no description available]	low	0	0	2-pyranones; aromatic ether
troglitazone sulfate	[no description available]	low	0	0	aromatic ether; thiazolidinone
arisugacin	[no description available]	low	0	0	aromatic ether; delta-lactone; enone; organic heterotetracyclic compound; tertiary alcohol	antimicrobial agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; metabolite; Penicillium metabolite
saracatinib	[no description available]	low	0	0	aromatic ether; benzodioxoles; diether; N-methylpiperazine; organochlorine compound; oxanes; quinazolines; secondary amino compound	anticoronaviral agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; radiosensitizing agent
fonsecinone a	[no description available]	low	0	0	aromatic ether; aromatic ketone; biaryl; cyclic ketone; naphtho-gamma-pyrone; polyphenol	antibacterial agent; Aspergillus metabolite
aiphanol	[no description available]	low	0	0	aromatic ether; benzodioxine; lignan; stilbenoid	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor
nigerloxin	[no description available]	low	0	0	aromatic ether; benzamides; benzoic acids; phenols; styrenes	antioxidant; Aspergillus metabolite; EC 1.1.1.21 (aldehyde reductase) inhibitor; lipoxygenase inhibitor; radical scavenger
msdc-0160	[no description available]	low	0	0	aromatic ether
dihydroxanthohumol	[no description available]	low	0	0	aromatic ether; dihydrochalcones; polyphenol	EC 1.14.13.39 (nitric oxide synthase) inhibitor; metabolite
PB28	[no description available]	low	0	0	aromatic ether; piperazines; tetralins	anticoronaviral agent; antineoplastic agent; apoptosis inducer; sigma-2 receptor agonist
7-phloroeckol	[no description available]	low	0	0	aromatic ether; phlorotannin	antioxidant; EC 3.1.1.3 (triacylglycerol lipase) inhibitor; metabolite
3,5-dimethoxy-4-hydroxybenzyl alcohol-4-O-beta-D-glucopyranoside	[no description available]	low	0	0	aromatic ether; benzyl alcohols; beta-D-glucoside; monosaccharide derivative; primary alcohol	antineoplastic agent; metabolite
fluoxastrobin	[no description available]	low	0	0	aromatic ether; dioxazine; monochlorobenzenes; organofluorine compound; oxime O-ether; pyrimidines; strobilurin antifungal agent	antifungal agrochemical; mitochondrial cytochrome-bc1 complex inhibitor
flumorph	[no description available]	low	0	0	aromatic ether; enamide; morpholines; organofluorine compound; tertiary carboxamide
regorafenib	[no description available]	low	0	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; monofluorobenzenes; phenylureas; pyridinecarboxamide	antineoplastic agent; hepatotoxic agent; tyrosine kinase inhibitor
erastin	[no description available]	low	0	0	aromatic ether; diether; monochlorobenzenes; N-acylpiperazine; N-alkylpiperazine; quinazolines; tertiary carboxamide	antineoplastic agent; ferroptosis inducer; voltage-dependent anion channel inhibitor
brivanib	[no description available]	low	0	0	aromatic ether; diether; fluoroindole; pyrrolotriazine; secondary alcohol	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; drug metabolite; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist
fg-4592	[no description available]	low	0	0	aromatic ether; isoquinolines; N-acylglycine	EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor; EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor
picoxystrobin	[no description available]	low	0	0	aromatic ether; enoate ester; enol ether; methoxyacrylate strobilurin antifungal agent; organofluorine compound; pyridines	antifungal agrochemical; mitochondrial cytochrome-bc1 complex inhibitor
cenicriviroc	[no description available]	low	0	0	aromatic ether; benzazocine; diether; imidazoles; secondary carboxamide; sulfoxide	anti-HIV agent; anti-inflammatory agent; antirheumatic drug; chemokine receptor 2 antagonist; chemokine receptor 5 antagonist
mandipropamid	[no description available]	low	0	0	aromatic ether; monocarboxylic acid amide; monochlorobenzenes; terminal acetylenic compound
glyceryl ferulate	[no description available]	low	0	0	1-monoglyceride; aromatic ether; enoate ester; phenols	antioxidant; plant metabolite; ultraviolet filter
ki 8751	[no description available]	low	0	0	aromatic ether
ceratamine a	[no description available]	low	0	0	alkaloid; aromatic ether; cyclic ketone; organic heterobicyclic compound; organobromine compound; secondary amino compound; tertiary amine	antimitotic; metabolite
bay94 9172	[no description available]	low	0	0	(18)F radiopharmaceutical; aromatic ether; polyether; secondary amino compound; stilbenoid; substituted aniline	radioactive imaging agent
olodaterol	[no description available]	low	0	0	aromatic ether; benzoxazine; phenols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent
dorsomorphin	[no description available]	low	0	0	aromatic ether; piperidines; pyrazolopyrimidine; pyridines	bone morphogenetic protein receptor antagonist; EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor
cj-042794	[no description available]	low	0	0	aromatic ether
ki11502	[no description available]	low	0	0	aromatic ether; benzamides; quinolines; thioureas	antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
apremilast	[no description available]	low	0	0	aromatic ether; N-acetylarylamine; phthalimides; sulfone	non-steroidal anti-inflammatory drug; phosphodiesterase IV inhibitor
PF-00835231	[no description available]	low	0	0	aromatic ether; indolecarboxamide; L-leucine derivative; primary alcohol; pyrrolidin-2-ones; secondary carboxamide	anticoronaviral agent; drug metabolite; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine	[no description available]	low	0	0	aminopyridine; aromatic ether; dichlorobenzene; organofluorine compound; pyrazolylpiperidine; racemate	antineoplastic agent; biomarker; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
chir-265	[no description available]	low	0	0	aromatic ether
aminocandin	[no description available]	low	0	0	aromatic ether; echinocandin; homodetic cyclic peptide	antiinfective agent
zk 756326	[no description available]	low	0	0	aromatic ether
bay 60-6583	[no description available]	low	0	0	aminopyridine; aromatic ether; aryl sulfide; cyanopyridine; cyclopropanes; monocarboxylic acid amide	adenosine A2B receptor agonist; anti-inflammatory agent; cardioprotective agent
4-[5-(4-ethoxyphenyl)-3-isoxazolyl]-N-[(4-methylphenyl)methyl]butanamide	[no description available]	low	0	0	aromatic ether
bgt226	[no description available]	low	0	0	aromatic ether; imidazoquinoline; N-arylpiperazine; organofluorine compound; pyridines	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
n-desmethylrosiglitazone	[no description available]	low	0	0	aromatic ether
4-(5-methyl-3-nitro-1-pyrazolyl)-N-[3-(4-methylphenoxy)-5-nitrophenyl]butanamide	[no description available]	low	0	0	aromatic ether
verruculogen	[no description available]	low	0	0	aromatic ether; diol; indole alkaloid; organic heterohexacyclic compound; organic peroxide	Aspergillus metabolite; GABA modulator; mycotoxin; Penicillium metabolite; potassium channel blocker
1-O-feruloyl-beta-D-glucose	[no description available]	low	0	0	aromatic ether; beta-D-glucoside; cinnamate ester; phenols	antioxidant; plant metabolite
2,2',4,5'-tetrabromodiphenyl ether	[no description available]	low	0	0	aromatic ether; organobromine compound
hexabromodiphenyl ether 154	[no description available]	low	0	0	aromatic ether; organobromine compound
bde 183	[no description available]	low	0	0	aromatic ether; organobromine compound
l-798106	[no description available]	low	0	0	aromatic ether; bromobenzenes; N-sulfonylcarboxamide	prostaglandin receptor antagonist
aflatoxin m1	[no description available]	low	0	0	aflatoxin; aromatic ether; aromatic ketone; tertiary alcohol	Aspergillus metabolite; human xenobiotic metabolite; mammalian metabolite
macitentan	[no description available]	low	0	0	aromatic ether; organobromine compound; pyrimidines; ring assembly; sulfamides	antihypertensive agent; endothelin receptor antagonist; orphan drug
CDN1163	[no description available]	low	0	0	aromatic ether; quinolines; secondary carboxamide	SERCA activator
e 7050	[no description available]	low	0	0	aromatic ether
N-[(5-chloro-2-thiophenyl)methyl]-5-[(2,6-difluorophenoxy)methyl]-3-isoxazolecarboxamide	[no description available]	low	0	0	aromatic ether
dafadine C	[no description available]	low	0	0	aromatic amide; aromatic ether; difluorobenzene; isoxazoles; N-acylpiperidine; pyridines	P450 inhibitor
dafadine B	[no description available]	low	0	0	aromatic amide; aromatic ether; isoxazoles; monochlorobenzenes; monofluorobenzenes; N-acylpiperidine; pyridines	P450 inhibitor
3-[5-(5-methyl-2-thiophenyl)-1,3,4-oxadiazol-2-yl]-N-[2-(3-pyridinyloxy)propyl]propanamide	[no description available]	low	0	0	aromatic ether
violaceol II	[no description available]	low	0	0	aromatic ether; catechols; resorcinols	mycotoxin
pamapimod	[no description available]	low	0	0	aromatic amine; aromatic ether; difluorobenzene; diol; primary alcohol; pyridopyrimidine; secondary amino compound	antirheumatic drug; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
gsk690693	[no description available]	low	0	0	1,2,5-oxadiazole; acetylenic compound; aromatic amine; aromatic ether; imidazopyridine; piperidines; primary amino compound; tertiary alcohol	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
cnf 2024	[no description available]	low	0	0	2-aminopurines; aromatic ether; organochlorine compound; pyridines	antineoplastic agent; Hsp90 inhibitor
uk 453,061	[no description available]	low	0	0	aromatic ether
zm323881	[no description available]	low	0	0	aromatic ether; benzyl ether; fluorophenol; halophenol; monofluorobenzenes; organic cation; quinazolines; secondary amino compound; substituted aniline	vascular endothelial growth factor receptor antagonist
compound w	[no description available]	low	0	0	aromatic ether
2-[[4-[2-[(2-methylpropan-2-yl)oxy]anilino]-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol	[no description available]	low	0	0	aromatic ether
interiotherin b	[no description available]	low	0	0	aromatic ether; fatty acid ester; lignan; organic heteropentacyclic compound; oxacycle	anti-HIV agent; metabolite
5,7-dihydroxy-3-(3-hydroxy-4-methoxybenzyl)-6-methoxychroman-4-one	[no description available]	low	0	0	aromatic ether; homoisoflavonoid; polyphenol	angiogenesis modulating agent; plant metabolite
ph 797804	[no description available]	low	0	0	aromatic ether; benzamides; organobromine compound; organofluorine compound; pyridone	anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
diorcinol	[no description available]	low	0	0	aromatic ether; phenols	fungal metabolite; marine metabolite; metabolite
2-[[4-(2-phenoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol	[no description available]	low	0	0	aromatic ether
2-[[4-(1-pyrrolidinyl)-6-[2-(trifluoromethoxy)anilino]-1,3,5-triazin-2-yl]amino]ethanol	[no description available]	low	0	0	aromatic ether
2-[[4-(5-chloro-2-ethoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol	[no description available]	low	0	0	aromatic ether
2-[[4-(5-chloro-2-propan-2-yloxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol	[no description available]	low	0	0	aromatic ether
mk 5108	[no description available]	low	0	0	aromatic ether
1-azepanyl-[5-[(4-chloro-3,5-dimethylphenoxy)methyl]-3-isoxazolyl]methanone	[no description available]	low	0	0	aromatic ether
4-(1-((5-((2,6-dimethylphenoxy)methyl)-3-isoxazolyl)carbonyl)-4-piperidinyl)pyridine	[no description available]	low	0	0	aromatic amide; aromatic ether; isoxazoles; N-acylpiperidine; pyridines	geroprotector; P450 inhibitor
dafadine D	[no description available]	low	0	0	aromatic amide; aromatic ether; isoxazoles; N-acylpiperidine; organofluorine compound; pyridines	P450 inhibitor
1-[(1-ethyl-3-methyl-4-pyrazolyl)methyl]-N-[4-(2-fluorophenoxy)phenyl]-4-piperidinecarboxamide	[no description available]	low	0	0	aromatic ether
dafadine O	[no description available]	low	0	0	aromatic amide; aromatic ether; isoxazoles; N-acylpiperidine; pyridines; ring assembly	P450 inhibitor
5-[(3,4-dimethylphenoxy)methyl]-N-methyl-N-(4-oxanylmethyl)-3-isoxazolecarboxamide	[no description available]	low	0	0	aromatic ether
pci 32765	[no description available]	low	0	0	acrylamides; aromatic amine; aromatic ether; N-acylpiperidine; pyrazolopyrimidine; tertiary carboxamide	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
florbetapir f 18	[no description available]	low	0	0	(18)F radiopharmaceutical; aromatic ether; organofluorine compound; pyridines; substituted aniline	radioactive imaging agent
AMG-208	[no description available]	low	0	0	aromatic ether; quinolines; triazolopyridazine	antineoplastic agent; c-Met tyrosine kinase inhibitor
6-methoxyspirotryprostatin b	[no description available]	low	0	0	aromatic ether; azaspiro compound; indole alkaloid; indolones	antineoplastic agent; Aspergillus metabolite
lucitanib	[no description available]	low	0	0	aromatic ether; cyclopropanes; naphthalenecarboxamide; primary amino compound; quinolines	antineoplastic agent; fibroblast growth factor receptor antagonist; vascular endothelial growth factor receptor antagonist
act-132577	[no description available]	low	0	0	aromatic ether; organobromine compound; pyrimidines; sulfamides	antihypertensive agent; drug metabolite; endothelin receptor antagonist; xenobiotic metabolite
cabozantinib	[no description available]	low	0	0	aromatic ether; dicarboxylic acid diamide; organofluorine compound; quinolines	antineoplastic agent; tyrosine kinase inhibitor
poziotinib	[no description available]	low	0	0	acrylamides; aromatic ether; dichlorobenzene; diether; monofluorobenzenes; N-acylpiperidine; quinazolines; secondary amino compound; substituted aniline	antineoplastic agent; apoptosis inducer; epidermal growth factor receptor antagonist
gsk 2126458	[no description available]	low	0	0	aromatic ether; difluorobenzene; pyridazines; pyridines; quinolines; sulfonamide	anticoronaviral agent; antineoplastic agent; autophagy inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor; radiosensitizing agent
gsk 1363089	[no description available]	low	0	0	aromatic ether
1-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-propan-2-ylurea	[no description available]	low	0	0	aromatic ether
1-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-3-propan-2-ylurea	[no description available]	low	0	0	aromatic ether
3-cyclohexyl-1-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[[oxo-(propan-2-ylamino)methyl]amino]-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methylurea	[no description available]	low	0	0	aromatic ether
3-cyclohexyl-1-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-10-[[oxo-(propan-2-ylamino)methyl]amino]-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methylurea	[no description available]	low	0	0	aromatic ether
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide	[no description available]	low	0	0	aromatic ether
1-(3,5-dimethyl-4-isoxazolyl)-3-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]urea	[no description available]	low	0	0	aromatic ether
monepantel	[no description available]	low	0	0	(trifluoromethyl)benzenes; aromatic ether; aryl sulfide; nitrile; secondary carboxamide	anthelminthic drug; nematicide
an2728	[no description available]	low	0	0	aromatic ether; benzoxaborole; nitrile	antipsoriatic; non-steroidal anti-inflammatory drug; phosphodiesterase IV inhibitor
grazoprevir	[no description available]	low	0	0	aromatic ether; azamacrocycle; carbamate ester; cyclopropanes; lactam; N-sulfonylcarboxamide; quinoxaline derivative	antiviral drug; hepatitis C protease inhibitor; hepatoprotective agent
hordatine a	[no description available]	low	0	0	aromatic ether; benzofurans; dicarboxylic acid diamide; guanidines; phenols	adrenergic antagonist; metabolite
5-chloro-2-(3,5-dimethylphenyl)-4-(4-methoxyphenoxy)-3-pyridazinone	[no description available]	low	0	0	aromatic ether
tak-632	[no description available]	low	0	0	(trifluoromethyl)benzenes; aromatic ether; benzothiazoles; cyclopropylcarboxamide; monofluorobenzenes; nitrile; secondary carboxamide	antineoplastic agent; apoptosis inducer; B-Raf inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor; necroptosis inhibitor
quinolobactin	[no description available]	low	0	0	aromatic ether; monohydroxyquinoline; phenols; quinolinemonocarboxylic acid	bacterial metabolite; siderophore
AZD1979	[no description available]	low	0	0	aromatic ether; azaspiro compound; carboxamide; N-acylazetidine; oxadiazole; oxaspiro compound; oxetanes	melanin-concentrating hormone receptor antagonist
ML240	[no description available]	low	0	0	aromatic amine; aromatic ether; benzimidazoles; primary amino compound; quinazolines; secondary amino compound	antineoplastic agent
aripiprazole lauroxil	[no description available]	low	0	0	aromatic ether; delta-lactam; dichlorobenzene; dodecanoate ester; N-alkylpiperazine; N-arylpiperazine; quinolone	H1-receptor antagonist; prodrug; second generation antipsychotic; serotonergic agonist
abt-199	[no description available]	low	0	0	aromatic ether; C-nitro compound; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; N-sulfonylcarboxamide; oxanes; pyrrolopyridine	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
xl765	[no description available]	low	0	0	aromatic amine; aromatic ether; benzamides; quinoxaline derivative; sulfonamide	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
DMH1	[no description available]	low	0	0	aromatic ether; pyrazolopyrimidine; quinolines	antineoplastic agent; bone morphogenetic protein receptor antagonist; protein kinase inhibitor
2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide	[no description available]	low	0	0	aromatic ether; methylpyridines; olefinic compound; quinazolines; secondary amino compound; secondary carboxamide; toluenes
pf 4800567	[no description available]	low	0	0	aromatic ether; monochlorobenzenes; oxanes; pyrazolopyrimidine	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
propenylphosphonic acid	[no description available]	low	0	0	aromatic ether
abt-333	[no description available]	low	0	0	aromatic ether; naphthalenes; pyrimidone; sulfonamide	antiviral drug; nonnucleoside hepatitis C virus polymerase inhibitor
ceritinib	[no description available]	low	0	0	aminopyrimidine; aromatic ether; organochlorine compound; piperidines; secondary amino compound; sulfone	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
MK-8353	[no description available]	low	0	0	aromatic ether; dihydropyridine; indazoles; methyl sulfide; N-alkylpyrrolidine; pyridines; pyrrolidinecarboxamide; secondary carboxamide; tertiary carboxamide; triazoles	antineoplastic agent; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
HG-10-102-01	[no description available]	low	0	0	aminopyrimidine; aromatic ether; monocarboxylic acid amide; morpholines; organochlorine compound; secondary amino compound	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
N-[(5-methyl-2-furanyl)methylideneamino]-2-phenoxybenzamide	[no description available]	low	0	0	aromatic ether
saroglitazar	[no description available]	low	0	0	aromatic ether; methyl sulfide; monocarboxylic acid; pyrroles	hypoglycemic agent; PPARalpha agonist; PPARgamma agonist
fertaric acid	[no description available]	low	0	0	aromatic ether; cinnamate ester; dicarboxylic acid; phenols; tetraric acid derivative
2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol	[no description available]	low	0	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; tertiary alcohol; triazoles
pf-06463922	[no description available]	low	0	0	aminopyridine; aromatic ether; azamacrocycle; benzamides; cyclic ether; monofluorobenzenes; nitrile; organic heterotetracyclic compound; pyrazoles	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
DDR1-IN-1	[no description available]	low	0	0	(trifluoromethyl)benzenes; aromatic ether; benzamides; N-alkylpiperazine; oxindoles; secondary carboxamide	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
ldc4297	[no description available]	low	0	0	aromatic ether; piperidines; pyrazoles; pyrazolotriazine; secondary amino compound	antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
biliatresone	[no description available]	low	0	0	aromatic ether; aromatic ketone; benzodioxoles; enone; phenols	plant metabolite; toxin
tak 491	[no description available]	low	0	0	1,2,4-oxadiazole; aromatic ether; benzimidazoles; carboxylic ester; cyclic carbonate ester; dioxolane	angiotensin receptor antagonist; antihypertensive agent; prodrug
azilsartan	[no description available]	low	0	0	1,2,4-oxadiazole; aromatic ether; benzimidazolecarboxylic acid	angiotensin receptor antagonist; antihypertensive agent
hydrazinocurcumin	[no description available]	low	0	0	aromatic ether; olefinic compound; polyphenol; pyrazoles	angiogenesis modulating agent; antineoplastic agent; EC 2.3.1.48 (histone acetyltransferase) inhibitor; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
mirodenafil	[no description available]	low	0	0	aromatic ether; N-alkylpiperazine; primary alcohol; pyrrolopyrimidine; sulfonamide	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
cerulomycin	[no description available]	low	0	0	aldoxime; aromatic ether; bipyridines; pyridine alkaloid	antineoplastic agent; bacterial metabolite; marine metabolite
undecylprodigiosin	[no description available]	low	0	0	alkaloid; aromatic ether; tripyrrole	antibacterial agent; antineoplastic agent; apoptosis inducer; bacterial metabolite; biological pigment; immunosuppressive agent; radiosensitizing agent
2-[[4-(trifluoromethoxy)phenyl]methylthio]-1,5,6,7-tetrahydrocyclopenta[d]pyrimidin-4-one	[no description available]	low	0	0	aromatic ether
PF-07304814	[no description available]	low	0	0	aromatic ether; indolecarboxamide; L-leucine derivative; phosphate monoester; pyrrolidin-2-ones; secondary carboxamide	anticoronaviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; prodrug

Article	Year
Reversing dobutamine-induced tachycardia using ivabradine increases stroke volume with neutral effect on cardiac energetics in left ventricular post-ischaemia dysfunction. Acta physiologica (Oxford, England), Volume: 218, Issue: 2	2016
Population plasma and urine pharmacokinetics of ivabradine and its active metabolite S18982 in healthy Korean volunteers. Journal of clinical pharmacology, Volume: 56, Issue: 4	2016
The Effect of Silibinin on the Pharmacokinetics of Ivabradine and N-Desmethylivabradine in Rats. Pharmacology, Volume: 96, Issue: 3-4	2015
The effect of clopidogrel on pharmacokinetics of ivabradine and its metabolite in rats. Drug development and industrial pharmacy, Volume: 41, Issue: 9	2015
Pharmacokinetic and safety profile of ivabradine in healthy Chinese men: a phase I, randomized, open-label, increasing single- and multiple-dose study. Clinical therapeutics, Volume: 35, Issue: 12	2013
Development and validation of a sensitive LC-MS/MS-ESI method for the determination of ivabradine in human plasma: application to a pharmacokinetic study. Biomedical chromatography : BMC, Volume: 27, Issue: 12	2013
Evaluation of pharmacokinetic and pharmacodynamic profiles and tolerability after single (2.5, 5, or 10 mg) and repeated (2.5, 5, or 10 mg bid for 4.5 days) oral administration of ivabradine in healthy male Korean volunteers. Clinical therapeutics, Volume: 35, Issue: 6	2013
Pharmacokinetic interaction between ivabradine and phenytoin in healthy subjects. Clinical drug investigation, Aug-01, Volume: 32, Issue: 8	2012
Pharmacodynamic effects of ivabradine, a negative chronotropic agent, in healthy cats. Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, Volume: 13, Issue: 4	2011
Pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers. Journal of clinical pharmacy and therapeutics, Volume: 36, Issue: 2	2011
Pharmacokinetics of oral ivabradine in healthy cats. Journal of veterinary pharmacology and therapeutics, Volume: 34, Issue: 5	2011
Ivabradine: pharmacodynamic aspects of its clinical use. Methods and findings in experimental and clinical pharmacology, Volume: 30, Issue: 8	2008
Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial. Journal of clinical pharmacology, Volume: 46, Issue: 10	2006
Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. Journal of clinical pharmacology, Volume: 46, Issue: 10	2006
Optimal design of a population pharmacodynamic experiment for ivabradine. Pharmaceutical research, Volume: 18, Issue: 1	2001
An identifiability analysis of a parent-metabolite pharmacokinetic model for ivabradine. Journal of pharmacokinetics and pharmacodynamics, Volume: 28, Issue: 1	2001
A pharmacokinetic simulation model for ivabradine in healthy volunteers. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Volume: 10, Issue: 4	2000
Development of a sequential linked pharmacokinetic and pharmacodynamic simulation model for ivabradine in healthy volunteers. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Volume: 10, Issue: 4	2000
Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clinical pharmacology and therapeutics, Volume: 64, Issue: 2	1998
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Expert Consensus on Ivabradine-based Therapy for Heart Rate Management in Chronic Coronary Syndrome and Heart Failure with Reduced Ejection Fraction in India. Current cardiology reviews, Volume: 19, Issue: 5	2023
Sustained-Release Ivabradine Hemisulfate in Patients With Systolic Heart Failure. Journal of the American College of Cardiology, 08-09, Volume: 80, Issue: 6	2022
First derivative synchronous spectrofluorimetric analysis of bisoprolol fumarate and ivabradine in pharmaceutical and biological matrices. Investigation of the method greenness. Luminescence : the journal of biological and chemical luminescence, Volume: 37, Issue: 10	2022
Fluorescence spectroscopy method for estimation of Ivabradine in bulk and the tablet dosage form. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, Jan-05, Volume: 264	2022
Efficacy of ivabradine in HIV-associated dilated cardiomyopathy. Recenti progressi in medicina, Volume: 112, Issue: 4	2021
An Integrative Approach for Improved Assessment of Cardiovascular Safety Data. The Journal of pharmacology and experimental therapeutics, Volume: 377, Issue: 2	2021
Optimizing heart failure treatment following cardiac resynchronization therapy. Clinical research in cardiology : official journal of the German Cardiac Society, Volume: 109, Issue: 5	2020
Ivabradine reversed nondipping heart rate in rats with l-NAME-induced hypertension. Clinical and experimental pharmacology & physiology, Volume: 46, Issue: 6	2019
[Pharmacological therapy of heart failure with reduced ejection fraction]. Therapeutische Umschau. Revue therapeutique, Volume: 75, Issue: 3	2018
IVABRADINE LOADED SOLID LIPID MICROPARTICLES: FORMULATION, CHARACTERIZATION AND OPTIMIZATION BY CENTRAL COMPOSITE ROTATABLE DESIGN. Acta poloniae pharmaceutica, Volume: 74, Issue: 1	2017
Ivabradine in Postural Orthostatic Tachycardia Syndrome: Preliminary Experience in Children. American journal of cardiovascular drugs : drugs, devices, and other interventions, Volume: 18, Issue: 1	2018
Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure. Journal of the American College of Cardiology, Sep-05, Volume: 70, Issue: 10	2017
Is There a Role for Ivabradine in the Contemporary Management of Patients with Chronic Heart Failure in Academic and Community Heart Failure Clinics in Canada? Advances in therapy, Volume: 34, Issue: 6	2017
Adjunctive ivabradine in combination with amiodarone: A novel therapy for pediatric congenital junctional ectopic tachycardia. Heart rhythm, Volume: 13, Issue: 6	2016
New Novel Treatment Approaches for Heart Failure With Reduced Ejection Fraction. Journal of pharmacy practice, Volume: 30, Issue: 5	2017
Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. European journal of heart failure, Volume: 18, Issue: 5	2016
[Clinical and Economic Efficacy of Ivabradine in Patients Suffered Myocardial Infarction]. Kardiologiia, Volume: 55, Issue: 3	2015
Population plasma and urine pharmacokinetics of ivabradine and its active metabolite S18982 in healthy Korean volunteers. Journal of clinical pharmacology, Volume: 56, Issue: 4	2016
Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population. Cardiology, Volume: 131, Issue: 4	2015
Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study. Advances in therapy, Volume: 32, Issue: 2	2015
Ivabradine in combination with Beta-blockers in patients with chronic stable angina after percutaneous coronary intervention. Advances in therapy, Volume: 32, Issue: 2	2015
Nemaline myopathy and heart failure: role of ivabradine; a case report. BMC cardiovascular disorders, Jan-19, Volume: 15	2015
Case report of ivabradine intoxication. Journal of analytical toxicology, Volume: 38, Issue: 4	2014
Ivabradine therapy to unmask heart rate-independent effects of β-blockers on pulse wave reflections. Clinical research in cardiology : official journal of the German Cardiac Society, Volume: 103, Issue: 6	2014
Pharmacokinetic and safety profile of ivabradine in healthy Chinese men: a phase I, randomized, open-label, increasing single- and multiple-dose study. Clinical therapeutics, Volume: 35, Issue: 12	2013
Heart rate reduction for 36 months with ivabradine reduces left ventricular mass in cardiac allograft recipients: a long-term follow-up study. Drug design, development and therapy, Volume: 7	2013
Effects of ivabradine on 6-minute walk test and quality of life in patients with previously implanted CRT-D. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, Volume: 61, Issue: 6	2013
Evaluation of pharmacokinetic and pharmacodynamic profiles and tolerability after single (2.5, 5, or 10 mg) and repeated (2.5, 5, or 10 mg bid for 4.5 days) oral administration of ivabradine in healthy male Korean volunteers. Clinical therapeutics, Volume: 35, Issue: 6	2013
Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and β-receptor blockade. Hypertension (Dallas, Tex. : 1979), Volume: 59, Issue: 5	2012
Pharmacokinetics of oral ivabradine in healthy cats. Journal of veterinary pharmacology and therapeutics, Volume: 34, Issue: 5	2011
Safety and effectiveness of ivabradine after cardiac transplantation. Transplantation proceedings, Volume: 42, Issue: 8	2010
Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice. American journal of cardiovascular drugs : drugs, devices, and other interventions, Volume: 9 Suppl 1	2009
Heart rate reduction for 12 months with ivabradine reduces left ventricular mass in cardiac allograft recipients. Transplantation, Sep-27, Volume: 88, Issue: 6	2009
Specific inhibition of HCN channels slows rhythm differently in atria, ventricle and outflow tract and stabilizes conduction in the anoxic-reoxygenated embryonic heart model. Pharmacological research, Volume: 61, Issue: 1	2010
Effect of ivabradine, a novel antianginal agent, on driving performance: A randomized, double-blind, placebo-controlled trial in healthy volunteers. Clinical drug investigation, Volume: 29, Issue: 5	2009
Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. European heart journal, Volume: 30, Issue: 5	2009
Ivabradine: a selective If current inhibitor in the treatment of stable angina. Recent patents on cardiovascular drug discovery, Volume: 1, Issue: 3	2006
Clinical results of I(f) current inhibition by ivabradine. Drugs, Volume: 67 Suppl 2	2007
Heart rate slowing versus other pharmacological antianginal strategies. Advances in cardiology, Volume: 43	2006
Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. The Journal of pharmacology and experimental therapeutics, Volume: 308, Issue: 1	2004
A pharmacokinetic simulation model for ivabradine in healthy volunteers. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Volume: 10, Issue: 4	2000
Development of a sequential linked pharmacokinetic and pharmacodynamic simulation model for ivabradine in healthy volunteers. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Volume: 10, Issue: 4	2000
Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clinical pharmacology and therapeutics, Volume: 64, Issue: 2	1998
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

ivabradine

Description

Cross-References

Synonyms (57)

Research Excerpts

Overview

Effects

Actions

Treatment

Roles (1)

Drug Classes (4)

Protein Targets (4)

Potency Measurements

Activation Measurements

Biological Processes (19)

Molecular Functions (7)

Ceullar Components (6)

Bioassays (24)

Research

Studies (1,077)

Study Types

Research Highlights

Safety/Toxicity (26)

Long-term Use (5)

Pharmacokinetics (21)

Bioavailability (7)

Dosage (46)

Interactions (12)

Article	Year
Ivabradine toxicity: a case report. Journal of medical case reports, Oct-24, Volume: 16, Issue: 1	2022
The role of ivabradine in doxorubicin-induced cardiotoxicity: exploring of underlying argument. Inflammopharmacology, Volume: 30, Issue: 6	2022
Efficacy and Safety of Ivabradine in Combination with Beta-Blockers in Patients with Stable Angina Pectoris: A Systematic Review and Meta-analysis. Advances in therapy, Volume: 39, Issue: 9	2022
Effectiveness and safety of ivabradine in the treatment of acute myocardial infarction: a systematic review and meta-analysis. Annals of palliative medicine, Volume: 10, Issue: 4	2021
An Integrative Approach for Improved Assessment of Cardiovascular Safety Data. The Journal of pharmacology and experimental therapeutics, Volume: 377, Issue: 2	2021
Efficacy and Safety of Ivabradine in Japanese Patients With Chronic Heart Failure　- J-SHIFT Study. Circulation journal : official journal of the Japanese Circulation Society, 09-25, Volume: 83, Issue: 10	2019
[MODERN ASPECTS OF DIAGNOSIS AND TREATMENT OF HEART FAILURE, AS A MANIFESTATION OF ANTHRACYCLINE CARDIOTOXICITY (REVIEW)]. Georgian medical news, Issue: 278	2018
Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial. ESC heart failure, Volume: 5, Issue: 3	2018
Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. European journal of heart failure, Volume: 17, Issue: 12	2015
Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. European journal of heart failure, Volume: 16, Issue: 7	2014
The efficacy and safety of ivabradine hydrochloride versus atenolol in Chinese patients with chronic stable angina pectoris. Pharmacoepidemiology and drug safety, Volume: 23, Issue: 11	2014
Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). The American journal of cardiology, Feb-01, Volume: 113, Issue: 3	2014
Pharmacokinetic and safety profile of ivabradine in healthy Chinese men: a phase I, randomized, open-label, increasing single- and multiple-dose study. Clinical therapeutics, Volume: 35, Issue: 12	2013
Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International journal of cardiology, Dec-10, Volume: 170, Issue: 2	2013
Safety of intravenous ivabradine in acute ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention: a randomized, placebo-controlled, double-blind, pilot study. European heart journal. Acute cardiovascular care, Volume: 2, Issue: 3	2013
Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. European journal of heart failure, Volume: 15, Issue: 11	2013
Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study. American journal of cardiovascular drugs : drugs, devices, and other interventions, Jun-01, Volume: 12, Issue: 3	2012
Therapeutic effects of ivabradine on hemodynamic parameters and cardiotoxicity induced by doxorubicin treatment in rat. Human & experimental toxicology, Volume: 31, Issue: 9	2012
Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy). The American journal of cardiology, Mar-15, Volume: 107, Issue: 6	2011
[The efficacy and safety of the combination of β-blocker bisoprolol and if inhibitor I(f) ivabradine in patients with stable angina and chronic obstructive pulmonary disease]. Kardiologiia, Volume: 50, Issue: 10	2010
Incremental value and safety of oral ivabradine for heart rate reduction in computed tomography coronary angiography. International journal of cardiology, Apr-05, Volume: 156, Issue: 1	2012
Safety and effectiveness of ivabradine after cardiac transplantation. Transplantation proceedings, Volume: 42, Issue: 8	2010
I f inhibition with ivabradine : electrophysiological effects and safety. Drug safety, Volume: 31, Issue: 2	2008
Long-term safety and efficacy of ivabradine in patients with chronic stable angina. Cardiology, Volume: 108, Issue: 4	2007
Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs, Volume: 67, Issue: 3	2007
Novel If current inhibitor ivabradine: safety considerations. Advances in cardiology, Volume: 43	2006
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Effect of ivabradine, captopril and melatonin on the behaviour of rats in L-nitro-arginine methyl ester-induced hypertension. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, Volume: 67, Issue: 6	2016
Modulation of sympathetic activity and heart rate variability by ivabradine. Cardiovascular research, Oct-01, Volume: 108, Issue: 1	2015
Preclinical results with I(f) current inhibition by ivabradine. Drugs, Volume: 67 Suppl 2	2007
Heart rate slowing for myocardial dysfunction/heart failure. Advances in cardiology, Volume: 43	2006
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Simultaneous Optimization of Oral and Transdermal Nanovesicles for Bioavailability Enhancement of Ivabradine Hydrochloride. International journal of nanomedicine, Volume: 16	2021
IVABRADINE LOADED SOLID LIPID MICROPARTICLES: FORMULATION, CHARACTERIZATION AND OPTIMIZATION BY CENTRAL COMPOSITE ROTATABLE DESIGN. Acta poloniae pharmaceutica, Volume: 74, Issue: 1	2017
Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessment. Journal of pharmacokinetics and pharmacodynamics, Volume: 43, Issue: 1	2016
[The efficacy of ivabradine in chronic heart failure (review)]. Georgian medical news, Issue: 241	2015
Pharmacokinetic interaction between ivabradine and phenytoin in healthy subjects. Clinical drug investigation, Aug-01, Volume: 32, Issue: 8	2012
Heart rate reduction induced by the if current inhibitor ivabradine improves diastolic function and attenuates cardiac tissue hypoxia. Journal of cardiovascular pharmacology, Volume: 59, Issue: 3	2012
Pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers. Journal of clinical pharmacy and therapeutics, Volume: 36, Issue: 2	2011
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Efficacy and Safety of Ivabradine in Combination with Beta-Blockers in Patients with Stable Angina Pectoris: A Systematic Review and Meta-analysis. Advances in therapy, Volume: 39, Issue: 9	2022
Protection of Ivabradine Combined with Trimetazidine on Myocardial Injury after Percutaneous Coronary Intervention in Patients with Coronary Artery Disease Evaluated by Magnetic Resonance Image under Convolutional Neural Network. Contrast media & molecular imaging, Volume: 2021	2021
Carvedilol Combined With Ivabradine Improves Left Ventricular Diastolic Dysfunction, Clinical Progression, and Survival in Cirrhosis. Journal of clinical gastroenterology, Volume: 54, Issue: 6	2020
[Assessment of Efficiency of Medicamentous Therapy in Correction of Structurally Functional Changes of The Cardiac Muscle at Patients With Arterial Hypertension in Combination With Bronchial Asthma]. Kardiologiia, Volume: 56, Issue: 6	2016
Ivabradine in Combination with Metoprolol Improves Symptoms and Quality of Life in Patients with Stable Angina Pectoris: A post hoc Analysis from the ADDITIONS Trial. Cardiology, Volume: 133, Issue: 2	2016
Ivabradine in combination with Beta-blockers in patients with chronic stable angina after percutaneous coronary intervention. Advances in therapy, Volume: 32, Issue: 2	2015
Ivabradine in combination with beta-blocker reduces symptoms and improves quality of life in elderly patients with stable angina pectoris: age-related results from the ADDITIONS study. Experimental gerontology, Volume: 59	2014
[Cerebral blood flow and endothelial functional activity in patients with coronary heart disease and arterial hypertension during therapy with ivabradine in combination with perindopril]. Terapevticheskii arkhiv, Volume: 84, Issue: 12	2012
Ca(2+)-stimulated adenylyl cyclase AC1 generates efficient biological pacing as single gene therapy and in combination with HCN2. Circulation, Jul-31, Volume: 126, Issue: 5	2012
Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. Clinical research in cardiology : official journal of the German Cardiac Society, Volume: 101, Issue: 5	2012
Efficacy of ivabradine in combination with Beta-blocker versus uptitration of Beta-blocker in patients with stable angina. Cardiovascular drugs and therapy, Volume: 25, Issue: 6	2011
Ivabradine in combination with beta-blocker therapy for the treatment of stable angina pectoris in every day clinical practice. Clinical research in cardiology : official journal of the German Cardiac Society, Volume: 99, Issue: 10	2010
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

ivabradine

Description

Cross-References

Synonyms (57)

Research Excerpts

Overview

Effects

Actions

Treatment

Roles (1)

Drug Classes (4)

Protein Targets (4)

Potency Measurements

Activation Measurements

Biological Processes (19)

Molecular Functions (7)

Ceullar Components (6)

Bioassays (24)

Research

Studies (1,077)

Study Types

Related Drugs (1,310)

Related Conditions (1,061)

Research Highlights

Safety/Toxicity (26)

Long-term Use (5)

Pharmacokinetics (21)

Bioavailability (7)

Dosage (46)

Interactions (12)